Immatics (IMTX) 20-F 23 Mar 22 2021 FY Annual report (foreign) Financial data

Cover Page

Cover Page	12 Months Ended
	Dec. 31, 2021shares
Document Information [Line Items]
Document Type	20-F
Amendment Flag	false
Document Period End Date	Dec. 31, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	FY
Entity Registrant Name	Immatics N.V.
Entity Central Index Key	0001809196
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding	62,926,816
Entity Voluntary Filers	No
Entity Shell Company	false
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Document Annual Report	true
Entity Interactive Data Current	Yes
ICFR Auditor Attestation Flag	false
Document Accounting Standard	International Financial Reporting Standards
Entity Incorporation, State or Country Code	P7
Entity File Number	001-39363
Entity Address, Address Line One	Paul-Ehrlich-Straße 15
Entity Address, City or Town	Tübingen
Entity Address, Country	DE
Entity Address, Postal Zip Code	72076
Document Registration Statement	false
Document Shell Company Report	false
Document Transition Report	false
Auditor Name	PricewaterhouseCoopers GmbH Wirtschaftsprüfungsgesellschaft
Auditor Firm ID	1275
Auditor Location	Stuttgart, Germany
Business Contact [Member]
Document Information [Line Items]
Contact Personnel Name	Edward A. Sturchio
Entity Address, Address Line One	2130 W. Holcombe Blvd., Suite 900
Entity Address, City or Town	Houston
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	77030
City Area Code	281
Local Phone Number	810-7545
Common Shares [Member]
Document Information [Line Items]
Title of 12(b) Security	Ordinary shares, nominal value €0.01 per share
Security Exchange Name	NASDAQ
Trading Symbol	IMTX
Warrants [Member]
Document Information [Line Items]
Title of 12(b) Security	Warrants to purchase ordinary shares
Security Exchange Name	NASDAQ
Trading Symbol	IMTXW

Consolidated Statement of Finan

Consolidated Statement of Financial Position of Immatics N.V. - EUR (€) € in Thousands	Dec. 31, 2021	Dec. 31, 2020
Current assets
Cash and cash equivalents	€ 132,994	€ 207,530
Other financial assets	12,123	24,448
Accounts receivable	682	1,250
Other current assets	6,408	5,763
Total current assets	152,207	238,991
Non-current assets
Property, plant and equipment	10,506	7,868
Intangible assets	1,315	914
Right-of-use assets	9,982	6,149
Other non-current assets	636	724
Total non-current assets	22,439	15,655
Total assets	174,646	254,646
Current liabilities
Provisions	51	51
Accounts payable	11,624	10,052
Deferred revenue	50,402	46,600
Other financial liabilities	27,859	16,869
Lease liabilities	2,711	1,881
Other current liabilities	2,501	2,025
Total current liabilities	95,148	77,478
Non-current liabilities
Deferred revenue	48,225	85,475
Lease liabilities	7,142	4,306
Other non-current liabilities	68
Total non-current liabilities	55,435	89,781
Shareholders' equity
Share capital	629	629
Share premium	565,192	538,695
Accumulated deficit	(537,813)	(444,478)
Other reserves	(3,945)	(7,459)
Total shareholders' equity	24,063	87,387
Total liabilities and shareholders' equity	€ 174,646	€ 254,646

Consolidated Statement of Loss

Consolidated Statement of Loss of Immatics N.V. - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Profit or loss [abstract]
Revenue from collaboration agreements	€ 34,763	€ 31,253	€ 18,449
Research and development expenses	(87,574)	(67,085)	(40,091)
General and administrative expenses	(33,808)	(34,186)	(11,756)
Other income	325	303	385
Operating result	(86,294)	(69,715)	(33,013)
Financial income	5,675	2,949	790
Financial expenses	(1,726)	(10,063)	(264)
Change in fair value of warrant liabilities	(10,990)	17,775
Share listing expense		(152,787)
Financial result	(7,041)	(142,126)	526
Loss before taxes	(93,335)	(211,841)	(32,487)
Taxes on income	0	0	0
Net loss	(93,335)	(211,841)	(32,487)
Attributable to:
Equity holders of the parent	(93,335)	(211,284)	(31,571)
Non-controlling interest		(557)	(916)
Net loss	€ (93,335)	€ (211,841)	€ (32,487)
Net loss per share—basic and diluted	€ (1.48)	€ (4.40)	€ (0.95)
Weighted average shares outstanding—basic and diluted	62,912,921	48,001,228	33,093,838

Consolidated Statement of Compr

Consolidated Statement of Comprehensive Loss of Immatics N.V. - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Statement of comprehensive income [abstract]
Net Loss	€ (93,335)	€ (211,841)	€ (32,487)
Items that may be reclassified subsequently to profit or loss, net of tax
Currency translation differences from foreign operations	3,514	(6,689)	(29)
Total comprehensive loss for the period	(89,821)	(218,530)	(32,516)
Attributable to:
Equity holders of the parent	(89,821)	(217,973)	(31,600)
Non-controlling interest	0	(557)	(916)
Total comprehensive loss for the period	€ (89,821)	€ (218,530)	€ (32,516)

Consolidated Statement of Cash

Consolidated Statement of Cash Flows - EUR (€) € in Thousands		12 Months Ended
		Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Cash flows from operating activities
Loss before taxation		€ (93,335)	€ (211,841)	€ (32,487)
Adjustments for:
Interest income		(133)	(850)	(790)
Depreciation and amortization		5,260	4,424	3,858
Interest expense		566	289	170
Share listing expense			152,787
Equity settled share-based payment		26,403	22,908	152
MD Anderson compensation expense			45	700
(Decrease) Increase in other liabilities resulting from share appreciation rights			(2,036)	1,864
Payment related to share-based compensation awards previously classified as equity-settled			(4,322)
Net foreign exchange differences		554	(4,477)	3
Change in fair value of warrant liabilities		10,990	(17,775)
Changes in:
Decrease (increase) in accounts receivable		569	(294)	(563)
(Increase) in other assets		(483)	(1,600)	(1,497)
(Decrease) increase in accounts payable and other current liabilities		(31,784)	(23,387)	98,937
Interest received		175	808	790
Interest paid		(566)	(289)	(170)
Net cash (used in)/provided by operating activities		(81,784)	(85,610)	70,967
Cash flows from investing activities
Payments for property, plant and equipment		(5,106)	(7,420)	(2,143)
Cash paid for investments in Other financial assets	[1]	(11,298)	(58,087)	(77,810)
Cash received from maturity of investments classified in Other financial assets	[1]	24,448	49,662	74,888
Payments for intangible assets		(551)	(104)	(91)
Proceeds from disposal of property, plant and equipment				97
Net cash (used in)/provided by investing activities		7,493	(15,949)	(5,059)
Cash flows from financing activities
Proceeds from issuance of shares to equity holders of the parent		94	217,918
Transaction cost deducted from equity			(7,939)
Payments for leases		(2,707)	(2,096)	(1,862)
Net cash (used in)/provided by financing activities		(2,613)	207,883	(1,862)
Net (decrease)/increase in cash and cash equivalents		(76,904)	106,324	64,046
Cash and cash equivalents at beginning of period		207,530	103,353	39,367
Effects of exchange rate changes on cash and cash equivalents		2,368	(2,147)	(60)
Cash and cash equivalents at end of period		€ 132,994	€ 207,530	€ 103,353
[1]	See Note 2 for details regarding the revision of prior period numbers as a result of a correction in presentation of cash paid for investments in Other financial assets and Cash received from maturity of investments classified in Other financial assets

Consolidated Statement of Chang

Consolidated Statement of Changes in Shareholders' equity (deficit) of Immatics N.V. - EUR (€) € in Thousands	Total	Share capital [member]	Share premium [member]	Accumulated deficit [member]	Other reserves [member]	Total equity (deficit) attributable to shareholders of the parent [member]	Non-controlling interests [member]
Beginning Balance at Dec. 31, 2018	€ (9,171)	€ 1,164	€ 190,793	€ (201,623)	€ (741)	€ (10,407)	€ 1,236
Other comprehensive income (loss)	(29)				(29)	(29)
Net loss	(32,487)			(31,571)		(31,571)	(916)
Comprehensive income/(loss) for the year	(32,516)			(31,571)	(29)	(31,600)	(916)
Equity-settled share-based compensation	152		152			152
PIPE Financing, net of transaction costs	700
MD Anderson compensation expense	700						700
Ending Balance at Dec. 31, 2019	(40,835)	1,164	190,945	(233,194)	(770)	(41,855)	1,020
Other comprehensive income (loss)	(6,689)				(6,689)	(6,689)
Net loss	(211,841)			(211,284)		(211,284)	(557)
Comprehensive income/(loss) for the year	(218,530)			(211,284)	(6,689)	(217,973)	(557)
Equity-settled share-based compensation	22,908		22,908			22,908
Reorganization		(833)	833
MD Anderson Share Exchange		7	501			508	(508)
PIPE Financing, net of transaction costs	90,077	104	89,973			90,077
ARYA Merger, net of transaction costs	238,044	180	237,864			238,044
SAR conversion		7	(7)
Total issuance of share capital	328,121	298	328,331			328,629	(508)
Payment related to share-based compensation awards previously classified as equity-settled	(4,322)		(4,322)			(4,322)
MD Anderson compensation expense	45						€ 45
Ending Balance at Dec. 31, 2020	87,387	629	538,695	(444,478)	(7,459)	87,387
Other comprehensive income (loss)	3,514				3,514	3,514
Net loss	(93,335)			(93,335)		(93,335)
Comprehensive income/(loss) for the year	(89,821)			(93,335)	3,514	(89,821)
Equity-settled share-based compensation	26,403		26,403			26,403
Share options exercised	94		94			94
Ending Balance at Dec. 31, 2021	€ 24,063	€ 629	€ 565,192	€ (537,813)	€ (3,945)	€ 24,063

Group information

Group information	12 Months Ended
	Dec. 31, 2021
Text Block [Abstract]
Group information	1. Group information Immatics N.V, together with its German subsidiary Immatics Biotechnologies GmbH and its U.S. subsidiary, Immatics US Inc., (“Immatics” or “the Group”) is a biotechnology company that is primarily engaged in the research and development of T cell redirecting immunotherapies for the treatment of cancer patients. Immatics N.V., a Dutch public limited liability company, was converted on July 1, 2020 from Immatics B.V., a Dutch company with limited liability. Immatics Biotechnologies GmbH and Immatics US Inc. became wholly-owned subsidiaries of Immatics N.V. as part of the ARYA Merger (defined below) on July 1, 2020. Immatics N.V is registered with the commercial register at the Netherlands Chamber of Commerce under RSIN 861058926 with a corporate seat in Amsterdam and is located at Paul-Ehrlich Str. 15 in 72076 Tübingen, Germany. Prior to July 1, 2020, Immatics N.V. was a shell company with no active trade or business or subsidiaries and all relevant assets and liabilities as well as income and expenses were borne by Immatics Biotechnologies GmbH and its U.S. subsidiary Immatics US, Inc. Therefore, the comparable consolidated financial statements as of December 31, 2019 and for the years ended December 31, 2019 represent consolidated financial statements of Immatics Biotechnologies GmbH. These annual consolidated financial statements of the Group for the year ended December 31, 2021 were authorized for issue by the Board of Directors of Immatics N.V. on March 22, 2022.

Basis of presentation

Basis of presentation	12 Months Ended
	Dec. 31, 2021
Text Block [Abstract]
Basis of presentation	2. Basis of presentation The consolidated financial statements of the Group have been prepared in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”), taking into account the recommendations of the International Financial Reporting Standards Interpretations Committee (“IFRS IC”). The consolidated financial statements are presented in Euro. Amounts are stated in thousands of Euros, unless otherwise indicated. The Group had a non-controlling non-controlling During the preparation of the annual consolidated financial statements for the year ended December 31, 2021, the Group identified an error in the presentation of ‘Cash paid for investments in Other financial assets’ and ‘Cash received from maturity of investments classified in Other financial assets’ in the statement of cash flows. The error resulted in a gross up of cash paid and cash received from maturity of investments within million (unaudited), €42.4 million (unaudited) and €42.5 million (unaudited) for the three months ended March 3 1 The Company has evaluated the effect of this misclassification, both qualitatively and quantitatively, and concluded that the correction did not have a material impact on, nor require amendment of, any previously filed financial statements. 2.1 Going concern Since inception, the Group’s activities have consisted primarily of raising capital and performing research and development activities to advance its technologies. The Group is still in the development phase and has not yet marketed any products commercially. Immatics’ ongoing success depends on the successful development and regulatory approval of its products and its ability to finance operations. The Group will seek additional funding to reach its development and commercialization objectives. The Group plans to seek funds through further private or public equity financings, debt financings, collaboration agreements and marketing, distribution or licensing arrangements. The Group may not be able to obtain financing or enter into collaboration or other arrangements on acceptable terms. If the Group is unable to obtain funding, it could be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect its business prospects. However, Immatics’ cash and cash equivalents as well as short-term deposits will be sufficient to fund operating expenses and capital expenditure requirements for at least twelve months from the issuance date. The accompanying consolidated financial statements have been prepared on a going concern basis. This contemplates the Group will continue in operation for the foreseeable future and will be able to realize its assets and discharge its liabilities in the normal course of operations. The consolidated financial statements do not reflect any adjustments relating to the recoverability and classification of assets or the amounts and classification of liabilities that would be necessary, was the Group unable to continue as a going concern. 2.4 COVID-19 In December 2019, a novel strain of coronavirus (“COVID-19”) travel Management continues to monitor the situation and enacted significant measures to protect the Group’s supply chain, employees, and the execution of clinical trials. To date, the pandemic has not significantly impacted the Group. The ongoing spread of COVID-19 COVID-19 COVID-19

ARYA Merger

ARYA Merger	12 Months Ended
	Dec. 31, 2021
Text Block [Abstract]
ARYA Merger	3. ARYA Merger On March 17, 2020, Immatics entered into a definitive merger agreement with ARYA Sciences Acquisition Corp. (“ARYA”), a special purpose acquisition company sponsored by Perceptive Advisors. The transaction closed on July 1, 2020. The merger (“ARYA Merger”) was effectuated as follows: • The shareholders of Immatics Biotechnologies GmbH exchanged their interest for ordinary shares in the share capital of Immatics B.V. (“the Reorganization”). The Reorganization is accounted for as a recapitalization, with Immatics Biotechnologies GmbH being the accounting predecessor. The Reorganization resulted in a €0.8 million decrease in share capital and an offsetting increase in share premium. Subsequent to the Reorganization, Immatics B.V. was converted into Immatics N.V., after the share exchange of Immatics shareholders. As part of the Reorganization, the minority shareholder in Immatics US, Inc., MD Anderson Cancer Center (“MD Anderson”) exchanged its interest in Immatics US, Inc. for ordinary shares in the share capital of Immatics N.V. (“MD Anderson Share Exchange”). This resulted in a decrease to non-controlling interest of € million, with corresponding increases to share capital and share premium. (See note 20). • ARYA merged into Immatics N.V., with former ARYA shareholders receiving one ordinary share of Immatics N.V. for each issued and outstanding ordinary share of ARYA and one warrant to purchase ordinary shares in Immatics N.V., for each issued and outstanding warrant to acquire ordinary shares in ARYA. The merger of ARYA constituted a transaction by Immatics N.V., which is accounted for within the scope of IFRS 2. As part of the transaction, former shareholders of ARYA received shares of Immatics N.V. and warrants (“Immatics Warrants”) to purchase ordinary shares of Immatics N.V. In exchange, Immatics received the net assets held by ARYA, which had a fair value of € million upon closing of the transaction on July 1, 2020. The net assets included € million of cash and cash equivalents held in ARYA’s trust account and current liabilities of € million as well as the fair value of the warrants in the amount of € million. In accordance with IFRS 2, the difference between the fair value of the net assets contributed by ARYA and the fair value of equity instruments provided to former ARYA shareholders is treated as an expense, resulting in a € million Share listing expense classified within the financial result (See Note 17) and an increase in equity. The 7,187,500 Immatics Warrants give the holder the right, but not the obligation, to subscribe to Immatics’ shares at a fixed or determinable price for a specified period of time subject to the provision of the Warrant Agreement. Those instruments were considered to be part of the net assets acquired and therefore, management applied the provisions of debt and equity classification under IAS 32. Due to an option of cashless exercise of the Immatics Warrants, which gives Immatics a choice over how the warrant is settled with a settlement alternative, that results in Immatics delivering a variable number of shares. Therefore, the Immatics Warrants are accounted for as financial liability through profit and loss. • Immatics N.V. raised an additional net €90.1 million in net equity proceeds through a private placement of ordinary shares with existing shareholders of Immatics, ARYA and other new investors (“PIPE Financing”). The PIPE Financing is treated as a capital contribution, which resulted in increases of €0.1 million and €90.0 million to share capital and share premium, respectively. Both the ARYA Merger and PIPE Financing closed as of July 1, 2020. Upon consummation of the transactions, Immatics N.V. became a publicly traded corporation at the Nasdaq Capital Market under the ticker IMTX. The Immatics Warrants are traded under the ticker IMTXW. Immatics incurred incremental transaction costs directly attributable to the issuance of new shares to ARYA shareholders and the PIPE Financing of €7.9 million, which it netted against the equity proceeds as a reduction in share premium. Immatics also amended existing share-based compensation agreements held by employees of Immatics GmbH prior to the ARYA Merger (See Note 18), in addition to making additional cash and share-based payments to key management personnel (See Note 26).

Application of new and revised

Application of new and revised international financial reporting standards	12 Months Ended
	Dec. 31, 2021
Text Block [Abstract]
Disclosure of changes in accounting policies, accounting estimates and errors [text block]	4. Application of new and revised international financial reporting standards 4.1 Application of new standards The accounting policies adopted in the preparation of the consolidated financial statements are consistent with those followed in the preparation of the Group’s annual consolidated financial statements for the year ended December 31, 2020, except for the adoption of new standards and interpretations effective as of January 1, 2021. The Group has not early adopted any standard, interpretation or amendment that has been issued but is not yet effective. New standards and interpretations applied for the first time: Standard/interpretation Effective date Amendment to IFRS 16, ‘Leases’ – COVID-19 April 1, 2021 Changes to IFRS 4 – Effective date of IFRS 9 for insurance companies January 1, 2021 Amendments to IFRS 9, IAS 39, IFRS 7, IFRS 4 and IFRS 16 – Interest rate benchmark reform – Phase 2 January 1, 2021 Those amendments on standards and interpretations had no effect on the consolidated financial statements of the Group. 4.2 Assessment of potential impact of future standards, amendments to existing standards and interpretations The following standards and interpretations have been issued by the IASB, but were not yet mandatory for the year ended December 31, 2021: Standard/interpretation Effective date Material effect expected Amendments to IFRS 3, ‘Business combinations’, IAS 16,’ Property, plant and equipment’, and IAS 37 ‘Provisions, contingent liabilities and contingent assets’ January 1, 2022 No Annual Improvements 2018-2020 January 1, 2022 No IFRS 17, ‘Insurance contracts’ as amended in June 2020 by amendments to IFRS 17, Insurance Contracts January 1, 2023 No Amendments to IAS 1, ‘Presentation of financial statements’, on classification of liabilities January 1, 2023 No Amendments to IAS 1, ‘Presentation of financial statements’, IFRS Practice statement 2 and IAS 8,’ Accounting policies, changes in accounting estimates and errors’ January 1, 2023 No

Summary of accounting policies

Summary of accounting policies applied by the Group for the annual reporting period ending December 31, 2021	12 Months Ended
	Dec. 31, 2021
Text Block [Abstract]
Disclosure of significant accounting policies [text block]	5. Summary of accounting policies applied by the Group for the annual reporting period ending December 31, 2021 The following are the significant accounting policies applied by the Group in preparing its consolidated financial statements: 5.1 Segment information The Group manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The Group’s focus is on the research and development of T cell redirecting immunotherapies for the treatment of cancer. The Chief Executive Officer is the chief operating decision maker who regularly reviews the consolidated operating results and makes decisions about the allocation of the Group’s resources. 5.2 Cash and cash equivalents Cash and cash equivalents in the Consolidated Statement of Financial Position is comprised of cash held at banks (including money market funds) and short-term deposits with an original maturity of three months or less. 5.3 Financial assets Initial recognition and measurement Financial assets within the scope of IFRS 9 include cash and cash equivalents, short-term deposits, bonds and receivables. Immatics determines the classification of its financial assets at initial recognition. All financial assets are recognized initially at fair value plus transaction costs. Purchases and sales of financial assets are recognized on their trade date, on which the Group commits to purchase or sell the asset. The subsequent measurement of financial assets depends on their classification as described below. Short-term deposits Immatics has short-term deposits with original maturities between three and nine months, which are classified as Other financial assets. Short-term deposits with an original maturity of three months or less are classified as cash and cash equivalents. Under IFRS 9 short-term deposits are classified within financial assets at amortized costs. Bonds Immatics holds bonds, which are classified as Other financial assets. The bonds` contractual cash flows represent solely payments of principal and interest and Immatics intends to hold the bonds to collect the contractual cash flows. The Group therefore accounts for the bonds as a financial asset at amortized cost. Receivables The Group has receivables from collaboration agreements. A receivable must be capitalized at the point in time at which the Group has become a contractual partner and a unconditional claim to cash and cash equivalents has arisen. In subsequent reporting periods, a receivable is measured at amortized cost using the effective interest method. Since the receivables are short-term receivables without a fixed interest rate, these receivables are capitalized at the original invoice or contract amount. Receivable balances are classified as current assets, because all of the Group’s receivables have an expected maturity of less than 12 months. Interest and other finance income and expense Interest income and expenses from financial instruments are recorded using the effective interest rate (“EIR”). EIR is the rate that discounts the estimated future cash payments or receipts over the expected life of the financial instrument or a shorter period, where appropriate, to the net carrying amount of the financial asset or liability. Interest income and expenses are classified as financial income and expense. As of December 31, 2020, Immatics was a counterparty in foreign exchange forward contracts. The contracts did not meet the criteria to apply hedge accounting and are therefore separately accounted for and measured at fair value. Any change in the fair value was considered within the Consolidated Statement of Loss. As of December 31, 2021, Immatics is not a counterparty in foreign exchange forward contracts. 5.4 Property, plant and equipment Property, plant and equipment is stated at cost, net of accumulated depreciation and accumulated impairment losses, if any. All repair and maintenance costs are recognized as expense when incurred. Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets. The estimated useful lives are generally within the following ranges:​​​​​​​ Category Estimated useful life Computer equipment 1 – 10 years Laboratory equipment 1 – 15 years Office equipment 2 – 20 years 5.5 Intangible assets Acquired intangible assets are initially recognized at cost. Following initial recognition, intangible assets are carried at cost less accumulated amortization and accumulated impairment losses, if any. Intangible assets with finite lives are amortized over their useful economic lives and assessed for impairment, whenever there is an indication that the intangible asset may be impaired. The amortization period and the amortization method for an intangible asset with a finite useful life, is reviewed at least at the end of each reporting period. Immatics does not have any internally developed intangible assets or intangible assets with indefinite useful lives. Immatics reviews potential triggering events to identify the need for an impairment test. Amortization is calculated on a straight-line basis over the estimated useful lives of the assets as follows: Category Estimated useful life Licenses 5 – 30 years Software 1 – 5 years 5.6 Research and development Research expenses are defined as costs incurred for current or planned investigations undertaken with the prospect of gaining new scientific or technical knowledge and understanding. All Research costs are expensed as incurred. An intangible asset arising from development expenditure on an individual project is recognized only when the Group can demonstrate the technical feasibility of completing the intangible asset so that it will be available for use or sale, its intention to complete and its ability to use or sell the asset, how the asset will generate future economic benefits, the availability of resources to complete and the ability to measure reliably the expenditure during the development. The Group did not recognize any intangible assets from development expenditures in 2021, 2020 and 2019 due to the existing uncertainties in connection with its development activities. Research and development expenses include the following types of costs: 1. salaries, benefits and other related costs, including stock-based compensation, for personnel engaged in research and development functions; 2. expenses incurred in connection with the preclinical development of our programs and clinical trials of our product candidates, including under agreements with third parties, such as consultants, contractors, academic institutions and contract research organizations; 3. the cost of manufacturing product candidates for use in clinical trials, including under agreements with third parties, such as, consultants and contractors; 4. laboratory costs; 5. leased facility costs, equipment depreciation and other expenses, which include direct and allocated expenses; and 6. intellectual property costs incurred in connection with filing and prosecuting patent applications as well as third-party license fees. 5.7 Financial liabilities: Initial recognition and measurement Financial liabilities within the scope of IFRS 9 are classified as financial liabilities at fair value through profit or loss or at amortized cost, as appropriate. The Group determines the classification of its financial liabilities at initial recognition. All financial liabilities are recognized initially at fair value and, in the case of loans and borrowings, carried at amortized cost. This includes directly attributable transaction costs. The Company’s financial liabilities include accounts payable, other current liabilities and warrant liabilities. Immatics recognized accounts payable and other current liabilities as other financial liabilities at amortized costs. Warrants are accounted for as derivative financial instruments and therefore as financial liabilities through profit and loss as they give the holder the right to obtain a variable number of ordinary shares. Such derivative financial instruments are initially recognized at fair value on the date on which the merger is consummated and are subsequently remeasured at fair value through profit or loss. The warrants will expire five years after the completion of the ARYA Merger or earlier upon redemption or liquidation in accordance with their terms. The Group does not engage in hedging transactions that meet the criteria to apply hedge accounting. 5.8 Leases The Group adopted IFRS 16 (“Leases”) effective January 1, 2019. The Group leases various offices, equipment and vehicles. Rental contracts are typically made for fixed periods of two to seven years but may have extension options as described in below. Contracts may contain both lease and non-lease elected not to separate lease and non-lease right-of-use Assets and liabilities arising from a lease are initially measured on a present value basis. Lease liabilities include the net present value of the following lease payments: 1. fixed payments (including in-substance 2. amounts expected to be payable by the Group under residual value guarantees. 3. the exercise price of a purchase option if the Group is reasonably certain to exercise that option; and 4. payments of penalties for terminating the lease, if the lease term reflects the Group exercising that option. The lease term consists of the non-cancellable right-of-use To determine the IBR, the Group: 1. uses a build-up 2. makes adjustments specific to the lease, including lease term, country, currency and security Right-of-use 1. the amount of the initial measurement of lease liability 2. any lease payments made at or before the commencement date less any lease incentives received 3. any initial direct costs, and 4. restoration costs. Right-of-use right-of-use Payments associated with short-term leases of equipment and vehicles and all leases of low-value Low-value Extension and termination options are included in a number of property and equipment leases across the Group. These are used to maximize operational flexibility in terms of managing the assets used in the Group’s operations. The extension and termination options held are exercisable only by the Group and not by the respective lessor. For relevant leases which include an extension option, Immatics performed an assessment as of December 31, 2021 to determine whether option extensions are reasonably certain. 5.9 Revenue from collaboration agreements The Group earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. As of December 31, 2021, the Group had three strategic collaboration agreements in place with Genmab A/S, Copenhagen/Denmark (“Genmab”), Celgene Switzerland LLC (“BMS”) and GlaxoSmithKline Intellectual Property Development Limited (“GSK”). Each of the Group’s three strategic collaboration agreements are in the pre-clinical 20 To determine the recognition of revenue from arrangements that fall within the scope of IFRS 15, the Group performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Group satisfies a performance obligation. Under the terms of these agreements, Immatics agrees to collaborate in the development, manufacture, and commercialization of cancer immunotherapy treatments for specified targets identified through the use of Immatics XPRESIDENT technology. As part of the collaboration arrangements, Immatics grants licensing rights for the development and commercialization of future product candidates, developed for targets defined in the collaboration agreements. Additionally, Immatics agrees to perform certain research activities under the collaboration agreements, including screening of highly specific molecules for reactivity with the specified targets and off-targets know-how, The Group performs an analysis to identify the performance obligations under the contract, including licenses and rights to future intellectual property developed under the contract and research activities. As these agreements comprise several promises, it must be assessed whether these promises are capable of being distinct and distinct within the context of the contract. Up-front cost-to-cost The licenses contributed under the collaboration agreements currently in place do not represent distinct performance obligations, because the Group’s collaboration partners would likely be unable to derive significant benefits from their access to these targets without Immatics’ research activities. Identification of a viable product candidate that will bind to the targets specified in the agreements requires use of the Group’s XPRESIDENT technology and database of target and off-target non-refundable Under IFRS 15, the Group applies significant judgement when evaluating whether the obligations under these agreements represent one or more combined performance obligations, the allocation of the transaction price to identified performance obligations, and the determination of whether milestone payments should be included in the transaction price. Upfront payment Each of the Group’s strategic collaboration agreements included a non-refundable cost-to-cost The cost-to-cost Reimbursement for services Under the collaboration agreement with Genmab, the Group receives reimbursement for employee research and development costs. These employee costs are presented as research and development expenses, while reimbursements of those costs, which is based on an FTE rate defined in the contract, are presented as revenue and not deducted from expenses. Development and Commercial Milestones The collaboration agreements include contingent payments related to development and commercial milestone events. These milestone payments represent variable consideration that are not initially recognized within the transaction price, due to the scientific uncertainties and the required commitment from the collaboration partners to develop and commercialize a product candidate. The Group assesses the probability of significant reversals for any amounts that become likely to be realized prior to recognizing the variable consideration, associated with these payments within the transaction price. Sales-based milestones and royalty payments The collaboration agreements also include sales-based royalty payments upon successful commercialization of a licensed product. In accordance with IFRS 15.B63, the Group recognizes revenue from sales-based milestone and royalty payments at the later of (i) the occurrence of the subsequent sale; or (ii) the performance obligation to which some or all of the sales-based milestone, or royalty payments has been allocated. The Group anticipates recognizing these milestones and royalty payments, when subsequent sales are generated from a licensed product by the collaboration partner. Cost to fulfill contracts The Group incurs costs for personnel, supplies and other costs related to its laboratory operations as well as fees from third parties and license expenses in connection with its research and development obligations under the collaboration and licensing agreement. These costs are recognized as research and development expenses over the period in which services are performed. Cost to obtain a contract For some collaboration agreements, the Group incurs incremental costs of obtaining a contract with a customer. The Group capitalizes those incremental costs if the costs are expected to be recovered. The recognized asset is amortized consistent with the method used to determine the pattern of revenue recognition of the underlying contract. 5.10 Share-based payment The Group’s employees as well as others providing similar services to the Group, receive remuneration in the form of share-based payments, which are equity-settled transactions. The Group`s equity-settled option plans include Matching Stock Options, Converted Stock Options, Service Options and PSUs and are described in detail in Note 18. The costs of equity-settled transactions are determined by the fair value at grant date, using an appropriate valuation model. Share-based expenses for the respective vesting periods, are recognized in research and development expenses and general and administrative expenses, reflecting a corresponding increase in equity. 5.11 Other income The Group primarily earns other income from government research grants. Government grants are recognized as income when there is reasonable assurance that the grant will be received and all required conditions have been complied with. Grants from governmental agencies for the support of specific research and development projects are recorded as other income to the extent the related expenses have been incurred. Grant agreements include a budget that specifies the amount and nature of expenses allowed during the entire grant term. Expenses incurred under the grants are calculated according to agreed-upon terms on a quarterly basis, filed with the governmental agencies, and recorded as income. The governmental agencies make payments to the Group based on these calculations of expenses incurred under the grants. If these estimated calculations change, the Group will then adjust grant income in the subsequent period. The Group believes that its calculations are based on the agreed-upon terms as stated in the grant agreements. The governmental agencies generally have the right to audit the Group’s calculations. If the governmental agencies disagree with the Group’s calculations the amount of grant income recognized could change. 5.12 Foreign currency Transactions and balances in Germany and in the USA The consolidated financial statements are presented in Euro, which is the parents’, Immatics N.V. functional and reporting currency. Assets and liabilities of foreign operations are translated into Euros at the rate of exchange prevailing at the reporting date. The Consolidated Statement of Loss is translated at average exchange rates. The currency translation differences are recognized in other comprehensive loss. Transactions in foreign currencies are initially recorded by the Group’s entities at their respective functional currency spot rates, at the date the transaction first qualifies for recognition. The Group determined the functional currency of Immatics Biotechnologies GmbH to be Euros and of Immatics US Inc. to be USD. The Group used the following exchange rates to convert the financial statements of its U.S. subsidiary: 2021 2020 2019 Year-end Average Year-end Average Year-end Average Euros per U.S. Dollar 0.88292 0.84495 0.8149 0.8762 0.8902 0.8932 5.13 Fair value of financial instruments Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either: • in the principal market for the asset or liability or • in the absence of a principal market, in the most advantageous market for the asset or liability that is accessible by the Group. The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest. The Group uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximizing the use of relevant observable inputs and minimizing the use of unobservable inputs. All assets and liabilities for which fair value is measured or disclosed in the consolidated financial statements are categorized within the fair value hierarchy, described as follows, based on the lowest level input that is significant to the fair value measurement as a whole: • Level 1 — Quoted (unadjusted) market prices in active markets for identical assets or liabilities. • Level 2 — Valuation techniques, for which the lowest level input that is significant to the fair value measurement is directly or indirectly observable. • Level 3 — Valuation techniques, for which the lowest level input that is significant to the fair value measurement is unobservable. For assets and liabilities that are recognized in the consolidated financial statements at fair value on a recurring basis, the Group determines whether transfers have occurred between levels in the hierarchy by re-assessing 5.14 Provisions Provisions are recognized when the Group has a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. Where the Group expects some or all of a provision to be reimbursed, for example under an insurance contract, the reimbursement is recognized as a separate asset but only when it is virtually certain that reimbursement will be received if the Group settles the obligation. If the effect of the time value of money is material, provisions are discounted using a current pre-tax 5.15 Income Tax Deferred income tax results from temporary differences between the carrying amount of an asset or a liability and its tax base. Deferred income tax is provided in full using the liability method on temporary differences. In accordance with IAS 12 (“Income Taxes”), the deferred tax assets and liabilities reflect all temporary valuation and accounting differences between financial statements prepared for tax purposes and our consolidated financial statements. Tax losses carried forward are considered in deferred tax assets calculation. The Group offsets tax assets and liabilities if and only if it has a legally enforceable right to set off current tax assets, current tax liabilities, deferred tax assets and deferred tax liabilities which relate to income taxes levied by the same tax authority.

Significant accounting judgment

Significant accounting judgments, estimates and assumptions	12 Months Ended
	Dec. 31, 2021
Text Block [Abstract]
Significant accounting judgments, estimates and assumptions	6. Significant accounting judgements, estimates and assumptions The preparation of the Group’s consolidated financial statements requires management to make judgements, estimates and assumptions that affect the reported amounts of revenue, expenses, assets and liabilities, income taxes and the accompanying disclosures. Uncertainty about these assumptions and estimates could result in outcomes that require a material adjustment to the carrying amount of the asset or liability affected in future periods. Estimates – Taxes Uncertainties exist with respect to the interpretation of complex tax regulations, changes in tax laws, and the amount and timing of future taxable income. Given the wide range and complexity of existing contractual agreements, differences arising between the actual results and the assumptions made, or future changes to such assumptions, could necessitate future adjustments to tax income and expense already recorded. Deferred tax assets are recognized for unused tax losses to the extent, that it is probable that taxable profit will be available which can be utilized against the losses. Significant management judgement is required to determine the amount of deferred tax assets that can be recognized, based upon the likely timing and the level of future taxable profits together with future tax planning strategies. Due to the Group’s history of loss-making over the last several years as well as the plans for the foreseeable future, the Group has not recognized any deferred tax assets on tax losses carried forward. Changes in the estimation of our potential to use tax losses carried forward can have a material effect on the Group`s net income. Revenue recognition from collaboration agreements As the collaboration agreements comprise several promises, it must be assessed whether these promises are capable of being distinct within the context of the contract. For the three collaboration agreements the Group assessed that these promises are not capable of being distinct within the context of the contract, which results in accounting for all goods and services promised as a single performance obligation with a single measure of progress. The performance obligation is accounted for as a performance obligation, satisfied over time using a cost-to-cost Up-front Immatics provides development and manufacturing services to customers and recognizes revenue over time using an input-based method to measure progress toward complete satisfaction of the service, because the customer simultaneously receives and consumes the benefits provided. Forecast values are used for the calculation of expected future revenue for the remaining term of the contract. These costs estimated as part of the budgeting process must be reviewed and approved before the Group can use them for recognition purposes. Significant management judgment is required to determine the level of effort required under an arrangement, and the period over which the Company expects to complete its performance obligations under the arrangement which includes total internal personnel costs and external costs to be incurred. Changes in these estimates can have a material effect on revenue recognized. Share-based payments Determining the fair value of share-based payment transactions requires the most appropriate valuation for the specific program, which depends on the underlying terms and conditions. Management determined the value of share-based awards with the assistance of a third-party valuation specialist using certain assumptions, such as volatility, risk-free interest rate, exercise pattern and expected dividends. Changes in these estimates can have a material effect on share-based expenses recognized. For 2019, the vested SARs under the 2010 Plan could only be exercised in an event that more than 50% of the shareholdings in the Company will be acquired by a third person (“Change of control”) and the vested SARs of the 2016 Plan might only be exercised upon the occurrence of a change in control or expiration of the applicable lock-up Classification of Warrants As of December 31, 2021, there were 7,187,500 Immatics Warrants outstanding, which were assumed as part of the ARYA Merger (see Note 3). The warrants entitle the holder to purchase one ordinary share of Immatics N.V. at an exercise price of $11.50 per share. Until warrant holders acquire the Groups ordinary shares upon exercise of such warrants, they will have no rights with respect to the Groups ordinary shares. The warrants will expire on July 1, 2025, five years after the ARYA Merger close date, or earlier upon redemption or liquidation in accordance with their terms. As described in Note 3 ARYA Merger Immatics Warrants give the holder the right, but not the obligation, to subscribe to Immatics’ shares at a fixed or determinable price for a specified period of time subject to the provision of the Warrant Agreement. Those instruments were considered to be part of the net assets acquired and therefore, management applied the provisions of debt and equity classification under IAS 32. Due to an option of cashless exercise of the Immatics Warrants, which gives Immatics a choice over how the warrant is settled with a settlement alternative, that results in Immatics delivering a variable number of shares. Therefore, the Immatics Warrants are accounted for as a financial liability through profit and loss.

Accounts receivable

Accounts receivable	12 Months Ended
	Dec. 31, 2021
Text Block [Abstract]
Accounts receivable	7. Accounts receivable As of December 31, December 31, (Euros in thousands) Receivables from collaboration agreements 682 1,250 Accounts receivable 682 1,250 As of December 31, 2021, and 2020, no receivables were considered impaired.

Other current and non-current a

Other current and non-current assets	12 Months Ended
	Dec. 31, 2021
Text Block [Abstract]
Other current and non-current assets	8. Other current and non-current Other current assets As of December 31, December 31, (Euros in thousands) Grant receivable 762 875 Prepaid expenses 3,781 2,389 Positive market value forward contract — 914 Value added tax receivable 915 798 Other assets 950 787 Other current assets 6,408 5,763 The Group recognizes receivables for government grants when it is reasonably assured that the grant will be received, and all contractual conditions have been complied with. As of December 31, 2021, and 2020, no Prepaid expenses include prepaid insurance expenses of € million and € million as of December , and , respectively. The Group accrued € million and € million of incremental cost for the successful arrangement of the BMS and Genmab collaboration agreements as of December , and , respectively. Additionally, prepaid expenses include expenses for licenses and software of € million and € million as of December , and , respectively. Furthermore prepaid expenses include expenses for maintenance of € million and € million as of December , and , respectively. The remaining amount is related to CRO expenses. Other assets include receivables from capital gains tax of € million and € million as of December , and , respectively. The remaining amount is mainly related to prepaid deposit expenses. Other non-current As of December 31, December 31, (Euros in thousands) Prepaid expenses 636 724 Total non-current 636 724 Prepaid expenses consist of €0.3 million and €0.7 million of incremental cost paid for the successful arrangement of the BMS and Genmab collaboration agreements as of December 31, 2021 and 2020, respectively. The remaining amount is related to a long-term maintenance contract.

Property, plant and equipment

Property, plant and equipment	12 Months Ended
	Dec. 31, 2021
Text Block [Abstract]
Property, plant and equipment	9. Property, plant and equipment Changes to property, plant and equipment during 2021 and 2020 consisted of the following: (Euros in thousands) Laboratory Computer Office Total Cost as of January 1, 2020 12,723 2,956 1,753 17,432 Additions 3,545 406 1,427 5,379 Disposals 1 — 6 7 Currency translation differences 299 40 28 367 Cost as of December 31, 2020 15,968 3,322 3,146 22,437 Accumulated depreciation as of January 1, 2020 9,303 2,050 1,359 12,712 Additions 1,384 404 315 2,102 Disposals 1 — 6 7 Currency translation differences 210 26 3 239 Accumulated depreciation as of December 31, 2020 10,476 2,428 1,665 14,568 Net book value as of December 31, 2020 5,493 894 1,481 7,868 Cost as of January 1, 2021 15,968 3,322 3,146 22,437 Additions 3,487 1,105 489 5,081 Disposals 144 — — 144 Currency translation differences 319 43 26 388 Cost as of December 31, 2021 19,630 4,470 3,661 27,761 Accumulated depreciation as of January 1, 2021 10,476 2,428 1,665 14,568 Additions 1,501 508 565 2,574 Disposals 144 — — 144 Currency translation differences 219 30 7 256 Accumulated depreciation as of December 31, 2021 12,052 2,966 2,237 17,255 Net book value as of December 31, 2021 7,578 1,504 1,424 10,506 Year ended December 31, 2021 2020 2019 (Euros in thousands) Research and development expenses 1,684 1,502 1,315 General and administrative expenses 890 600 482 Total 2,574 2,102 1,797

Intangible assets

Intangible assets	12 Months Ended
	Dec. 31, 2021
Text Block [Abstract]
Intangible assets	10. Intangible assets Changes to intangible assets during 2021 and 2020 consisted of the following: (Euros in thousands) Patents Software Total Cost as of January 1, 2020 1,220 643 1,863 Additions — 104 104 Currency translation differences (88 ) (9 ) (97 ) Cost as of December 31, 2020 1,132 738 1,870 Accumulated amortization as of January 1, 2020 369 486 855 Additions 56 71 126 Currency translation differences (22 ) (3 ) (25 ) Accumulated amortization as of December 31, 2020 403 554 957 Net book value as of December 31, 2020 730 184 914 Cost as of January 1, 2021 1,132 738 1,870 Additions 320 162 481 Currency translation differences 99 8 107 Cost as of December 31, 2021 1,551 908 2,459 Accumulated amortization as of January 1, 2021 403 554 957 Additions 54 106 160 Currency translation differences 23 4 27 Accumulated amortization as of December 31, 2021 480 664 1,144 Net book value as of December 31, 2021 1,071 244 1,315 Amortization expense is classified as follows within the Consolidated Statement of Loss: Year ended December 31, 2021 2020 2019 (Euros in thousands) Research and development expenses 35 31 28 General and administrative expenses 125 95 83 Total 160 126 111

Leases

Leases	12 Months Ended
	Dec. 31, 2021
Presentation of leases for lessee [abstract]
Leases	11. Leases Right-of As of December 31, December 31, (Euros in thousands) Buildings 9,028 5,760 Laboratory equipment 669 — IT and telecommunication 177 258 Vehicles 74 90 Other assets 34 41 Total 9,982 6,149 Lease liabilities consist of the following: As of December 31, December 31, (Euros in thousands) Lease liability – current 2,711 1,881 Lease liability – non-current 7,142 4,306 Total 9,853 6,187 Additions to the right-of-use and liab i Currency translation differences included in right-of-use Expenses related to right-of-use Year ended December 31, Depreciation charges of right-of-use 2021 2020 (Euros in thousands) Buildings 2,199 2,036 Laboratory equipment 162 — IT and telecommunication 98 101 Vehicles 59 50 Other assets 8 8 Total 2,526 2,195 Interest expenses from leases 288 260 Expense relating to short-term leases and low-value 95 51 The total cash payments for leases were €3.2 million and €2.4 million as of December 31, 2021 and 2020, respectively. As of December 31, 2021, the Group has committed lease payments associated with lease liability of €10.3 million, of which €2.9 million will occur in the next 12 months. The remaining lease payments will occur between January 1, 2023 and March 31, 2028.

Accounts payable

Accounts payable	12 Months Ended
	Dec. 31, 2021
Text Block [Abstract]
Accounts payable	12. Accounts payable As of December 31, December 31, (Euros in thousands) Accounts payable 3,009 2,554 Other accrued liabilities 8,615 7,498 Total accounts payable 11,624 10,052 Other accrued liabilities classified within accounts payable mainly relate to outstanding invoices totaling €8.6 million and €7.5 million as of December 31, 2021 and 2020, respectively.

Revenue from collaboration agre

Revenue from collaboration agreements	12 Months Ended
	Dec. 31, 2021
Text Block [Abstract]
Revenue from collaboration agreements	13. Revenue from collaboration agreements The Group earns revenue through strategic collaboration agreements with third party pharmaceutical and biotechnology companies. As of December 31, 2021, the Group had three strategic collaboration agreements in place after one collaboration was terminated. All collaboration agreements are still at pre-clinical As part of these collaboration arrangement, Immatics grants exclusive licensing rights or options thereto for the development and commercialization of future product candidates, developed for several targets defined in the respective collaboration agreements, in addition to research activities, including screening of highly specific molecules for reactivity with the specified targets and off-targets know-how, Immatics reassessed the total forecasted cost as part of the Group’s annual budget process and adjusted the total forecasted cost accordingly. Amgen Collaboration Agreement In December 2016, Immatics Biotechnologies GmbH entered into a research collaboration and license agreement with Amgen to develop next-generation, T cell engaging bispecific immunotherapies targeting multiple cancers. Under the terms of the agreement, Immatics contributed its XPRESIDENT target discovery and T cell receptor (“TCR”) capabilities to the pre-clinical ® ” The Group received a non-refundable cost-to-cost cost-to-cost The collaboration with Amgen has been discontinued in October 2021. As a result, the Group will not receive any future milestone or royalty payments under the collaboration. The Group recognized the remaining deferred revenue balance of €10.2 million as of December 31, 2021, no further revenue will be recognized from the collaboration thereafter. The Group recognized €10.2 million, €4.9 million and €6.2 million of revenue associated with the upfront payment during the years ended December 31, 2021, 2020 and 2019, respectively. Total deferred revenue under the agreement was €0.0 million and €10 million as of December 31, 2021 and 2020 respectively. Genmab Collaboration Agreement In July 2018, Immatics Biotechnologies GmbH entered into a research collaboration and license agreement with Genmab to develop next-generation, T cell engaging bispecific immunotherapies targeting multiple cancer indications. Under the agreement, Immatics and Genmab conduct joint research to combine Immatics’ XPRESIDENT and Bispecific TCR technology platforms with Genmab’s proprietary antibody technologies to develop multiple bispecific immunotherapies in oncology. The two companies plan to develop immunotherapies directed against three proprietary targets. Genmab will be responsible for development, manufacturing and worldwide commercialization. Immatics will have an option to contribute certain promotion efforts at predetermined levels in selected countries in the EU. The Genmab collaboration agreement contains a maximum of $550 million of milestone payments for each licensed product resulting from the collaboration. In addition, Immatics is entitled to receive royalty payments. Royalty rates are based on aggregate net sales of a licensed product. The agreement provides for higher royalty rates as annual net sales of a licensed product increases. Under the agreement, the royalty rates begin in the high single-digits, increasing to the low tens as a percentage of aggregate annual net sales of a licensed product. The Group received a non-refundable and €11.2 million of revenue associated with cost-to-cost cost-to-cost BMS Collaboration Agreement In August 2019, Immatics Biotechnologies GmbH and BMS entered into a collaboration and option agreement to develop novel adoptive cell therapies targeting multiple cancers. Under the agreement, Immatics may develop T Cell Receptor Engineered T Cell Therapy (TCR-T) TCR-T opt-in TCR-T Immatics would have certain early-stage co-development co-funding TCR-T million for each licensed product in option exercise payments, development, regulatory and commercial milestone payments as well as tiered royalties on net sales. In addition, Immatics is entitled to royalty payments. Royalty rates are based on aggregate net sales of a licensed product resulting from the collaboration. The agreement provides for higher royalty rates as annual net sales of a licensed product increases. Under each contract, the royalty rates begin in the mid-single-digits, The Group received a non-refundable cost-to-cost cost-to-cost respectively. GSK In December 2019, Immatics entered into a collaboration agreement with GSK to develop novel adoptive cell therapies targeting multiple cancer indications. Immatics and GSK plan to collaborate on the identification, research and development of next-generation TCR Therapeutics focusing on solid tumors. The collaboration will initially focus on the development of autologous T cell therapies and GSK has an option to develop allogeneic T cell therapies using Immatics ACTallo approach. Immatics and GSK intend to utilize proprietary TCRs identified by Immatics TCR discovery platform XCEPTOR which are planned to be directed against two proprietary targets. Those proprietary targets were discovered and validated by the respective XPRESIDENT technology. Immatics will be mainly responsible for the development and validation of the TCR-T TCR-T co-develop TCR-Ts The Group received a non-refundable The Group classified the initial receipt of the upfront payment as deferred revenue. The Group recognized €4.5. million and €3.7 million of revenue associated with the upfront payment as of December 31, 2021 and 2020, respectively. The Group has not recognized revenue associated with the upfront payment during 2019. Total deferred revenue under the agreement was €37 million and €41 million as of December 31, 2021 and 2020, respectively. The Group has not recognized any royalty or milestone revenue under the collaboration agreements, due to the scientific uncertainty of achieving the milestones or the successful commercialization of a product. As of December 31, 2021, Immatics had not received any milestone or royalty payments in connection with the collaboration agreements. The Group plans to recognize the remaining deferred revenue balance into revenue as it performs the related performance obligations under each contract. Deferred revenue related to the collaboration agreements consist of the following: As of December 31, December 31, (Euros in thousands) Current 50,402 46,600 Non-current 48,225 85,475 Total 98,627 132,075 Cost to obtain a contract The Group incurred costs from a third party, who assists in identifying collaboration partners. The Group recognizes an asset to the extent these costs are incremental and directly related to a specific contract. The Group then amortizes the asset consistently with the pattern of revenue recognition for the related contracts. Total assets, net of amortization, for these capitalized costs of obtaining a contract were €0.9 million and €1.2 million as of December 31, 2021 and 2020, respectively, which are classified in other current assets and other non-current As of December 31, 2021, the Group is potentially liable to pay €1.6 million ($2 million) to a third-party upon successful completing the milestone of the first clinical lead selection in connection with Immatics’ collaboration agreements. The Group does not recognize a liability for these contingent payments due to the scientific uncertainty of achieving the related milestones. Each of the Group’s strategic collaboration agreements included a non-refundable

Other income

Other income	12 Months Ended
	Dec. 31, 2021
Text Block [Abstract]
Other income	14. Other income Other income includes grant income andimmaterial amounts from other sources. The Group receives income through government grants for specific research and development projects. The Group recognizes grant income as it performs research and development activities specified by the grant agreements. Total grant income was €0.0 million, €0.2 million, and €0.03 million during the years ended December 31, 2021, 2020 and 2019, respectively. There are no unfulfilled conditions or contingencies attached to these grants. The Group had a receivable under these agreements of €0.8 million and €0.9 million as of December 31, 2021 and 2020, respectively. The Group classifies receivables under these agreements within other current assets.

Other current liabilities

Other current liabilities	12 Months Ended
	Dec. 31, 2021
Text Block [Abstract]
Other current liabilities	15. Other current liabilities The components of other current liabilities are: As of December 31, December 31, (Euros in thousands) Payroll tax 1,760 1,185 Accrual for vacation 607 525 Accrued bonuses — 154 Other 134 161 Total 2,501 2,025 Other current liabilities are non-interest-bearing

Financial income and expenses

Financial income and expenses	12 Months Ended
	Dec. 31, 2021
Text Block [Abstract]
Financial income and expenses	16. Financial income and expenses Financial income and financial expenses consist of the following: Year ended December 31, 2021 2020 2019 (Euros in thousands) Interest income from short-term deposits 133 850 790 Foreign currency gains 5,542 — — Gain on other financial instruments — 2,099 — Financial income 5,675 2,949 790 Interest expenses (566 ) (289 ) (170 ) Foreign currency losses (276 ) (9,774 ) (94 ) Losses on other financial instruments (884 ) — — Financial expenses (1,726 ) (10,063 ) (264 ) Foreign currency gains and losses mainly consist of realized and unrealized gains and losses in connection with our USD holdings of both cash and cash equivalents as well as short-term deposits. Losses on other financial instruments includes an unrealized loss of 0.9 million and a realized gain of 0.03 million from foreign currency forward contracts for the year ended December 31, 2021. Gain on other financial instruments includes an unrealized gain of 0.9 million and a realized gain of 1.2 million from foreign currency forward contracts for the year ended December 31, 2020.

Share listing expense and chang

Share listing expense and change in fair value of warrant liabilities	12 Months Ended
	Dec. 31, 2021
Text Block [Abstract]
Share listing expense and change in fair value of warrant liabilities	17. Share listing expense and change in fair value of warrant liabilities As described in Note , the ARYA Merger led to a share listing expense. Immatics issued shares with a fair value of € million to ARYA shareholders, comprised of the fair value of Immatics shares, that were issued to ARYA shareholders of € per share. In exchange, Immatics received the identifiable net assets held by ARYA, which had a fair value upon closing of € million, comprising of cash and cash equivalents held in ARYA’s trust account partly offset by current liabilities by ARYA and financial liabilities in the amount of € million accounted for the ARYA Warrants considering a fair value of the warrants of € per warrant (price of ARYA Warrants at Closing of the ARYA Merger). The excess of the fair value of the equity instruments issued over the fair value of the identified net assets contributed, represents a non-cash one-time million, is recognized as Share listing expense presented as part of the financial result within the Consolidated Statement of Loss. Details of the calculation of the Share listing expense are as follows: (Euros in thousands, except share and per share data) Description Amount Number of shares/warrants (a) ARYA Ordinary Shares — 17,968,750 (b) Closing price of ARYA Ordinary Shares on Nasdaq as of July 1, 2020 € 13.53 — (c) Fair value of TopCo Shares issued to ARYA shareholders (a * b) € 243,071 — (d) Outstanding ARYA Warrants — 7,187,500 (e) Closing price of ARYA Warrants on Nasdaq as of July 1, 2020 € 4.82 — (f) Fair value of outstanding ARYA Warrants (d * e) € 34,644 — (g) Cash and cash equivalents held in ARYA’s trust account € 128,849 (h) Current liabilities by ARYA € 3,921 ARYA’s identifiable net assets (g-f-h) € 90,284 — IFRS 2 Expense on the closing date € 152,787 — Upon closing of the ARYA Merger, ARYA Warrants were converted into Immatics Warrants. The financial liability for the Immatics Warrants is accounted for at fair value through profit and loss. The fair value of warrants increased from €2.35 per warrant as of December 31, 2020 to €3.88 per warrant as of December 31, 2021. The result is a increase in fair value of warrant liabilities of €11.0 million for the year ended December 31, 2021. The fair value of warrants decreased from €4.82 per share as of July 1, 2020 to €2.35 per share as of December 31, 2020. The result is a change in fair value of warrant liabilities of €17.8 million for the year ended December 31, 2020.

Share-based payments

Share-based payments	12 Months Ended
	Dec. 31, 2021
Text Block [Abstract]
Share-based payments	18. Share-based payments Immatics Biotechnologies GmbH previously issued share-based awards to employees under two different plans. Under the Immatics Biotechnologies GmbH Stock Appreciation Program 2010 (the “2010 Plan”), the Company issued stock appreciation rights (“SARs”), which the Group accounted for as cash-settled awards. Under the Immatics Biotechnologies 2016 Equity Incentive Plan (“2016 Plan”), the Company issued tandem awards, which allowed employees to exercise their awards as either a SAR or a stock option. In 2020, prior to the ARYA Merger, Immatics N.V. established the new equity incentive plan (“2020 Equity Plan”). As part of the ARYA Merger, the 2010 Plan and the 2016 Plan were converted and were superseded by the 2020 Equity Plan as described below. Share appreciation rights (“the 2010 Plan”) Effective January 1, 2005, in addition to performance-related compensation, certain Immatics employees became eligible to participate in a Stock Appreciation Rights (SAR) Program as part of a long-term equity incentive scheme. The aim of this program was to give employees a long-term stake in the success of the Company. The SAR program was adopted by resolutions by the supervisory board in January 2005 and was subsequently amended on February 6, 2007 and September 7, 2010. Under the 2010 Plan, the beneficiaries received SAR awards, which did not require any cash investment into the company. SARs granted under this program carried no dividend or voting rights. The award holders had the right to execute the vested SARs only in a defined exit event. An exit event was defined as the acquisition of more tha n 50.00% of the outstanding shares by a third party. SARs granted under the 2010 Plan vested based on the satisfaction of service requirements (time-based vesting). These awards generally had a five-year graded vesting period. Employees leaving the Group were able to retain any vested awards as of their termination date, unless they were terminated for cause. Per the terms of the SAR agreements, employees were not entitled to subscribe to shares in the Group. Therefore, SARs granted under the 2010 Plan might be settled in cash only. As awards issued under the 2010 Plan were cash settled, the Group applied liability accounting and revalued the outstanding awards at each reporting date. The Group applied a Black Scholes pricing model to estimate the fair value of the SARs as of December 31, 2019 and 2018 based on a company value of $350,000 thousand and $160,000 thousand, respectively. December 31, Amounts in USD 2019 2018 Exercise price $ 1.12 $ 1.12 Underlying share price $ 67.87 $ 27.21 Volatility 73 % 64 % Time period (years) 1.25 5.00 Risk free rate 1.59 % 2.77 % Dividend yield 0.00 % 0.00 % Combined probability of exit events 80.00 % 25.00 % Expected volatility was determined by calculating the historic volatility in share prices of peer companies within the biotechnology industry. The expected life in the model has been adjusted, based on management’s best estimate, for the effects of non-transferability Set out below are summaries of SARs issued during 2019 and 2018: 2019 2018 Weighted average Number Weighted average Number SARs outstanding at January 1, $ 1.12 43,675 $ 1.12 43,978 SARs granted — — SARs forfeited 1.12 220 1.12 303 SARs outstanding at December 31, 1.12 43,455 1.12 43,675 SARs vested $ 1.12 117 $ 1.12 169 SARs exercisable — — There were no awards issued under the 2010 Plan as of December 31, 2020, 2019 or 2018. Resulting from these awards Immatics had other non-current 2016 Equity Incentive Plan (“the 2016 Plan”) On February 8, 2017, the Company established the “2016 Equity Incentive Plan” to provide employees and consultants of the Group the ability to share in the Company’s future success. Awards issued under the 2016 Plan were tandem awards, which consisted of an option to acquire a stated number of shares at a stated exercise price, or alternatively, the right to receive any appreciation in the value of the stated number of shares (“SAR portion”). Generally, the tandem awards issued under the 2016 Plan had a five-year vesting period. The first annual tranche vested on the first anniversary of the grant date. Following the first anniversary, the awards continued to vest on a monthly basis. Vesting was contingent on the recipient’s continued service to the Group. Employees which left the Group were able to retain any awards vested as of their termination date, unless they were terminated for cause. Former employees forfeited their awards, if they remained unexercised more than three months after an IPO or change in control. In the event of a change in control, the unvested portion of the Tandem Award should immediately vest. The Tandem Award (to the extent vested) might only be exercised after the contribution of all Immatics shares to a holding company for purposes of an indirect IPO, a change in control, or the expiration of a certain lock-up Under the terms of the 2016 Plan, options had to be settled in equity shares of the Group, while SAR portions might be settled in either equity shares or cash, at the Group’s discretion. While the Group did not have a policy or prior history of settling these awards, it intended to settle outstanding awards in equity shares. As a result, the Group was treating awards issued under the 2016 plan as equity settled. Subsequent settlements of SARs in cash, to the extent they occurred, would be recorded via an adjustment to equity. Each option or SAR issued under the plan might be settled for one common share of the Group in the event it is exercisable. Set out below are summaries of tandem awards issued during 2019 and 2018: 2019 2018 Weighted average Number Weighted average Number Tandem Awards outstanding at January 1, $ 16.65 74,401 $ 16.65 31,880 Tandem awards granted in June to September 18.30 26,557 16.65 43,964 Tandem awards granted in December 23.82 5,447 Tandem awards forfeited 16.81 2,936 16.65 1,443 Tandem awards outstanding at December 31, 17.45 103,469 16.65 74,401 Tandem awards vested $ 16.76 16,238 $ 16.65 14,350 Tandem awards exercisable — — Weighted average remaining contract life (years) 8.56 9.12 Weighted average fair value of options granted in USD till September 10.27 4.51 Weighted average fair value of options granted in USD for December 53.41 — The Group used a Black Scholes pricing model to estimate the fair value of equity settled tandem awards issued during 2019 until September 2019, based on a company valuation of $160 million. The fair value of tandem awards issued in December 2019 was based on a company valuation of $350 million. Amounts in USD December 2019 June 2019 - December 2018 Exercise price in USD $ 23.82 $ 18.30 $ 16.65 Underlying share price in USD $ 67.87 $ 16.94 $ 27.21 Volatility 73 % 78 % 64 % Time period (years) 1.25 2.10 5.00 Risk free rate 1.59 % 2.04 % 2.77 % Dividend yield 0.00 % 0.00 % 0.00 % Combined probability of exit events 80.00 % 60.00 % 25.00 % Expected volatility was determined by calculating the historic volatility in share prices of peer companies within the biotechnology industry. The expected life in the model has been adjusted, based on management’s best estimate, for the effects of non-transferability Conversion of 2010 Plan and 2016 Plan in connection with ARYA Merger As part of the ARYA Merger, all outstanding awards under the 2010 Plan and 2016 Plan were replaced by a combination of cash payments and share-based awards under the 2020 Equity Plan in Immatics N.V. Cash Payments In accordance with the employee award agreements, holders of vested awards under the 2010 Plan and 2016 Plan (including any awards scheduled to vest prior to 2021), agreed to receive a cash payment of $10.00 per award, less the applicable exercise price (“Award Cash Proceeds”). Per the terms of the employee award agreements, active employees were required to re-invest 25%-50% re-invest These cash payments represent a modification of awards previously issued under the 2010 Plan and 2016 Plan. The Group recognized €2.6 million in operating expense related to the modification of awards issued under the 2010 Plan and previously accounted for as a liability. The Group also recognized €4.3 million as a reduction in share premium, associated with the modification from previously equity-settled tandem awards, which were settled in cash as part of the modification. Share-based Awards The share-based awards, that were received by employees as part of the conversion, consisted of Re-investment In accordance with the employee re-investment (“Re-investment Re-investment For each ordinary Re-investment ten-year The Matching Stock Options award agreements had a service commencement date in June 2020. However, the grant date criteria for these awards, as specified in IFRS 2 and the underlying award agreements, were not met until July 1, 2020. Based on the July 1, 2020 grant date the Group assigned a fair value of $10.59. Immatics applied a Black Scholes pricing model to estimate the fair value of the Matching Stock Options, which the Group records as an expense over the four-year graded vesting period. As of June 30, Exercise price in USD $ 10.00 Underlying share price in USD $ 15.15 Volatility 75 % Time period (years) 5.5 Risk free rate 0.29 % Dividend yield 0.00 % Matching Stock Options outstanding as of December 31, 2021: 2021 Weighted average Number Matching Stock Options outstanding on January 1, 10.00 1,422,556 Matching Stock Options forfeited 10.00 9,254 Matching Stock Options exercised 10.00 6,834 Matching Stock Options expired — — Matching Stock Options outstanding on December 31, 10.00 1,406,468 Matching Stock Options vested 10.00 1,413,302 Weighted average remaining contract life (years) 8.50 Matching Stock Options outstanding as of December 31, 2020: 2020 Weighted average Number Matching Stock Options outstanding on January 1, — — Matching Stock Options granted in June 10.00 1,430,818 Matching Stock Options forfeited 10.00 8,262 Matching Stock Options exercised — — Matching Stock Options expired — — Matching Stock Options outstanding on December 31, 10.00 1,422,556 Matching Stock Options vested — — Weighted average remaining contract life (years) 9.50 Weighted average fair value of options granted in USD for June 10.59 For any outstanding 2016 Plan and 2010 Plan awards scheduled to vest on or after January 1, 2021, employees received replacement stock options (“Converted Options”) to acquire shares in Immatics N.V. The Converted Options have comparable terms as the previous awards, with revised exercise prices reflecting the reorganized capital structure of Immatics. The options granted under the 2020 Equity Plan that gives employees the right to acquire shares in Immatics N.V., are accounted for as a modification under IFRS 2, with the incremental fair value expensed over the remaining vesting period. The incremental fair value is the difference between the fair value of the options to purchase ordinary shares under the 2020 Equity Plan to acquire shares in Immatics N.V., and the fair value of the exchanged unvested SAR (both measured at the date on which the replacement award is issued). As of Average exercise price in USD $ 2.47 Underlying share price in USD $ 15.15 Volatility 75 % Time period (years) 5.6 Risk free rate 0.29 % Dividend yield 0.00 % Converted Options outstanding as of December 31, 2021: 2021 Weighted average Number Converted Options outstanding on January 1, 2.58 594,844 Converted Options forfeited 1.30 18,548 Converted Options exercised 1.29 8,180 Converted Options expired 1.29 1,805 Converted Options outstanding on December 31, 2.64 566,311 Converted Options vested 2.61 193,727 Weighted average remaining contract life (years) 6.01 Converted Options outstanding as of December 31, 2020: 2020 Weighted average Number Converted Options outstanding on January 1, — — Converted Options granted in June 2.49 632,384 Converted Options forfeited 1.08 37,540 Converted Options exercised — — Converted Options expired — — Converted Options outstanding on December 31, 2.58 594,844 Converted Options vested 2.45 53,856 Weighted average remaining contract life (years) 7.01 Weighted average fair value of options granted in USD for June 4.83 Additional grants under the 2020 Equity Plan Service Options Prior to the ARYA Merger, Immatics N.V. established the 2020 Equity Plan. After closing the ARYA Merger, employees, directors and officers received 1,087,242 employee stock options under the 2020 Equity Plan with a service requirement (“Service Options”), to acquire shares of Immatics N.V. The service-based options will vest solely on a four-year time-based vesting schedule. The Company granted Service Options on March 30, 2021, June 17, 2021, June 29, 2021, September 28 and 29, 2021, October 27, 2021 and on December 9, 2021, which were accounted for using the respective grant date fair value. Immatics applied a Black Scholes pricing model to estimate the fair value of the Service Options​​​​​​​, with a weighted average fair value of $11.22 for Service Option granted during the year ended December 31, 2021. As of As of As of As of Exercise price in USD $ 11.68 $ 12.05 $ 11.93 $ 12.92 Underlying share price in USD $ 11.68 $ 12.05 $ 11.93 $ 12.92 Volatility 85.77 % 84.67 % 84.53 % 83.57 % Time period (years) 6.11 6.11 6.11 6.11 Risk free rate 1.17 % 1.10 % 1.08 % 1.19 % Dividend yield 0.00 % 0.00 % 0.00 % 0.00 % As of As of As of Exercise price in USD $ 12.75 $ 13.45 $ 11.00 Underlying share price in USD $ 12.75 $ 13.45 $ 11.00 Volatility 83.51 % 82.07 % 81.80 % Time period (years) 6.11 6.11 6.11 Risk free rate 1.19 % 1.34 % 1.29 % Dividend yield 0.00 % 0.00 % 0.00 % The Company granted Service Options on June 30, 2020, September 14, 2020 and December 17, 2020, which were accounted for using the respective grant date fair value. Immatics applied a Black Scholes pricing model to estimate the fair value of the Service Options, with a weighted average fair value of $9.35 for Service Option granted during the year ended December 31, 2020. As of As of As of Exercise price in USD $ 10.00 $ 10.00 $ 9.70 Underlying share price in USD $ 15.15 $ 9.16 $ 9.70 Volatility 75 % 79 % 84 % Time period (years) 7.0 6.2 6.0 Risk free rate 0.29 % 0.37 % 0.49 % Dividend yield 0.00 % 0.00 % 0.00 % Service Options outstanding as of December 31, 2021: 2021 Weighted average Number Service Options outstanding on January 1, 9.87 1,910,182 Service Options granted in March, 11.68 90,325 Service Options granted in June, 11.97 75,980 Service Options granted in September, 12.81 88,875 Service Options granted in October, 13.45 53,324 Service Options granted in December, 11.00 1,659,204 Service Options forfeited 10.01 149,178 Service Options exercised 10.00 3,093 Service Options expired — — Service Options outstanding on December 31, 10.57 3,725,619 Service Options vested 9.86 557,401 Weighted average remaining contract life (years) 9.36 Service Options outstanding as of December 31, 2020: 2020 Weighted average Number Service Options outstanding on January 1, — — Service Options granted in June, 10.00 1,087,417 Service Options granted in September, 9.72 74,000 Service Options granted in December, 9.70 802,149 Service Options forfeited 10.00 53,384 Service Options exercised — — Service Options expired — — Service Options outstanding on December 31, 9.87 1,910,182 Service Options vested — — Weighted average remaining contract life (years) 9.72 Performance-Based Options (“PSUs”) In addition, after the closing of the ARYA Merger certain executive officers and key personnel of the Group received under the 2020 Equity Plan PSUs, vesting based both on achievement of market capitalization milestones and satisfaction of a four-year time-based vesting schedule. The PSUs are split into three equal tranches. The performance criteria for each of the three respective tranches requires Immatics to achieve a market capitalization of at least $1.5 billion, $2 billion and $3 billion, respectively. The amount of 3,644,000 of the PSUs granted on June 30, 2020, were accounted for by considering a fair value of $11.10. : As of Exercise price in USD $ 12.92 Underlying share price in USD $ 12.92 Volatility 77.16 % Time period (years) 3.75 Risk free rate 1.49 % Dividend yield 0.00 % The Company granted 255,000 PSUs on September 14, 2020, which were accounted for by considering a fair value of $6.41. A Monte-Carlo simulation model has been used to measure each fair value at grant date of the PSUs. As of June 30, As of September 14, Exercise price in USD $ 10.00 $ 10.00 Underlying share price in USD $ 15.15 $ 9.16 Volatility 79 % 78 % Time period (years) 7.0 6.7 Risk free rate 0.66 % 0.67 % Dividend yield 0.00 % 0.00 % PSUs outstanding as of December 31, 2021: 2021 Weighted average exercise Number PSUs outstanding on January 1, 10.00 3,644,000 PSUs granted in September 12.92 100,000 PSUs forfeited 10.00 48,000 PSUs outstanding on December 31, 10.08 3,696,000 PSUs vested — — Weighted average remaining contract life (years) 8.98 PSUs outstanding as of December 31, 2020: 2020 Weighted average exercise Number PSUs outstanding on January 1, — — PSUs granted in June 10.00 3,644,000 PSUs granted in September 10.00 255,000 PSUs forfeited 10.00 255,000 PSUs outstanding on December 31, 10.00 3,644,000 PSUs vested — — Weighted average remaining contract life (years) 9.60 The Group recognized total employee-related share-based compensation expense from all plans for the years ended December 31, 2021, 2020 and 2019 as set out below: Year ended 2021 2020 2019 (Euros in thousands) Research and development expenses 15,564 14,546 1,556 General and administrative expenses 10,839 10,973 460 Total share-based compensation 26,403 25,519 2,016

Shareholders' equity (deficit)

Shareholders' equity (deficit)	12 Months Ended
	Dec. 31, 2021
Text Block [Abstract]
Shareholders' equity (deficit)	19. Shareholders’ equity (deficit) As described in Note 1 and Note 3, Immatics N.V. was founded in 2020 with a share capital of €0.01 after the Reorganization. On July 1, 2020, upon closing of the ARYA Merger, Immatics N.V. had 62,908,617 outstanding ordinary shares with a par value of €0.01, resulting in a share capital of €629 thousand. In 2020, the ARYA Merger and PIPE Financing led to an increase in share premium by €327.8 million. As of December 31, 2021 and 2020, the total number of ordinary shares of Immatics N.V. outstanding is 62,926,816 and 62,908,617 with a par value of €0.01, respectively. As of December 31, 2019, the total number of ordinary shares of Immatics Biotechnologies GmbH outstanding is 1,163,625 with a par value of €1.00. Adjusted for the effect of the Reorganization as discussed in Note 3, which is applied retrospectively to all prior periods presented for purpose of calculation earni ng per shares Other reserves are related to accumulated foreign currency translation amounts associated with the Group’s US operations.

Non-controlling interests

Non-controlling interests	12 Months Ended
	Dec. 31, 2021
Text Block [Abstract]
Non-controlling interests	20. Non-controlling Non-controlling Until June 30, 2020, Immatics and MD Anderson were partners in a Restricted Stock Acquisition Agreement (the “RSAA”). Under the terms of the RSAA, MD Anderson was entitled to additional restricted shares in Immatics US, Inc. based on performance of certain work orders between August 14, 2018 and August 14, 2020. MD Anderson performed services in connection with our clinical trials in our ACT platform. The RSAA was cancelled as part of the ARYA Merger (See Note 3). On July 1, 2020 MD Anderson exchanged all of its 379,420 shares in Immatics US, Inc., that they acquired under the RSAA for 697,431 shares in Immatics N.V. The shares of Immatics N.V. had a fair value at the date of the exchange of $15.15 per share. Immediately prior to the exchange, the carrying amount of the existing 5.14% non-controlling non-controlling non-controlling Loss allocated to the non-controlling in 2020 and €0.9 million in 2019 Non-controlling In total, the Group recognized expenses in relation to MD Anderson’s performance under the RSAA of €0.04 million and €0.7 million as of December 31, 2020 and 2019, respectively. A corresponding increase in equity was recognized with an amount of €0.7 million as of December 31, 2019 for vested shares under the agreement.

Personnel expenses

Personnel expenses	12 Months Ended
	Dec. 31, 2021
Text Block [Abstract]
Personnel expenses	21. Personnel expenses The Group recognized the following personnel expenses: Year ended December 31, 2021 2020 2019 (Euros in thousands) Wages and salaries Research and development expenses 21,993 15,277 11,635 General and administrative expenses 7,105 6,968 3,596 Total Wages and salaries 29,098 22,245 15,231 Year ended December 31, 2021 2020 2019 (Euros in thousands) Other employee benefits Research and development expenses 3,550 2,624 2,035 General and administrative expenses 1,536 1,015 728 Total other employee benefits 5,086 3,639 2,763 Share-based compensation expense Research and development expenses 15,564 14,546 1,556 General and administrative expenses 10,839 10,973 460 Total share-based compensation expense 26,403 25,519 2,016 Total 60,587 51,403 20,010 Other employee benefit expenses include employee retirement fund contributions, health insurance, and statutory social expenses. Immatics US Inc. sponsors a defined contribution retirement plan for employees in the United States. During 2021, 2020 and 2019, total Group contributions to the defined contribution plan amounted to €0.2 million, €0.2 million and €0.1 million, respectively. For the year ended December 31, 2021, 2020 and 2019, other employee benefits also include employee health insurance costs amounting to €0.6 million, €0.4 million and €0.3 million for Immatics US Inc., statutory social expenses amounting to €2.4 million, €1.7 million and €1.3 million for our German operations and other miscellaneous expenses amounting to €0.1 million, €0.1 million and €0.07 million, respectively.

Income Tax

Income Tax	12 Months Ended
	Dec. 31, 2021
Text Block [Abstract]
Income Tax	22. Income Tax For the year ended December 31, 2021, 2020 and 2019, the Group generated losses in both Germany and the U.S. During 2021, 2020 and 2019, the Group’s German operations were subject to a statutory tax rate of 29.1%. In the U.S., the Group was subject to a corporate income tax rate of 21% for the year ended December 31, 2021, 2020 and 2019. As of December 31, 2021, 2020 and 2019, no deferred tax assets have been recognized in respect of these losses, due to the uncertainty of the Group’s ability to generate taxable profits in the foreseeable future. The current assessment regarding the usability of deferred tax assets may change, depending on the Group’s taxable income in future years. This may result in higher or lower deferred tax assets related to tax losses carried forward. Due to the ARYA Merger described in Note 3, there are certain limitations on tax losses carried forward for net operating losses incurred by Immatics US, Inc., under Section 382 of the U.S. Internal Revenue Code. A reconciliation between taxes on income reflected on the Consolidated Statement of Loss and the expected income tax benefit, based on the Group’s German statutory tax rate, for the years ended December 31, 2021, 2020 and 2019 is as follows: Year ended December 31, 2021 2020 2019 (Euros in thousands) Loss before tax (93,335 ) (211,841 ) (32,487 ) Expected tax benefit 27,160 61,646 9,454 Effects Difference in tax rates (3,274 ) (2,582 ) (1,875 ) Non-deductible tax-expenses (53 ) (599 ) (61 ) Government grants exempted from taxes — 45 8 Permanent Differences (10,881 ) (39,288 ) — Non-recognition of (12,953 ) (19,222 ) (7,526 ) Taxes on income — — — As of December 31, 2021, permanent differences relate to share-based compensation expenses and to the change in fair value of the financial liabilities for the warrants. For the year ended December 31, 2020, the main permanent difference relates to the Share listing expense of €153 million, which does not have a corresponding taxable expense. As of December 31, 2020, other permanent differences include transaction costs directly attributable and incremental to capital raises, expenses for equity-settled share-based compensation, as well as the change in fair value of the financial liabilities for the warrants. Deferred tax assets consist of the following: As of December 31, 2021 December 31, 2020 (Euros in thousands) Deferred Deferred Deferred Deferred Intangible assets 1,288 — 1,770 — Right-of-use — (2,629 ) — (1,713 ) Deferred revenue — — 180 — Other liabilities — — — — Lease liability 2,627 — 1,776 — Deferred expenses 12 — 3 — Recognized 3,927 (2,629 ) 3,729 (1,713 ) Netting (2,629 ) 2,629 (1,713 ) 1,713 Non-recognition (1,298 ) — (2,016 ) — Net tax — — — — As of December 31, 2021, and 2020, the Group had accumulated tax losses of €355 million and €288 million, respectively, that may be offset against future taxable profits of the Group subject to certain limitations. As of December 31, 2021, €26 million of total tax losses is subject to a twenty-year carry forward period. All other tax losses have an indefinite carry forward period. The Group has limited taxable temporary differences and no tax planning opportunities available that could partly support the recognition of these losses as deferred tax assets. On this basis, the Group has determined that it cannot recognize deferred tax assets on the tax losses carried forward as well as on temporary differences. Limitation on tax loss carry forwards in the US Inc. is 80.00% of each subsequent year`s net income starting with losses generated after January 1, 2018. These have an indefinite carry forward period, but no carry back option. Any losses generated prior to January 1, 2018 still can be utilized at 100.00% and are subject to a twenty-year carry forward expiration period. Due to the ARYA Merger described in Note 3, there are certain limitations on tax losses carried forward for net operating losses incurred by Immatics US, Inc., under Section 382 of the U.S. Internal Revenue Code. For Immatics Biotechnologies GmbH, we believe that the ARYA Merger did not lead to a forfeiture of tax losses carried forward in accordance with § 8c KStG. Deferred tax assets have not been recognized in respect of these losses due to the uncertainty of the Group’s ability to generate taxable profits in the foreseeable future. The current assessment regarding the usability of deferred tax assets may change depending on the income situation of future years and may result in higher deferred tax assets on net tax losses carried forward.

Financial Risk Management Objec

Financial Risk Management Objectives and Policies	12 Months Ended
	Dec. 31, 2021
Text Block [Abstract]
Financial Risk Management Objectives and Policies	23. Financial Risk Management Objectives and Policies The Group’s principal financial instruments comprise cash, cash equivalents and bonds. The main purpose of these financial instruments is to invest the proceeds of capital contributions and upfront payments from collaboration agreements. The Group has various other financial instruments such as other receivables and trade accounts payable, which arise directly from its operations. The main risks arising from the Group’s financial instruments are market risk and liquidity risk. The Board of Management reviews and agrees on policies for managing these risks as summarized below. The Group also monitors the market price risk arising from all financial instruments. Interest rate risk The exposure of the Group to changes in interest rates relates to investments in deposits and to changes in the interest for overnight deposits. Changes in the general level of interest rates may lead to an increase or decrease in the fair value of these investments. Regarding the liabilities shown in the Consolidated Statement of Financial Position, the Group is currently not subject to interest rate risks. The Group is subject to a limited risk resulting from negative interest rates on financial instruments, especially on cash and cash equivalents and Other financial assets. Credit risk Financial instruments that potentially subject the Group to concentrations of credit and liquidity risk consist primarily of cash and cash equivalents and bonds. The Group’s cash and cash equivalents are denominated in Euros and US Dollars and maintained with two high-quality financial institutions in Germany and two in the United States. The maximum default risk is €145 million and €232 million as of December 31, 2021 and 2020, respectively. These amounts consist of €133 million and €208 million cash and cash equivalents as well as €12 million and €24 million Other financial assets as of December 31, 2021 and 2020, respectively. The cash and cash equivalents are held with banks, which are rated BBB+ to Aa3 by S&P and Moody`s. Short-term deposits are graded within the investment category from P1 to P2 by the rating agency Moody`s. Bond investments are with banks, which are rated AAA by Moody`s and S&P. The Group continually monitors its positions with, and the credit quality of, the financial institutions and corporation, which are counterparts to its financial instruments and does not anticipate non-performance. . Currency risk Currency risk shows the risk that the value of a financial instrument will fluctuate due to changes in foreign exchange rates. In particular it poses a threat if the value of the currency in which liabilities are priced appreciates relative to the currency of the assets. The business transactions of the Group are generally conducted in Euros and U.S. dollars. The Group aims to match EUR cash inflows with EUR cash outflows and U.S. dollar cash inflows with U.S. Dollar cash outflows where possible. The objective of currency risk management is to identify, manage and control currency risk exposures within acceptable parameters. Due to the initial public offering in 2020, the Group has a significant U.S. dollar amount on its statements of financial position. In 2021 the Group recognized significant foreign exchange income as Immatics N.V.`s and Immatics GmbH´s functional currency is Euro, due to significant holdings of U.S. dollar amounts. In 2020 the Group recognized significant foreign exchange losses. Cash, cash equivalents and financial assets balances denominated in U.S. dollars held by entities with functional currency of EUR are as follows: Cash, cash equivalents and financial assets Immatics N.V. held in USD As of December 31, December 31, (Euros in thousands) Cash and cash equivalents 10,410 42,528 Financial assets — — Total assets exposed to the risk 10,410 42,528 Conversion rate EUR/USD as reporting date 1/1.13260 Cash, cash equivalents and financial assets Immatics GmbH held in USD As of December 31, December 31, (Euros in thousands) Cash and cash equivalents 11,787 6,788 Financial assets — 24,448 Total assets exposed to the risk 11,787 31,236 Conversion rate EUR/USD as of December 31, 2021: 1/1.13260 In 2021, if the euro had weakened/strengthened by 10% against U.S. dollars by considering that all other variables held constant, the Group`s loss would have been €2 million higher/€2.5 million lower, resulting from foreign exchange on translation of U.S. dollar assets of Immatics N.V. and Immatics GmbH. Sensitivity analysis Immatics N.V.: Conversion Profit/(loss) Carrying (Euros in thousands) Euro weakens by 1% against U.S. dollars 1.1439 (103 ) 10,307 Euro strengths by 1% against U.S. dollars 1.1213 105 10,516 Euro weakens by 5% against U.S. dollars 1.1892 (496 ) 9,915 Euro strengths by 5% against U.S. dollars 1.0760 548 10,958 Euro weakens by 10% against U.S. dollars 1.2459 (946 ) 9,464 Euro strengths by 10% against U.S. dollars 1.0193 1,157 11,567 Sensitivity analysis Immatics GmbH: Conversion Profit/(loss) Carrying (Euros in thousands) Euro weakens by 1% against U.S. dollars 1.1439 (117 ) 11,670 Euro strengths by 1% against U.S. dollars 1.1213 119 11,906 Euro weakens by 5% against U.S. dollars 1.1892 (561 ) 11,225 Euro strengths by 5% against U.S. dollars 1.0760 620 12,407 Euro weakens by 10% against U.S. dollars 1.2459 (1,072 ) 10,715 Euro strengths by 10% against U.S. dollars 1.0193 1,310 13,096 Conversion rate EUR/USD as of December 31, 2020: 1/1.2271 In 2020, if the Euro had weakened/strengthened by 10% against U.S. dollars by considering that all other variables held constant, the Group`s loss would have been €6.7 million higher/€8.2 million lower, resulting from foreign exchange on translation of U.S. dollar assets of Immatics N.V. and Immatics GmbH. The cash, cash equivalents and financial assets of Immatics GmbH held in USD and as well as sensitivity analysis were revised to reflect the correct USD amounts of December 31, 2020. Sensitivity analysis Immatics N.V.: Conversion Profit/ Carrying (Euros in thousands) Euro weakens by 1% against U.S. dollars 1.2394 (421 ) 42,107 Euro strengths by 1% against U.S. dollars 1.2148 430 42,958 Euro weakens by 5% against U.S. dollars 1.2885 (2,025 ) 40,503 Euro strengths by 5% against U.S. dollars 1.1657 2,238 44,766 Euro weakens by 10% against U.S. dollars 1.3498 (3,866 ) 38,662 Euro strengths by 10% against U.S. dollars 1.1044 4,725 47,253 Sensitivity analysis Immatics GmbH: Conversion Profit/ Carrying (Euros in thousands) Euro weakens by 1% against U.S. dollars 1.2394 (309 ) 30,927 Euro strengths by 1% against U.S. dollars 1.2148 316 31,552 Euro weakens by 5% against U.S. dollars 1.2885 (1,487 ) 29,749 Euro strengths by 5% against U.S. dollars 1.1657 1,644 32,880 Euro weakens by 10% against U.S. dollars 1.3498 (2,840 ) 28,396 Euro strengths by 10% against U.S. dollars 1.1044 3,471 34,707 Liquidity risk The Group continuously monitors its risk to a shortage of funds. The Group’s objective is to maintain a balance between continuity of funding and flexibility through the use of capital raises. All financial liabilities are due within six months. As of December 31, 2021, and 2020, the Group held the following funds which are expected to generate cash inflows in time, to counteract liquidity risk. As of December 31, December 31, (Euros in thousands) Cash and cash equivalents 132,994 207,530 Bonds 12,123 — Short-term deposits — 24,448 Total funds available 145,117 231,978 Market risk and currency risk of warrants The Group’s activities expose it to the financial risks of changes in price of the warrants. As the warrants are recognized at fair value through profit and loss on the consolidated statement of financial position of the Group, the Group’s exposure to market risks results from the volatility of the warrants price. The Warrants are publicly traded at the NASDAQ Stock Exchange. A reasonable increase (decrease) in the warrant price by 10%, with all other variables held constant, would lead to a (loss) gain before tax of €2.8 million with a corresponding effect in the equity as of December 31, 2021. A reasonable increase (decrease) in the warrant price by 10%, with all other variables held constant, would lead to a (loss) gain before tax of €1.7 million with a corresponding effect in the equity as of December 31, 2020. Currency risk shows the risk that the value of a financial instrument will fluctuate due to changes in foreign exchange rates. The warrants are traded in U.S. Dollar while the functional currency of Immatics N.V. is Euro. A reasonably increase (decrease) in the U.S. Dollar / Euro exchange rate by 10%, with all other variables held constant, would lead to a gain (loss) before tax of €3.1 million / (2.5 million) with a corresponding effect in the equity as of December 31, 2021. A reasonably increase (decrease) in the U.S. Dollar / Euro exchange rate by 10%, with all other variables held constant, would lead to a gain (loss) before tax of €1.9 million / (1.5 million) with a corresponding effect in the equity as of December 31, 2020. The risks associated with our warrants result in non-cash, non-operating

Financial Instruments

Financial Instruments	12 Months Ended
	Dec. 31, 2021
Text Block [Abstract]
Financial Instruments	24. Financial Instruments Set out below are the carrying amounts and fair values of the Group’s financial instruments that are carried in the consolidated financial statements. Euros in thousands Carrying amount Fair value IFRS 9 December 31, December 31, December 31, December 31, Financial assets Short-term deposits* other financial assets at — 24,448 — 24,448 Bonds other financial assets at 12,123 — 12,113 — Positive market value At fair value through — 914 — 914 Accounts receivable other financial assets at 682 1,250 682 1,250 Other current/non-current other financial assets at 691 1,586 691 1,586 Total financial assets** 13,496 28,198 13,486 28,198 Euros in thousands Carrying amount Fair value IFRS 9 December 31, December 31, December 31, December 31, Financial liabilities Accounts payable other financial liabilities 11,624 10,052 11,624 10,052 Other current liabilities other financial liabilities 727 962 727 962 Other financial liabilities At fair value through 27,859 16,869 27,859 16,869 Total financial liabilities 40,210 27,883 40,210 27,883 * “Short-term deposits” are classified within Other financial assets. “Bonds” are classified within Other financial assets. “Positive market value forward contract” are classified in Other current assets. “Negative market value forward contracts” are classified in Other current liabilities. ** Financial assets, other than cash and cash equivalents. The carrying value of financial instruments, such as cash and cash equivalents, deposits, accounts receivable and accounts payable approximate their fair value based on the short-term maturities of these instruments. The fair values of the financial assets and liabilities are included at the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced or liquidation sale. The following methods and assumptions were used to estimate the fair values: All financial assets, except for derivatives, which are categorized Level 2, are categorized Level 1 and therefore are valued using quoted (unadjusted) market prices. All financial liabilities are also categorized Level 1. The bonds` contractual cash flows represent solely payments of principal and interest and Immatics intends to hold the bonds to collect the contractual cash flows. The Group therefore accounts for the bonds as a financial asset at amortized cost. Other financial liabilities are comprised of the Immatics Warrants issued to investors with a cashless exercise mechanism as a current liability which the Company accounted for according to provisions of IAS 32. The Company measured the warrants at fair value by using the closing price of warrants at NASDAQ. The warrants were measured in each reporting period. Changes in the fair value were recognized in the Company’s consolidated statement of loss as financial income or expense, as appropriate. The warrants were classified as level 1.

Commitments and contingencies

Commitments and contingencies	12 Months Ended
	Dec. 31, 2021
Text Block [Abstract]
Commitments and contingencies	25. Commitments and contingencies The following table summarizes contractual obligations as of December 31, 2021: Payments due by period (Euros in thousands) Less than 1 - 3 3 - 5 More than Total Lease liabilities 2,913 4,477 2,007 932 10,329 Other lease obligations 66 1,258 1,362 2,040 4,726 Contract research organization agreements 1,681 — — — 1,681 Total contractual cash obligation 4,659 5,735 3,370 2,972 16,735 The following table summarizes contractual obligations as of December 31, 2020: Payments due by period (Euros in thousands) Less than 1 - 3 3 - 5 More than Total Lease liabilities 2,103 3,453 1,157 150 6,863 Other lease obligations 97 185 185 46 513 In-license 249 — — — 249 Contract research organization agreements 1,704 220 — — 1,924 Total contractual cash obligation 4,153 3,858 1,342 196 9,549 As of December 31, 2021, and 2020 the Group is potentially liable to pay €1.6 million to a third-party upon successful completing the milestone of the first clinical lead selection in connection with Immatics’ collaboration agreements. The Group does not recognize a liability for these contingent payments due to the scientific uncertainty of achieving the related milestones.

Related party disclosures

Related party disclosures	12 Months Ended
	Dec. 31, 2021
Text Block [Abstract]
Related party disclosures	26. Related party disclosures Key management personnel have been defined as Compensation of key management personnel: Year ended December 31, 2021 2020 2019 (Euros in thousands) Fixed 2,481 2,660 1,202 Variable 1,317 886 521 Share-based compensation expense 17,016 13,841 697 Total key management compensation 20,814 17,387 2,420 Fixed and variable key management compensation represent short-term employee benefits. In December 2021, the Group paid an additional €0.1 million to key management personnel that was subject to conditions that were fulfilled in January 2022. The payments were accounted for as Other current assets. The non-executive Total compensation for the non-executive (Euros in thousands) Peter Friedrich Michael G. Paul Heather L. Adam Christoph Eliot Total Board compensation 80 20 55 53 40 40 20 40 348 Travel expenses — 1 10 — 3 — — 1 15 Share-based compensation expense 1,143 30 114 114 114 114 — 122 1,751 Total cash compensation 1,223 51 179 167 157 154 20 163 2,114 On July 1, 2021, Immatics changed its structure from a two-tier one-tier non-executive Total compensation for the Supervisory Board amounted to €4.1 million in 2020: (Euros in thousands) Peter Harald F. Michael G. Paul Heather L. Adam Christoph Eliot Total Supervisory board compensation 140 16 28 26 20 20 20 12 282 Travel expenses 4 — — — — — — — 4 Payment Exit arrangement 2,394 — — — — — — — 2,394 Share-based compensation expense 1,046 — 70 70 70 70 70 40 1,436 Total cash compensation 3,584 16 98 96 90 90 90 52 4,116 Harald F. Stock and Peter Chambré were members of the Supervisory Board of Immatics in 2019. They received a fixed fee as Supervisory Board members and reimbursement for travel expenses. Total compensation for the Supervisory Board amounted to €0.4 million in 2019: Peter Harald Total (Euros in thousands) Supervisory board fee 300 9 309 Travel expenses 87 20 107 Total 387 29 416 Prior to the ARYA Merger, Immatics N.V. established the 2020 Incentive Plan. Immatics N.V. granted certain service-based options out of the 2020 Incentive Plan to its management and directors and in addition, performance-based options to its management upon closing of the ARYA Merger. The service-based options will vest based upon satisfaction of a four-year time-based vesting schedule, which The performance-based options will vest based both on achievement of certain market capitalization milestones and satisfaction of a four-year time-based vesting schedule, which provides for 25% vesting on the first anniversary of the vesting commencement date and quarterly vesting thereafter. The following options were granted to Immatics’ Directors: Type of options Grant date Number of Strike Expiration date Managing Director Harpreet Singh Performance- based options June 30, 2020 1,598,000 10.00 June 30, 2030 Harpreet Singh Service options June 30, 2020 168,000 10.00 June 30, 2030 Harpreet Singh Matching Stock options June 30, 2020 264,624 10.00 June 30, 2030 Harpreet Singh Converted options June 30, 2020 30,939 1.06 July 1, 2027 Harpreet Singh Converted options June 30, 2020 145,371 1.17 January 1, 2028 Harpreet Singh Service options December 17, 2020 168,000 9.70 December 17, 2030 Harpreet Singh Service options December 9, 2021 168,000 11.00 December 9, 2031 Type of options Grant date Number of Strike Expiration date Board of Directors Peter Chambré Service options June 30, 2020 25,000 10.00 June 30, 2030 Peter Chambré Matching Stock options June 30, 2020 211,974 10.00 June 30, 2030 Peter Chambré Service options December 9, 2021 15,000 11.00 December 9, 2031 Adam Stone Service options June 30, 2020 25,000 10.00 June 30, 2030 Adam Stone Service options December 9, 2021 15,000 11.00 December 9, 2031 Heather L. Mason Service options June 30, 2020 25,000 10.00 June 30, 2030 Heather L. Mason Service options December 9, 2021 15,000 11.00 December 9, 2031 Michael G. Atieh Service options June 30, 2020 25,000 10.00 June 30, 2030 Michael G. Atieh Service options December 9, 2021 15,000 11.00 December 9, 2031 Paul Carter Service options June 30, 2020 25,000 10.00 June 30, 2030 Paul Carter Service options December 9, 2021 15,000 11.00 December 9, 2031 Eliot Forster Service options September 14, 2020 25,000 9.16 September 13, 2030 Eliot Forster Service options December 9, 2021 15,000 11.00 December 9, 2031 Friedrich von Bohlen Service options June 17, 2021 25,000 12.05 June 17, 2031 Friedrich von Bohlen Service options December 9, 2021 15,000 11.00 December 9, 2031 An additional aggregate of 588,000 service options to purchase ordinary shares, were granted to other Immatics’ key management personnel, who are members of the Executive Committee but not Directors. Certain key management personnel were also participants in the share-based compensation plans of Immatics GmbH (2010 Plan and 2016 Plan). As part of the replacement awards issued in connection with the ARYA Merger (See Note 18), these key management personnel received in 2020 cash payments before taxes of €3.4 million, 417,415 converted options in Immatics N.V. and 750,076 matching stock options in Immatics N.V. The cash payments mainly covered wage tax obligations of the employees. Until December 31, 2021, no options granted to directors and executive officers forfeited or were exercised. Refer to section “18. Share-based payments” regarding further details of the Groups share-based compensation. The Group did not enter into transactions with related entities in 2021, 2020 and 2019 other than the mentioned compensation contracts.

Net loss per share

Net loss per share	12 Months Ended
	Dec. 31, 2021
Text Block [Abstract]
Net loss per share	27. Net loss per share Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the period, excluding common stock equivalents, adjusted for the effect of the corporate reorganization as discussed in Note 3 and applied retrospectively to all prior periods presented. The diluted net loss per share reflects the basic net loss per share, since the effects of potentially dilutive securities are antidilutive given the net loss for each period presented. For the periods included in these financial statements the Group was loss-making in all periods, therefore, anti-dilutive instruments are excluded in the calculation of diluted weighted average number of ordinary shares outstanding, including the outstanding equity awards during the periods and the 7,187,500 Immatics Warrants issued in 2020 and outstanding as of December 31, 2021. These warrants and options could potentially dilute basic earnings per share in the future. See Note 18 for details of outstanding share options.

Events occurring after the repo

Events occurring after the reporting period	12 Months Ended
	Dec. 31, 2021
Text Block [Abstract]
Events occurring after the reporting period	28. Events occurring after the reporting period On December 10, 2021, Immatics Biotechnologies GmbH has entered into a License, Development and Commercialization agreement with BMS. The Company concluded that the contract was not effective as of December 31, 2021 since it was contingent upon the successful completion of reviews under the HSR Act. The contract became effective in January 2022 and the Company received the upfront payment of $150 million in February 2022. The Company determined to not recognize any revenue in relation to the upfront payment, due to the missing HSR clearing as of December 31, 2021. The Company evaluated further subsequent events for recognition or disclosure through March 23

Summary of accounting policie_2

Summary of accounting policies applied by the Group for the annual reporting period ending December 31, 2021 (Policies)	12 Months Ended
	Dec. 31, 2021
Text Block [Abstract]
Going concern	2.1 Going concern Since inception, the Group’s activities have consisted primarily of raising capital and performing research and development activities to advance its technologies. The Group is still in the development phase and has not yet marketed any products commercially. Immatics’ ongoing success depends on the successful development and regulatory approval of its products and its ability to finance operations. The Group will seek additional funding to reach its development and commercialization objectives. The Group plans to seek funds through further private or public equity financings, debt financings, collaboration agreements and marketing, distribution or licensing arrangements. The Group may not be able to obtain financing or enter into collaboration or other arrangements on acceptable terms. If the Group is unable to obtain funding, it could be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect its business prospects. However, Immatics’ cash and cash equivalents as well as short-term deposits will be sufficient to fund operating expenses and capital expenditure requirements for at least twelve months from the issuance date. The accompanying consolidated financial statements have been prepared on a going concern basis. This contemplates the Group will continue in operation for the foreseeable future and will be able to realize its assets and discharge its liabilities in the normal course of operations. The consolidated financial statements do not reflect any adjustments relating to the recoverability and classification of assets or the amounts and classification of liabilities that would be necessary, was the Group unable to continue as a going concern.
Covid-19	2.4 COVID-19 In December 2019, a novel strain of coronavirus (“COVID-19”) travel Management continues to monitor the situation and enacted significant measures to protect the Group’s supply chain, employees, and the execution of clinical trials. To date, the pandemic has not significantly impacted the Group. The ongoing spread of COVID-19 COVID-19 COVID-19
Segment information	5.1 Segment information The Group manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The Group’s focus is on the research and development of T cell redirecting immunotherapies for the treatment of cancer. The Chief Executive Officer is the chief operating decision maker who regularly reviews the consolidated operating results and makes decisions about the allocation of the Group’s resources.
Cash and cash equivalents	5.2 Cash and cash equivalents Cash and cash equivalents in the Consolidated Statement of Financial Position is comprised of cash held at banks (including money market funds) and short-term deposits with an original maturity of three months or less.
Financial assets	5.3 Financial assets Initial recognition and measurement Financial assets within the scope of IFRS 9 include cash and cash equivalents, short-term deposits, bonds and receivables. Immatics determines the classification of its financial assets at initial recognition. All financial assets are recognized initially at fair value plus transaction costs. Purchases and sales of financial assets are recognized on their trade date, on which the Group commits to purchase or sell the asset. The subsequent measurement of financial assets depends on their classification as described below. Short-term deposits Immatics has short-term deposits with original maturities between three and nine months, which are classified as Other financial assets. Short-term deposits with an original maturity of three months or less are classified as cash and cash equivalents. Under IFRS 9 short-term deposits are classified within financial assets at amortized costs. Bonds Immatics holds bonds, which are classified as Other financial assets. The bonds` contractual cash flows represent solely payments of principal and interest and Immatics intends to hold the bonds to collect the contractual cash flows. The Group therefore accounts for the bonds as a financial asset at amortized cost. Receivables The Group has receivables from collaboration agreements. A receivable must be capitalized at the point in time at which the Group has become a contractual partner and a unconditional claim to cash and cash equivalents has arisen. In subsequent reporting periods, a receivable is measured at amortized cost using the effective interest method. Since the receivables are short-term receivables without a fixed interest rate, these receivables are capitalized at the original invoice or contract amount. Receivable balances are classified as current assets, because all of the Group’s receivables have an expected maturity of less than 12 months. Interest and other finance income and expense Interest income and expenses from financial instruments are recorded using the effective interest rate (“EIR”). EIR is the rate that discounts the estimated future cash payments or receipts over the expected life of the financial instrument or a shorter period, where appropriate, to the net carrying amount of the financial asset or liability. Interest income and expenses are classified as financial income and expense. As of December 31, 2020, Immatics was a counterparty in foreign exchange forward contracts. The contracts did not meet the criteria to apply hedge accounting and are therefore separately accounted for and measured at fair value. Any change in the fair value was considered within the Consolidated Statement of Loss. As of December 31, 2021, Immatics is not a counterparty in foreign exchange forward contracts.
Property, plant and equipment	5.4 Property, plant and equipment Property, plant and equipment is stated at cost, net of accumulated depreciation and accumulated impairment losses, if any. All repair and maintenance costs are recognized as expense when incurred. Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets. The estimated useful lives are generally within the following ranges:​​​​​​​ Category Estimated useful life Computer equipment 1 – 10 years Laboratory equipment 1 – 15 years Office equipment 2 – 20 years
Intangible assets	5.5 Intangible assets Acquired intangible assets are initially recognized at cost. Following initial recognition, intangible assets are carried at cost less accumulated amortization and accumulated impairment losses, if any. Intangible assets with finite lives are amortized over their useful economic lives and assessed for impairment, whenever there is an indication that the intangible asset may be impaired. The amortization period and the amortization method for an intangible asset with a finite useful life, is reviewed at least at the end of each reporting period. Immatics does not have any internally developed intangible assets or intangible assets with indefinite useful lives. Immatics reviews potential triggering events to identify the need for an impairment test. Amortization is calculated on a straight-line basis over the estimated useful lives of the assets as follows: Category Estimated useful life Licenses 5 – 30 years Software 1 – 5 years
Research and development	5.6 Research and development Research expenses are defined as costs incurred for current or planned investigations undertaken with the prospect of gaining new scientific or technical knowledge and understanding. All Research costs are expensed as incurred. An intangible asset arising from development expenditure on an individual project is recognized only when the Group can demonstrate the technical feasibility of completing the intangible asset so that it will be available for use or sale, its intention to complete and its ability to use or sell the asset, how the asset will generate future economic benefits, the availability of resources to complete and the ability to measure reliably the expenditure during the development. The Group did not recognize any intangible assets from development expenditures in 2021, 2020 and 2019 due to the existing uncertainties in connection with its development activities. Research and development expenses include the following types of costs: 1. salaries, benefits and other related costs, including stock-based compensation, for personnel engaged in research and development functions; 2. expenses incurred in connection with the preclinical development of our programs and clinical trials of our product candidates, including under agreements with third parties, such as consultants, contractors, academic institutions and contract research organizations; 3. the cost of manufacturing product candidates for use in clinical trials, including under agreements with third parties, such as, consultants and contractors; 4. laboratory costs; 5. leased facility costs, equipment depreciation and other expenses, which include direct and allocated expenses; and 6. intellectual property costs incurred in connection with filing and prosecuting patent applications as well as third-party license fees.
Financial liabilities: Initial recognition and measurement	5.7 Financial liabilities: Initial recognition and measurement Financial liabilities within the scope of IFRS 9 are classified as financial liabilities at fair value through profit or loss or at amortized cost, as appropriate. The Group determines the classification of its financial liabilities at initial recognition. All financial liabilities are recognized initially at fair value and, in the case of loans and borrowings, carried at amortized cost. This includes directly attributable transaction costs. The Company’s financial liabilities include accounts payable, other current liabilities and warrant liabilities. Immatics recognized accounts payable and other current liabilities as other financial liabilities at amortized costs. Warrants are accounted for as derivative financial instruments and therefore as financial liabilities through profit and loss as they give the holder the right to obtain a variable number of ordinary shares. Such derivative financial instruments are initially recognized at fair value on the date on which the merger is consummated and are subsequently remeasured at fair value through profit or loss. The warrants will expire five years after the completion of the ARYA Merger or earlier upon redemption or liquidation in accordance with their terms. The Group does not engage in hedging transactions that meet the criteria to apply hedge accounting.
Leases	5.8 Leases The Group adopted IFRS 16 (“Leases”) effective January 1, 2019. The Group leases various offices, equipment and vehicles. Rental contracts are typically made for fixed periods of two to seven years but may have extension options as described in below. Contracts may contain both lease and non-lease elected not to separate lease and non-lease right-of-use Assets and liabilities arising from a lease are initially measured on a present value basis. Lease liabilities include the net present value of the following lease payments: 1. fixed payments (including in-substance 2. amounts expected to be payable by the Group under residual value guarantees. 3. the exercise price of a purchase option if the Group is reasonably certain to exercise that option; and 4. payments of penalties for terminating the lease, if the lease term reflects the Group exercising that option. The lease term consists of the non-cancellable right-of-use To determine the IBR, the Group: 1. uses a build-up 2. makes adjustments specific to the lease, including lease term, country, currency and security Right-of-use 1. the amount of the initial measurement of lease liability 2. any lease payments made at or before the commencement date less any lease incentives received 3. any initial direct costs, and 4. restoration costs. Right-of-use right-of-use Payments associated with short-term leases of equipment and vehicles and all leases of low-value Low-value Extension and termination options are included in a number of property and equipment leases across the Group. These are used to maximize operational flexibility in terms of managing the assets used in the Group’s operations. The extension and termination options held are exercisable only by the Group and not by the respective lessor. For relevant leases which include an extension option, Immatics performed an assessment as of December 31, 2021 to determine whether option extensions are reasonably certain.
Revenue from collaboration agreements	5.9 Revenue from collaboration agreements The Group earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. As of December 31, 2021, the Group had three strategic collaboration agreements in place with Genmab A/S, Copenhagen/Denmark (“Genmab”), Celgene Switzerland LLC (“BMS”) and GlaxoSmithKline Intellectual Property Development Limited (“GSK”). Each of the Group’s three strategic collaboration agreements are in the pre-clinical 20 To determine the recognition of revenue from arrangements that fall within the scope of IFRS 15, the Group performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Group satisfies a performance obligation. Under the terms of these agreements, Immatics agrees to collaborate in the development, manufacture, and commercialization of cancer immunotherapy treatments for specified targets identified through the use of Immatics XPRESIDENT technology. As part of the collaboration arrangements, Immatics grants licensing rights for the development and commercialization of future product candidates, developed for targets defined in the collaboration agreements. Additionally, Immatics agrees to perform certain research activities under the collaboration agreements, including screening of highly specific molecules for reactivity with the specified targets and off-targets know-how, The Group performs an analysis to identify the performance obligations under the contract, including licenses and rights to future intellectual property developed under the contract and research activities. As these agreements comprise several promises, it must be assessed whether these promises are capable of being distinct and distinct within the context of the contract. Up-front cost-to-cost The licenses contributed under the collaboration agreements currently in place do not represent distinct performance obligations, because the Group’s collaboration partners would likely be unable to derive significant benefits from their access to these targets without Immatics’ research activities. Identification of a viable product candidate that will bind to the targets specified in the agreements requires use of the Group’s XPRESIDENT technology and database of target and off-target non-refundable Under IFRS 15, the Group applies significant judgement when evaluating whether the obligations under these agreements represent one or more combined performance obligations, the allocation of the transaction price to identified performance obligations, and the determination of whether milestone payments should be included in the transaction price. Upfront payment Each of the Group’s strategic collaboration agreements included a non-refundable cost-to-cost The cost-to-cost Reimbursement for services Under the collaboration agreement with Genmab, the Group receives reimbursement for employee research and development costs. These employee costs are presented as research and development expenses, while reimbursements of those costs, which is based on an FTE rate defined in the contract, are presented as revenue and not deducted from expenses. Development and Commercial Milestones The collaboration agreements include contingent payments related to development and commercial milestone events. These milestone payments represent variable consideration that are not initially recognized within the transaction price, due to the scientific uncertainties and the required commitment from the collaboration partners to develop and commercialize a product candidate. The Group assesses the probability of significant reversals for any amounts that become likely to be realized prior to recognizing the variable consideration, associated with these payments within the transaction price. Sales-based milestones and royalty payments The collaboration agreements also include sales-based royalty payments upon successful commercialization of a licensed product. In accordance with IFRS 15.B63, the Group recognizes revenue from sales-based milestone and royalty payments at the later of (i) the occurrence of the subsequent sale; or (ii) the performance obligation to which some or all of the sales-based milestone, or royalty payments has been allocated. The Group anticipates recognizing these milestones and royalty payments, when subsequent sales are generated from a licensed product by the collaboration partner. Cost to fulfill contracts The Group incurs costs for personnel, supplies and other costs related to its laboratory operations as well as fees from third parties and license expenses in connection with its research and development obligations under the collaboration and licensing agreement. These costs are recognized as research and development expenses over the period in which services are performed. Cost to obtain a contract For some collaboration agreements, the Group incurs incremental costs of obtaining a contract with a customer. The Group capitalizes those incremental costs if the costs are expected to be recovered. The recognized asset is amortized consistent with the method used to determine the pattern of revenue recognition of the underlying contract.
Share-based payment	5.10 Share-based payment The Group’s employees as well as others providing similar services to the Group, receive remuneration in the form of share-based payments, which are equity-settled transactions. The Group`s equity-settled option plans include Matching Stock Options, Converted Stock Options, Service Options and PSUs and are described in detail in Note 18. The costs of equity-settled transactions are determined by the fair value at grant date, using an appropriate valuation model. Share-based expenses for the respective vesting periods, are recognized in research and development expenses and general and administrative expenses, reflecting a corresponding increase in equity.
Other income	5.11 Other income The Group primarily earns other income from government research grants. Government grants are recognized as income when there is reasonable assurance that the grant will be received and all required conditions have been complied with. Grants from governmental agencies for the support of specific research and development projects are recorded as other income to the extent the related expenses have been incurred. Grant agreements include a budget that specifies the amount and nature of expenses allowed during the entire grant term. Expenses incurred under the grants are calculated according to agreed-upon terms on a quarterly basis, filed with the governmental agencies, and recorded as income. The governmental agencies make payments to the Group based on these calculations of expenses incurred under the grants. If these estimated calculations change, the Group will then adjust grant income in the subsequent period. The Group believes that its calculations are based on the agreed-upon terms as stated in the grant agreements. The governmental agencies generally have the right to audit the Group’s calculations. If the governmental agencies disagree with the Group’s calculations the amount of grant income recognized could change.
Foreign currency	5.12 Foreign currency Transactions and balances in Germany and in the USA The consolidated financial statements are presented in Euro, which is the parents’, Immatics N.V. functional and reporting currency. Assets and liabilities of foreign operations are translated into Euros at the rate of exchange prevailing at the reporting date. The Consolidated Statement of Loss is translated at average exchange rates. The currency translation differences are recognized in other comprehensive loss. Transactions in foreign currencies are initially recorded by the Group’s entities at their respective functional currency spot rates, at the date the transaction first qualifies for recognition. The Group determined the functional currency of Immatics Biotechnologies GmbH to be Euros and of Immatics US Inc. to be USD. The Group used the following exchange rates to convert the financial statements of its U.S. subsidiary: 2021 2020 2019 Year-end Average Year-end Average Year-end Average Euros per U.S. Dollar 0.88292 0.84495 0.8149 0.8762 0.8902 0.8932
Fair value of financial instruments	5.13 Fair value of financial instruments Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either: • in the principal market for the asset or liability or • in the absence of a principal market, in the most advantageous market for the asset or liability that is accessible by the Group. The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest. The Group uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximizing the use of relevant observable inputs and minimizing the use of unobservable inputs. All assets and liabilities for which fair value is measured or disclosed in the consolidated financial statements are categorized within the fair value hierarchy, described as follows, based on the lowest level input that is significant to the fair value measurement as a whole: • Level 1 — Quoted (unadjusted) market prices in active markets for identical assets or liabilities. • Level 2 — Valuation techniques, for which the lowest level input that is significant to the fair value measurement is directly or indirectly observable. • Level 3 — Valuation techniques, for which the lowest level input that is significant to the fair value measurement is unobservable. For assets and liabilities that are recognized in the consolidated financial statements at fair value on a recurring basis, the Group determines whether transfers have occurred between levels in the hierarchy by re-assessing
Provisions	5.14 Provisions Provisions are recognized when the Group has a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. Where the Group expects some or all of a provision to be reimbursed, for example under an insurance contract, the reimbursement is recognized as a separate asset but only when it is virtually certain that reimbursement will be received if the Group settles the obligation. If the effect of the time value of money is material, provisions are discounted using a current pre-tax
Income Tax	5.15 Income Tax Deferred income tax results from temporary differences between the carrying amount of an asset or a liability and its tax base. Deferred income tax is provided in full using the liability method on temporary differences. In accordance with IAS 12 (“Income Taxes”), the deferred tax assets and liabilities reflect all temporary valuation and accounting differences between financial statements prepared for tax purposes and our consolidated financial statements. Tax losses carried forward are considered in deferred tax assets calculation. The Group offsets tax assets and liabilities if and only if it has a legally enforceable right to set off current tax assets, current tax liabilities, deferred tax assets and deferred tax liabilities which relate to income taxes levied by the same tax authority.

Application of new and revise_2

Application of new and revised international financial reporting standards (Tables)	12 Months Ended
	Dec. 31, 2021
Text Block [Abstract]
Summary of Application of new standards	New standards and interpretations applied for the first time: Standard/interpretation Effective date Amendment to IFRS 16, ‘Leases’ – COVID-19 April 1, 2021 Changes to IFRS 4 – Effective date of IFRS 9 for insurance companies January 1, 2021 Amendments to IFRS 9, IAS 39, IFRS 7, IFRS 4 and IFRS 16 – Interest rate benchmark reform – Phase 2 January 1, 2021
Summary of Non Mandatory standards and interpretations issued by IASB	The following standards and interpretations have been issued by the IASB, but were not yet mandatory for the year ended December 31, 2021: Standard/interpretation Effective date Material effect expected Amendments to IFRS 3, ‘Business combinations’, IAS 16,’ Property, plant and equipment’, and IAS 37 ‘Provisions, contingent liabilities and contingent assets’ January 1, 2022 No Annual Improvements 2018-2020 January 1, 2022 No IFRS 17, ‘Insurance contracts’ as amended in June 2020 by amendments to IFRS 17, Insurance Contracts January 1, 2023 No Amendments to IAS 1, ‘Presentation of financial statements’, on classification of liabilities January 1, 2023 No Amendments to IAS 1, ‘Presentation of financial statements’, IFRS Practice statement 2 and IAS 8,’ Accounting policies, changes in accounting estimates and errors’ January 1, 2023 No

Summary of accounting policie_3

Summary of accounting policies applied by the Group for the annual reporting period ending December 31, 2020 (Tables)	12 Months Ended
	Dec. 31, 2021
Text Block [Abstract]
Summary of estimated Useful Lives of Property, Plant and Equipment	The estimated useful lives are generally within the following ranges: Category Estimated useful life Computer equipment 1 – 10 years Laboratory equipment 1 – 15 years Office equipment 2 – 20 years
Summary of useful life of intangible assets other than goodwill	Amortization is calculated on a straight-line basis over the estimated useful lives of the assets as follows: Category Estimated useful life Licenses 5 – 30 years Software 1 – 5 years
Summary of foreign exchange rates	The Group used the following exchange rates to convert the financial statements of its U.S. subsidiary: 2021 2020 2019 Year-end Average Year-end Average Year-end Average Euros per U.S. Dollar 0.88292 0.84495 0.8149 0.8762 0.8902 0.8932

Accounts receivable (Tables)

Accounts receivable (Tables)	12 Months Ended
	Dec. 31, 2021
Text Block [Abstract]
Summary of Trade receivables	As of December 31, December 31, (Euros in thousands) Receivables from collaboration agreements 682 1,250 Accounts receivable 682 1,250

Other current and non-current_2

Other current and non-current assets (Tables)	12 Months Ended
	Dec. 31, 2021
Text Block [Abstract]
Summary of Other current assets	As of December 31, December 31, (Euros in thousands) Grant receivable 762 875 Prepaid expenses 3,781 2,389 Positive market value forward contract — 914 Value added tax receivable 915 798 Other assets 950 787 Other current assets 6,408 5,763
Summary of Other non-current assets	As of December 31, December 31, (Euros in thousands) Prepaid expenses 636 724 Total non-current 636 724

Property, plant and equipment (

Property, plant and equipment (Tables)	12 Months Ended
	Dec. 31, 2021
Text Block [Abstract]
Summary of Changes to Property, Plant and Equipment	Changes to property, plant and equipment during 2021 and 2020 consisted of the following: (Euros in thousands) Laboratory Computer Office Total Cost as of January 1, 2020 12,723 2,956 1,753 17,432 Additions 3,545 406 1,427 5,379 Disposals 1 — 6 7 Currency translation differences 299 40 28 367 Cost as of December 31, 2020 15,968 3,322 3,146 22,437 Accumulated depreciation as of January 1, 2020 9,303 2,050 1,359 12,712 Additions 1,384 404 315 2,102 Disposals 1 — 6 7 Currency translation differences 210 26 3 239 Accumulated depreciation as of December 31, 2020 10,476 2,428 1,665 14,568 Net book value as of December 31, 2020 5,493 894 1,481 7,868 Cost as of January 1, 2021 15,968 3,322 3,146 22,437 Additions 3,487 1,105 489 5,081 Disposals 144 — — 144 Currency translation differences 319 43 26 388 Cost as of December 31, 2021 19,630 4,470 3,661 27,761 Accumulated depreciation as of January 1, 2021 10,476 2,428 1,665 14,568 Additions 1,501 508 565 2,574 Disposals 144 — — 144 Currency translation differences 219 30 7 256 Accumulated depreciation as of December 31, 2021 12,052 2,966 2,237 17,255 Net book value as of December 31, 2021 7,578 1,504 1,424 10,506
Summary of Depreciation Expense	Depreciation expense is included in the following line items of the Consolidated Statement of Loss Year ended December 31, 2021 2020 2019 (Euros in thousands) Research and development expenses 1,684 1,502 1,315 General and administrative expenses 890 600 482 Total 2,574 2,102 1,797

Intangible assets (Tables)

Intangible assets (Tables)	12 Months Ended
	Dec. 31, 2021
Text Block [Abstract]
Summary of Changes to Intangible Assets	Changes to intangible assets during 2021 and 2020 consisted of the following: (Euros in thousands) Patents Software Total Cost as of January 1, 2020 1,220 643 1,863 Additions — 104 104 Currency translation differences (88 ) (9 ) (97 ) Cost as of December 31, 2020 1,132 738 1,870 Accumulated amortization as of January 1, 2020 369 486 855 Additions 56 71 126 Currency translation differences (22 ) (3 ) (25 ) Accumulated amortization as of December 31, 2020 403 554 957 Net book value as of December 31, 2020 730 184 914 Cost as of January 1, 2021 1,132 738 1,870 Additions 320 162 481 Currency translation differences 99 8 107 Cost as of December 31, 2021 1,551 908 2,459 Accumulated amortization as of January 1, 2021 403 554 957 Additions 54 106 160 Currency translation differences 23 4 27 Accumulated amortization as of December 31, 2021 480 664 1,144 Net book value as of December 31, 2021 1,071 244 1,315
Summary of Depreciation Expense	Amortization expense is classified as follows within the Consolidated Statement of Loss: Year ended December 31, 2021 2020 2019 (Euros in thousands) Research and development expenses 35 31 28 General and administrative expenses 125 95 83 Total 160 126 111

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2021
Presentation of leases for lessee [abstract]
Summary of Right-of use assets	Right-of As of December 31, December 31, (Euros in thousands) Buildings 9,028 5,760 Laboratory equipment 669 — IT and telecommunication 177 258 Vehicles 74 90 Other assets 34 41 Total 9,982 6,149
Details of Lease liabilities	Lease liabilities consist of the following: As of December 31, December 31, (Euros in thousands) Lease liability – current 2,711 1,881 Lease liability – non-current 7,142 4,306 Total 9,853 6,187
Summary of expenses related to right-of-use assets and lease liabilities	Expenses related to right-of-use Year ended December 31, Depreciation charges of right-of-use 2021 2020 (Euros in thousands) Buildings 2,199 2,036 Laboratory equipment 162 — IT and telecommunication 98 101 Vehicles 59 50 Other assets 8 8 Total 2,526 2,195 Interest expenses from leases 288 260 Expense relating to short-term leases and low-value 95 51

Accounts payable (Tables)

Accounts payable (Tables)	12 Months Ended
	Dec. 31, 2021
Text Block [Abstract]
Summary of Accounts Payable	As of December 31, December 31, (Euros in thousands) Accounts payable 3,009 2,554 Other accrued liabilities 8,615 7,498 Total accounts payable 11,624 10,052

Revenue from collaboration ag_2

Revenue from collaboration agreements (Tables)	12 Months Ended
	Dec. 31, 2021
Text Block [Abstract]
Summary of Deferred revenue related to the collaboration agreements	Deferred revenue related to the collaboration agreements consist of the following: As of December 31, December 31, (Euros in thousands) Current 50,402 46,600 Non-current 48,225 85,475 Total 98,627 132,075

Other current liabilities (Tabl

Other current liabilities (Tables)	12 Months Ended
	Dec. 31, 2021
Text Block [Abstract]
Summary of other current liabilities	The components of other current liabilities are: As of December 31, December 31, (Euros in thousands) Payroll tax 1,760 1,185 Accrual for vacation 607 525 Accrued bonuses — 154 Other 134 161 Total 2,501 2,025

Financial income and expenses (

Financial income and expenses (Tables)	12 Months Ended
	Dec. 31, 2021
Text Block [Abstract]
Summary of finance income and costs	Financial income and financial expenses consist of the following: Year ended December 31, 2021 2020 2019 (Euros in thousands) Interest income from short-term deposits 133 850 790 Foreign currency gains 5,542 — — Gain on other financial instruments — 2,099 — Financial income 5,675 2,949 790 Interest expenses (566 ) (289 ) (170 ) Foreign currency losses (276 ) (9,774 ) (94 ) Losses on other financial instruments (884 ) — — Financial expenses (1,726 ) (10,063 ) (264 )

Share listing expense and cha_2

Share listing expense and change in fair value of warrant liabilities (Tables)	12 Months Ended
	Dec. 31, 2021
Text Block [Abstract]
Summary of Calculation of the Share listing expense	Details of the calculation of the Share listing expense are as follows: (Euros in thousands, except share and per share data) Description Amount Number of shares/warrants (a) ARYA Ordinary Shares — 17,968,750 (b) Closing price of ARYA Ordinary Shares on Nasdaq as of July 1, 2020 € 13.53 — (c) Fair value of TopCo Shares issued to ARYA shareholders (a * b) € 243,071 — (d) Outstanding ARYA Warrants — 7,187,500 (e) Closing price of ARYA Warrants on Nasdaq as of July 1, 2020 € 4.82 — (f) Fair value of outstanding ARYA Warrants (d * e) € 34,644 — (g) Cash and cash equivalents held in ARYA’s trust account € 128,849 (h) Current liabilities by ARYA € 3,921 ARYA’s identifiable net assets (g-f-h) € 90,284 — IFRS 2 Expense on the closing date € 152,787 —

Share-based payments (Tables)

Share-based payments (Tables)	12 Months Ended
	Dec. 31, 2021
Statements [Line Items]
Summary of Employee Related Share Based Compensation Expense	The Group recognized total employee-related share-based compensation expense from all plans for the years ended December 31, 2021, 2020 and 2019 as set out below: Year ended 2021 2020 2019 (Euros in thousands) Research and development expenses 15,564 14,546 1,556 General and administrative expenses 10,839 10,973 460 Total share-based compensation 26,403 25,519 2,016
Share Appreciation Rights [Member]
Statements [Line Items]
Summary of Options Granted Priced Using Black Scholes for SARs, Tandem Awards, Converted Options, Matching Stock Options and Monte Carlo Option Pricing Model	December 31, Amounts in USD 2019 2018 Exercise price $ 1.12 $ 1.12 Underlying share price $ 67.87 $ 27.21 Volatility 73 % 64 % Time period (years) 1.25 5.00 Risk free rate 1.59 % 2.77 % Dividend yield 0.00 % 0.00 % Combined probability of exit events 80.00 % 25.00 %
Summary of Employee Share Options	Set out below are summaries of SARs issued during 2019 and 2018: 2019 2018 Weighted average Number Weighted average Number SARs outstanding at January 1, $ 1.12 43,675 $ 1.12 43,978 SARs granted — — SARs forfeited 1.12 220 1.12 303 SARs outstanding at December 31, 1.12 43,455 1.12 43,675 SARs vested $ 1.12 117 $ 1.12 169 SARs exercisable — —
2016 Tandem Awards [Member]
Statements [Line Items]
Summary of Options Granted Priced Using Black Scholes for SARs, Tandem Awards, Converted Options, Matching Stock Options and Monte Carlo Option Pricing Model	The fair value of tandem awards issued in December 2019 was based on a company valuation of $350 million. Amounts in USD December 2019 June 2019 - December 2018 Exercise price in USD $ 23.82 $ 18.30 $ 16.65 Underlying share price in USD $ 67.87 $ 16.94 $ 27.21 Volatility 73 % 78 % 64 % Time period (years) 1.25 2.10 5.00 Risk free rate 1.59 % 2.04 % 2.77 % Dividend yield 0.00 % 0.00 % 0.00 % Combined probability of exit events 80.00 % 60.00 % 25.00 %
Summary of Activities Under Share Based Payment Arrangement	Set out below are summaries of tandem awards issued during 2019 and 2018: 2019 2018 Weighted average Number Weighted average Number Tandem Awards outstanding at January 1, $ 16.65 74,401 $ 16.65 31,880 Tandem awards granted in June to September 18.30 26,557 16.65 43,964 Tandem awards granted in December 23.82 5,447 Tandem awards forfeited 16.81 2,936 16.65 1,443 Tandem awards outstanding at December 31, 17.45 103,469 16.65 74,401 Tandem awards vested $ 16.76 16,238 $ 16.65 14,350 Tandem awards exercisable — — Weighted average remaining contract life (years) 8.56 9.12 Weighted average fair value of options granted in USD till September 10.27 4.51 Weighted average fair value of options granted in USD for December 53.41 —
Matching Stock Options [Member]
Statements [Line Items]
Summary of Options Granted Priced Using Black Scholes for SARs, Tandem Awards, Converted Options, Matching Stock Options and Monte Carlo Option Pricing Model	Immatics applied a Black Scholes pricing model to estimate the fair value of the Matching Stock Options, which the Group records as an expense over the four-year graded vesting period. As of June 30, Exercise price in USD $ 10.00 Underlying share price in USD $ 15.15 Volatility 75 % Time period (years) 5.5 Risk free rate 0.29 % Dividend yield 0.00 %
Summary of Employee Share Options	Matching Stock Options outstanding as of December 31, 2021: 2021 Weighted average Number Matching Stock Options outstanding on January 1, 10.00 1,422,556 Matching Stock Options forfeited 10.00 9,254 Matching Stock Options exercised 10.00 6,834 Matching Stock Options expired — — Matching Stock Options outstanding on December 31, 10.00 1,406,468 Matching Stock Options vested 10.00 1,413,302 Weighted average remaining contract life (years) 8.50 Matching Stock Options outstanding as of December 31, 2020: 2020 Weighted average Number Matching Stock Options outstanding on January 1, — — Matching Stock Options granted in June 10.00 1,430,818 Matching Stock Options forfeited 10.00 8,262 Matching Stock Options exercised — — Matching Stock Options expired — — Matching Stock Options outstanding on December 31, 10.00 1,422,556 Matching Stock Options vested — — Weighted average remaining contract life (years) 9.50 Weighted average fair value of options granted in USD for June 10.59
Converted Options [Member]
Statements [Line Items]
Summary of Options Granted Priced Using Black Scholes for SARs, Tandem Awards, Converted Options, Matching Stock Options and Monte Carlo Option Pricing Model	Immatics applied a Black Scholes pricing model to estimate the fair value of the Converted Options. As of Average exercise price in USD $ 2.47 Underlying share price in USD $ 15.15 Volatility 75 % Time period (years) 5.6 Risk free rate 0.29 % Dividend yield 0.00 %
Summary of Employee Share Options	Converted Options outstanding as of December 31, 2021: 2021 Weighted average Number Converted Options outstanding on January 1, 2.58 594,844 Converted Options forfeited 1.30 18,548 Converted Options exercised 1.29 8,180 Converted Options expired 1.29 1,805 Converted Options outstanding on December 31, 2.64 566,311 Converted Options vested 2.61 193,727 Weighted average remaining contract life (years) 6.01 Converted Options outstanding as of December 31, 2020: 2020 Weighted average Number Converted Options outstanding on January 1, — — Converted Options granted in June 2.49 632,384 Converted Options forfeited 1.08 37,540 Converted Options exercised — — Converted Options expired — — Converted Options outstanding on December 31, 2.58 594,844 Converted Options vested 2.45 53,856 Weighted average remaining contract life (years) 7.01 Weighted average fair value of options granted in USD for June 4.83
Additional Grants Under 2020 Plan [Member]
Statements [Line Items]
Summary of Options Granted Priced Using Black Scholes for SARs, Tandem Awards, Converted Options, Matching Stock Options and Monte Carlo Option Pricing Model	Immatics applied a Black Scholes pricing model to estimate the fair value of the Service Options As of As of As of As of Exercise price in USD $ 11.68 $ 12.05 $ 11.93 $ 12.92 Underlying share price in USD $ 11.68 $ 12.05 $ 11.93 $ 12.92 Volatility 85.77 % 84.67 % 84.53 % 83.57 % Time period (years) 6.11 6.11 6.11 6.11 Risk free rate 1.17 % 1.10 % 1.08 % 1.19 % Dividend yield 0.00 % 0.00 % 0.00 % 0.00 % As of As of As of Exercise price in USD $ 12.75 $ 13.45 $ 11.00 Underlying share price in USD $ 12.75 $ 13.45 $ 11.00 Volatility 83.51 % 82.07 % 81.80 % Time period (years) 6.11 6.11 6.11 Risk free rate 1.19 % 1.34 % 1.29 % Dividend yield 0.00 % 0.00 % 0.00 %
Summary of Employee Share Options	Service Options outstanding as of December 31, 2021: 2021 Weighted average Number Service Options outstanding on January 1, 9.87 1,910,182 Service Options granted in March, 11.68 90,325 Service Options granted in June, 11.97 75,980 Service Options granted in September, 12.81 88,875 Service Options granted in October, 13.45 53,324 Service Options granted in December, 11.00 1,659,204 Service Options forfeited 10.01 149,178 Service Options exercised 10.00 3,093 Service Options expired — — Service Options outstanding on December 31, 10.57 3,725,619 Service Options vested 9.86 557,401 Weighted average remaining contract life (years) 9.36 2020 Weighted average Number Service Options outstanding on January 1, — — Service Options granted in June, 10.00 1,087,417 Service Options granted in September, 9.72 74,000 Service Options granted in December, 9.70 802,149 Service Options forfeited 10.00 53,384 Service Options exercised — — Service Options expired — — Service Options outstanding on December 31, 9.87 1,910,182 Service Options vested — — Weighted average remaining contract life (years) 9.72
Performance Based Options [Member]
Statements [Line Items]
Summary of Options Granted Priced Using Black Scholes for SARs, Tandem Awards, Converted Options, Matching Stock Options and Monte Carlo Option Pricing Model	In addition to the probability of achieving the market capitalization performance criteria, the inputs used in the measurements of the fair value at grant date of the PSUs were as follows As of Exercise price in USD $ 12.92 Underlying share price in USD $ 12.92 Volatility 77.16 % Time period (years) 3.75 Risk free rate 1.49 % Dividend yield 0.00 % As of June 30, As of September 14, Exercise price in USD $ 10.00 $ 10.00 Underlying share price in USD $ 15.15 $ 9.16 Volatility 79 % 78 % Time period (years) 7.0 6.7 Risk free rate 0.66 % 0.67 % Dividend yield 0.00 % 0.00 %
Summary of Employee Share Options	PSUs outstanding as of December 31, 2021: 2021 Weighted average exercise Number PSUs outstanding on January 1, 10.00 3,644,000 PSUs granted in September 12.92 100,000 PSUs forfeited 10.00 48,000 PSUs outstanding on December 31, 10.08 3,696,000 PSUs vested — — Weighted average remaining contract life (years) 8.98 PSUs outstanding as of December 31, 2020: 2020 Weighted average exercise Number PSUs outstanding on January 1, — — PSUs granted in June 10.00 3,644,000 PSUs granted in September 10.00 255,000 PSUs forfeited 10.00 255,000 PSUs outstanding on December 31, 10.00 3,644,000 PSUs vested — — Weighted average remaining contract life (years) 9.60

Personnel expenses (Tables)

Personnel expenses (Tables)	12 Months Ended
	Dec. 31, 2021
Text Block [Abstract]
Summary of Personnel Expenses	The Group recognized the following personnel expenses: Year ended December 31, 2021 2020 2019 (Euros in thousands) Wages and salaries Research and development expenses 21,993 15,277 11,635 General and administrative expenses 7,105 6,968 3,596 Total Wages and salaries 29,098 22,245 15,231 Year ended December 31, 2021 2020 2019 (Euros in thousands) Other employee benefits Research and development expenses 3,550 2,624 2,035 General and administrative expenses 1,536 1,015 728 Total other employee benefits 5,086 3,639 2,763 Share-based compensation expense Research and development expenses 15,564 14,546 1,556 General and administrative expenses 10,839 10,973 460 Total share-based compensation expense 26,403 25,519 2,016 Total 60,587 51,403 20,010

Income Tax (Tables)

Income Tax (Tables)	12 Months Ended
	Dec. 31, 2021
Text Block [Abstract]
Summary of Reconciliation Between Taxes On Income And Expected Income Tax Benefit	A reconciliation between taxes on income reflected on the Consolidated Statement of Loss and the expected income tax benefit, based on the Group’s German statutory tax rate, for the years ended December 31, 2021, 2020 and 2019 is as follows: Year ended December 31, 2021 2020 2019 (Euros in thousands) Loss before tax (93,335 ) (211,841 ) (32,487 ) Expected tax benefit 27,160 61,646 9,454 Effects Difference in tax rates (3,274 ) (2,582 ) (1,875 ) Non-deductible tax-expenses (53 ) (599 ) (61 ) Government grants exempted from taxes — 45 8 Permanent Differences (10,881 ) (39,288 ) — Non-recognition of (12,953 ) (19,222 ) (7,526 ) Taxes on income — — —
Summary of Deferred Tax Assets	Deferred tax assets consist of the following: As of December 31, 2021 December 31, 2020 (Euros in thousands) Deferred Deferred Deferred Deferred Intangible assets 1,288 — 1,770 — Right-of-use — (2,629 ) — (1,713 ) Deferred revenue — — 180 — Other liabilities — — — — Lease liability 2,627 — 1,776 — Deferred expenses 12 — 3 — Recognized 3,927 (2,629 ) 3,729 (1,713 ) Netting (2,629 ) 2,629 (1,713 ) 1,713 Non-recognition (1,298 ) — (2,016 ) — Net tax — — — —

Financial Risk Management Obj_2

Financial Risk Management Objectives and Policies (Tables)	12 Months Ended
	Dec. 31, 2021
Text Block [Abstract]
Summary of Currency Risk Exposure	Cash, cash equivalents and financial assets Immatics N.V. held in USD As of December 31, December 31, (Euros in thousands) Cash and cash equivalents 10,410 42,528 Financial assets — — Total assets exposed to the risk 10,410 42,528 Conversion rate EUR/USD as reporting date 1/1.13260 Cash, cash equivalents and financial assets Immatics GmbH held in USD As of December 31, December 31, (Euros in thousands) Cash and cash equivalents 11,787 6,788 Financial assets — 24,448 Total assets exposed to the risk 11,787 31,236
Summary of Sensitivity Analysis of Foreign Currency Risk	Sensitivity analysis Immatics N.V.: Conversion Profit/(loss) Carrying (Euros in thousands) Euro weakens by 1% against U.S. dollars 1.1439 (103 ) 10,307 Euro strengths by 1% against U.S. dollars 1.1213 105 10,516 Euro weakens by 5% against U.S. dollars 1.1892 (496 ) 9,915 Euro strengths by 5% against U.S. dollars 1.0760 548 10,958 Euro weakens by 10% against U.S. dollars 1.2459 (946 ) 9,464 Euro strengths by 10% against U.S. dollars 1.0193 1,157 11,567 Sensitivity analysis Immatics GmbH: Conversion Profit/(loss) Carrying (Euros in thousands) Euro weakens by 1% against U.S. dollars 1.1439 (117 ) 11,670 Euro strengths by 1% against U.S. dollars 1.1213 119 11,906 Euro weakens by 5% against U.S. dollars 1.1892 (561 ) 11,225 Euro strengths by 5% against U.S. dollars 1.0760 620 12,407 Euro weakens by 10% against U.S. dollars 1.2459 (1,072 ) 10,715 Euro strengths by 10% against U.S. dollars 1.0193 1,310 13,096 Conversion Profit/ Carrying (Euros in thousands) Euro weakens by 1% against U.S. dollars 1.2394 (421 ) 42,107 Euro strengths by 1% against U.S. dollars 1.2148 430 42,958 Euro weakens by 5% against U.S. dollars 1.2885 (2,025 ) 40,503 Euro strengths by 5% against U.S. dollars 1.1657 2,238 44,766 Euro weakens by 10% against U.S. dollars 1.3498 (3,866 ) 38,662 Euro strengths by 10% against U.S. dollars 1.1044 4,725 47,253 Sensitivity analysis Immatics GmbH: Conversion Profit/ Carrying (Euros in thousands) Euro weakens by 1% against U.S. dollars 1.2394 (309 ) 30,927 Euro strengths by 1% against U.S. dollars 1.2148 316 31,552 Euro weakens by 5% against U.S. dollars 1.2885 (1,487 ) 29,749 Euro strengths by 5% against U.S. dollars 1.1657 1,644 32,880 Euro weakens by 10% against U.S. dollars 1.3498 (2,840 ) 28,396 Euro strengths by 10% against U.S. dollars 1.1044 3,471 34,707
Summary of Liquidity Risk	As of December 31, 2021, and 2020, the Group held the following funds which are expected to generate cash inflows in time, to counteract liquidity risk. As of December 31, December 31, (Euros in thousands) Cash and cash equivalents 132,994 207,530 Bonds 12,123 — Short-term deposits — 24,448 Total funds available 145,117 231,978

Financial Instruments (Tables)

Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2021
Text Block [Abstract]
Summary of Carrying Amounts and Fair values of Group's Financial Instruments	Set out below are the carrying amounts and fair values of the Group’s financial instruments that are carried in the consolidated financial statements. Euros in thousands Carrying amount Fair value IFRS 9 December 31, December 31, December 31, December 31, Financial assets Short-term deposits* other financial assets at — 24,448 — 24,448 Bonds other financial assets at 12,123 — 12,113 — Positive market value At fair value through — 914 — 914 Accounts receivable other financial assets at 682 1,250 682 1,250 Other current/non-current other financial assets at 691 1,586 691 1,586 Total financial assets** 13,496 28,198 13,486 28,198 Euros in thousands Carrying amount Fair value IFRS 9 December 31, December 31, December 31, December 31, Financial liabilities Accounts payable other financial liabilities 11,624 10,052 11,624 10,052 Other current liabilities other financial liabilities 727 962 727 962 Other financial liabilities At fair value through 27,859 16,869 27,859 16,869 Total financial liabilities 40,210 27,883 40,210 27,883 * “Short-term deposits” are classified within Other financial assets. “Bonds” are classified within Other financial assets. “Positive market value forward contract” are classified in Other current assets. “Negative market value forward contracts” are classified in Other current liabilities. ** Financial assets, other than cash and cash equivalents.

Commitments and contingencies (

Commitments and contingencies (Tables)	12 Months Ended
	Dec. 31, 2021
Text Block [Abstract]
Summary of Contractual Obligations	The following table summarizes contractual obligations as of December 31, 2021: Payments due by period (Euros in thousands) Less than 1 - 3 3 - 5 More than Total Lease liabilities 2,913 4,477 2,007 932 10,329 Other lease obligations 66 1,258 1,362 2,040 4,726 Contract research organization agreements 1,681 — — — 1,681 Total contractual cash obligation 4,659 5,735 3,370 2,972 16,735 The following table summarizes contractual obligations as of December 31, 2020: Payments due by period (Euros in thousands) Less than 1 - 3 3 - 5 More than Total Lease liabilities 2,103 3,453 1,157 150 6,863 Other lease obligations 97 185 185 46 513 In-license 249 — — — 249 Contract research organization agreements 1,704 220 — — 1,924 Total contractual cash obligation 4,153 3,858 1,342 196 9,549

Related party disclosures (Tabl

Related party disclosures (Tables)	12 Months Ended
	Dec. 31, 2021
Text Block [Abstract]
Summary of Compensation of Key Management Personnel	Compensation of key management personnel: Year ended December 31, 2021 2020 2019 (Euros in thousands) Fixed 2,481 2,660 1,202 Variable 1,317 886 521 Share-based compensation expense 17,016 13,841 697 Total key management compensation 20,814 17,387 2,420 Fixed and variable key management compensation represent short-term employee benefits.
Summary of Compensation for the Supervisory Board	Total compensation for the non-executive (Euros in thousands) Peter Friedrich Michael G. Paul Heather L. Adam Christoph Eliot Total Board compensation 80 20 55 53 40 40 20 40 348 Travel expenses — 1 10 — 3 — — 1 15 Share-based compensation expense 1,143 30 114 114 114 114 — 122 1,751 Total cash compensation 1,223 51 179 167 157 154 20 163 2,114 (Euros in thousands) Peter Harald F. Michael G. Paul Heather L. Adam Christoph Eliot Total Supervisory board compensation 140 16 28 26 20 20 20 12 282 Travel expenses 4 — — — — — — — 4 Payment Exit arrangement 2,394 — — — — — — — 2,394 Share-based compensation expense 1,046 — 70 70 70 70 70 40 1,436 Total cash compensation 3,584 16 98 96 90 90 90 52 4,116 Total compensation for the Supervisory Board amounted to €0.4 million in 2019: Peter Harald Total (Euros in thousands) Supervisory board fee 300 9 309 Travel expenses 87 20 107 Total 387 29 416
Summary of Options Granted to Managing Director and Supervisory Directors	The following options were granted to Immatics’ Directors: Type of options Grant date Number of Strike Expiration date Managing Director Harpreet Singh Performance- based options June 30, 2020 1,598,000 10.00 June 30, 2030 Harpreet Singh Service options June 30, 2020 168,000 10.00 June 30, 2030 Harpreet Singh Matching Stock options June 30, 2020 264,624 10.00 June 30, 2030 Harpreet Singh Converted options June 30, 2020 30,939 1.06 July 1, 2027 Harpreet Singh Converted options June 30, 2020 145,371 1.17 January 1, 2028 Harpreet Singh Service options December 17, 2020 168,000 9.70 December 17, 2030 Harpreet Singh Service options December 9, 2021 168,000 11.00 December 9, 2031 Type of options Grant date Number of Strike Expiration date Board of Directors Peter Chambré Service options June 30, 2020 25,000 10.00 June 30, 2030 Peter Chambré Matching Stock options June 30, 2020 211,974 10.00 June 30, 2030 Peter Chambré Service options December 9, 2021 15,000 11.00 December 9, 2031 Adam Stone Service options June 30, 2020 25,000 10.00 June 30, 2030 Adam Stone Service options December 9, 2021 15,000 11.00 December 9, 2031 Heather L. Mason Service options June 30, 2020 25,000 10.00 June 30, 2030 Heather L. Mason Service options December 9, 2021 15,000 11.00 December 9, 2031 Michael G. Atieh Service options June 30, 2020 25,000 10.00 June 30, 2030 Michael G. Atieh Service options December 9, 2021 15,000 11.00 December 9, 2031 Paul Carter Service options June 30, 2020 25,000 10.00 June 30, 2030 Paul Carter Service options December 9, 2021 15,000 11.00 December 9, 2031 Eliot Forster Service options September 14, 2020 25,000 9.16 September 13, 2030 Eliot Forster Service options December 9, 2021 15,000 11.00 December 9, 2031 Friedrich von Bohlen Service options June 17, 2021 25,000 12.05 June 17, 2031 Friedrich von Bohlen Service options December 9, 2021 15,000 11.00 December 9, 2031

Group information - Additional

Group information - Additional Information (Detail)	Mar. 22, 2022	Dec. 31, 2021
Disclosure of non-adjusting events after reporting period [line items]
Date of end of reporting period		Dec. 31, 2021
Authorization Of Financial Statements [Member]
Disclosure of non-adjusting events after reporting period [line items]
Date of authorisation for issue of financial statements	Mar. 22, 2022

Basis of presentation - Additio

Basis of presentation - Additional Information (Detail) - EUR (€) € in Millions	Jun. 30, 2020	Mar. 31, 2021	Jun. 30, 2021	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure of subsidiaries [line items]
Ownership interests held by non-controlling interests	5.14%
Payments to acquire investment					€ 24.8	€ 57.3
Payments for overstated and understated of payments for investment		€ 21.3	€ 42.4	€ 42.5
Immatics US Inc [Member]
Disclosure of subsidiaries [line items]
Ownership interests held by non-controlling interests						3.96%

ARYA Merger - Additional Inform

ARYA Merger - Additional Information (Detail) € in Thousands	Jul. 01, 2020EUR (€)sharesWarrants	Jun. 30, 2020EUR (€)	Dec. 31, 2020EUR (€)	Dec. 31, 2019EUR (€)	Dec. 31, 2021EUR (€)Warrantsshares
Disclosure of detailed information about business combination [line items]
Increase decrease through Changes in Noncontrolling Interest		€ 500
Share listing expense			€ 152,787
Increase through other contributions by owners, equity			90,077	€ 700
Share issue related cost	€ 7,900
Issued capital [member]
Disclosure of detailed information about business combination [line items]
Increase Decrease Through Reorganization Equity			(833)
Increase decrease through Changes in Noncontrolling Interest			7
Increase through other contributions by owners, equity	100		104
Share premium [member]
Disclosure of detailed information about business combination [line items]
Increase Decrease Through Reorganization Equity			833
Increase decrease through Changes in Noncontrolling Interest			501
Increase through other contributions by owners, equity	90,000		€ 89,973
PIPE Financing [Member]
Disclosure of detailed information about business combination [line items]
Proceeds from issue of ordinary shares	90,100
ARYA [Member]
Disclosure of detailed information about business combination [line items]
Increase Decrease Through Reorganization Equity	800
Increase decrease through Changes in Noncontrolling Interest	€ 500
Description Of How Acquirer Obtained Control Of Acquire	one ordinary share of Immatics N.V. for each issued and outstanding ordinary share of ARYA and one warrant to purchase ordinary shares in Immatics N.V., for each issued and outstanding warrant to acquire ordinary shares
Net Assets Acquired (Liabilities Assumed)	€ 90,300				€ 90,284
Cash and cash equivalents recognised as of acquisition date	128,800
Current liabilities recognised as of acquisition date	3,900				€ 3,921
Share listing expense	152,800
Fair value of warrant liabilities assumed in a business acquisition	€ 34,600
ARYA [Member] | Warrants [Member]
Disclosure of detailed information about business combination [line items]
Number of instruments issued or issuable | Warrants	7,187,500				7,187,500
ARYA [Member] | Ordinary shares [member]
Disclosure of detailed information about business combination [line items]
Number of instruments issued or issuable | shares	17,968,750				17,968,750

Application of new and revise_3

Application of new and revised international financial reporting standards - Summary of Application of new standards (Detail)	12 Months Ended
	Dec. 31, 2021
Amendment to IFRS 16
Disclosure of expected impact of initial application of new standards or interpretations [line items]
Title of new IFRS	Amendment to IFRS 16, ‘Leases’ – COVID-19 related rent concessions
Date by which application of new IFRS is required	Apr. 1, 2021
Changes to IFRS 4
Disclosure of expected impact of initial application of new standards or interpretations [line items]
Title of new IFRS	Changes to IFRS 4 – Effective date of IFRS 9 for insurance companies
Date by which application of new IFRS is required	Jan. 1, 2021
Interest Rate Benchmark Reform-Phase 2
Disclosure of expected impact of initial application of new standards or interpretations [line items]
Title of new IFRS	Amendments to IFRS 9, IAS 39, IFRS 7, IFRS 4 and IFRS 16 – Interest rate benchmark reform – Phase 2
Date by which application of new IFRS is required	Jan. 1, 2021

Application of new and revise_4

Application of new and revised international financial reporting standards - Summary of Non Mandatory standards and interpretations issued by IASB (Detail)	12 Months Ended
	Dec. 31, 2021
Amendments to IFRS 3 Business combinations IAS 16
Disclosure of expected impact of initial application of new standards or interpretations [line items]
Title of new IFRS	Amendments to IFRS 3, ‘Business combinations’, IAS 16,’ Property, plant and equipment’, and IAS 37 ‘Provisions, contingent liabilities and contingent assets’
Date by which application of new IFRS is required	Jan. 1, 2022
Annual Improvements to IFRS Standards 2018-20
Disclosure of expected impact of initial application of new standards or interpretations [line items]
Title of new IFRS	Annual Improvements 2018-2020
Date by which application of new IFRS is required	Jan. 1, 2022
IFRS 17
Disclosure of expected impact of initial application of new standards or interpretations [line items]
Title of new IFRS	IFRS 17, ‘Insurance contracts’ as amended in June 2020 by amendments to IFRS 17, Insurance Contracts
Date by which application of new IFRS is required	Jan. 1, 2023
Amendments To IAS 1
Disclosure of expected impact of initial application of new standards or interpretations [line items]
Title of new IFRS	Amendments to IAS 1, ‘Presentation of financial statements’, on classification of liabilities
Date by which application of new IFRS is required	Jan. 1, 2023
Amendments to IAS 1, ‘Presentation of financial statements
Disclosure of expected impact of initial application of new standards or interpretations [line items]
Title of new IFRS	Amendments to IAS 1, ‘Presentation of financial statements’, IFRS Practice statement 2 and IAS 8,’ Accounting policies, changes in accounting estimates and errors’
Date by which application of new IFRS is required	Jan. 1, 2023

Summary of accounting policie_4

Summary of accounting policies applied by the Group for the annual reporting period ending December 31, 2021 - Summary of estimated Useful Lives of Property, Plant and Equipment (Detail)	12 Months Ended
	Dec. 31, 2021
Bottom of range [member] | Computer equipment [member]
Disclosure Of Property Plant And Equipment Estimated Useful Lives [Line Items]
Useful life measured as period of time, property, plant and equipment	1 year
Bottom of range [member] | Laboratory equipment [Member]
Disclosure Of Property Plant And Equipment Estimated Useful Lives [Line Items]
Useful life measured as period of time, property, plant and equipment	1 year
Bottom of range [member] | Office equipment [member]
Disclosure Of Property Plant And Equipment Estimated Useful Lives [Line Items]
Useful life measured as period of time, property, plant and equipment	2 years
Top of range [member] | Computer equipment [member]
Disclosure Of Property Plant And Equipment Estimated Useful Lives [Line Items]
Useful life measured as period of time, property, plant and equipment	10 years
Top of range [member] | Laboratory equipment [Member]
Disclosure Of Property Plant And Equipment Estimated Useful Lives [Line Items]
Useful life measured as period of time, property, plant and equipment	15 years
Top of range [member] | Office equipment [member]
Disclosure Of Property Plant And Equipment Estimated Useful Lives [Line Items]
Useful life measured as period of time, property, plant and equipment	20 years

Summary of accounting policie_5

Summary of accounting policies applied by the Group for the annual reporting period ending December 31, 2021 - Summary of useful life of intangible assets other than goodwill (Detail)	12 Months Ended
	Dec. 31, 2021
Licences [member] | Bottom of range [member]
Disclosure Of Detailed Information About Useful Life Measured As Period Of Time Intangible Assets Other Than Goodwill [Line Items]
Useful life measured as period of time, intangible assets other than goodwill	5 years
Licences [member] | Top of range [member]
Disclosure Of Detailed Information About Useful Life Measured As Period Of Time Intangible Assets Other Than Goodwill [Line Items]
Useful life measured as period of time, intangible assets other than goodwill	30 years
Computer software [member] | Bottom of range [member]
Disclosure Of Detailed Information About Useful Life Measured As Period Of Time Intangible Assets Other Than Goodwill [Line Items]
Useful life measured as period of time, intangible assets other than goodwill	1 year
Computer software [member] | Top of range [member]
Disclosure Of Detailed Information About Useful Life Measured As Period Of Time Intangible Assets Other Than Goodwill [Line Items]
Useful life measured as period of time, intangible assets other than goodwill	5 years

Summary of accounting policie_6

Summary of accounting policies applied by the Group for the annual reporting period ending December 31, 2021 - Summary of foreign exchange rates (Detail)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure Of Detailed Information About Foreign Exchange Rates [Line Items]
Closing foreign exchange rate	0.88292	0.8149	0.8902
Average foreign exchange rate	0.84495	0.8762	0.8932

Summary of accounting policie_7

Summary of accounting policies applied by the Group for the annual reporting period ending December 31, 2021 - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2021
Statements [Line Items]
Description of functional currency	The Group determined the functional currency of Immatics Biotechnologies GmbH to be Euros and of Immatics US Inc. to be USD.
Bottom of range [member]
Statements [Line Items]
Rental Contract Term	two
Top of range [member]
Statements [Line Items]
Rental Contract Term	seven

Significant accounting judgemen

Significant accounting judgements, estimates and assumptions - Additional Information (Detail) - ARYA [Member]	Dec. 31, 2021$ / sharesshares
Disclosure of detailed information about business combination [line items]
Number of warrants outsatnding | shares	7,187,500
Exercise price per share | $ / shares	$ 11.50

Accounts receivable - Summary o

Accounts receivable - Summary of Trade receivables (Detail) - EUR (€) € in Thousands	Dec. 31, 2021	Dec. 31, 2020
Trade and other current receivables [abstract]
Receivables From Collaboration Agreements	€ 682	€ 1,250
Accounts receivable	€ 682	€ 1,250

Accounts receivable - Additiona

Accounts receivable - Additional Information (Detail) - EUR (€) € in Thousands	Dec. 31, 2021	Dec. 31, 2020
Trade and other current receivables [abstract]
Trade receivables	€ 0	€ 0

Other current and non-current_3

Other current and non-current assets -Summary of Other current assets (Detail) - EUR (€) € in Thousands	Dec. 31, 2021	Dec. 31, 2020
Trade and other receivables [abstract]
Grant receivable	€ 762	€ 875
Prepaid expenses	3,781	2,389
Positive market value forward contract	0	914
Value added tax receivable	915	798
Other assets	950	787
Other current assets	€ 6,408	€ 5,763

Other current and non-current_4

Other current and non-current assets - Additional Information (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Disclosure of subsidiaries [line items]
Prepaid insurance expenses	€ 1,300	€ 1,000
Prepaid expenses of licenses and software	500	600
Other assets	950	787
Non-current prepayments	636	724
Current prepaid maintenance expenses	800	200
Receivables From Capital Gains Tax [Member]
Disclosure of subsidiaries [line items]
Other assets	300	400
Celgene Switzerland LLC And Genmab AS [Member]
Disclosure of subsidiaries [line items]
Current Incremental cost for collaboration agreement	700	500
Non-current prepayments	€ 300	€ 700

Other current and non-current_5

Other current and non-current assets - Summary of Other non-current assets (Detail) - EUR (€) € in Thousands	Dec. 31, 2021	Dec. 31, 2020
Trade and other non-current receivables [abstract]
Prepaid expenses	€ 636	€ 724
Total non-current assets	€ 636	€ 724

Property, plant and equipment -

Property, plant and equipment - Summary of Changes to property, plant and equipment (Detail) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Disclosure of detailed information about property, plant and equipment [line items]
Beginning Cost	€ 7,868
Ending Cost	10,506	€ 7,868
Laboratory Equipment [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Beginning Cost	5,493
Ending Cost	7,578	5,493
Computer equipment [member]
Disclosure of detailed information about property, plant and equipment [line items]
Beginning Cost	894
Ending Cost	1,504	894
Office equipment [member]
Disclosure of detailed information about property, plant and equipment [line items]
Beginning Cost	1,481
Ending Cost	1,424	1,481
Gross carrying amount [member]
Disclosure of detailed information about property, plant and equipment [line items]
Beginning Cost	22,437	17,432
Additions	5,081	5,379
Disposals	144	7
Currency translation differences	388	367
Ending Cost	27,761	22,437
Gross carrying amount [member] | Laboratory Equipment [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Beginning Cost	15,968	12,723
Additions	3,487	3,545
Disposals	144	1
Currency translation differences	319	299
Ending Cost	19,630	15,968
Gross carrying amount [member] | Computer equipment [member]
Disclosure of detailed information about property, plant and equipment [line items]
Beginning Cost	3,322	2,956
Additions	1,105	406
Currency translation differences	43	40
Ending Cost	4,470	3,322
Gross carrying amount [member] | Office equipment [member]
Disclosure of detailed information about property, plant and equipment [line items]
Beginning Cost	3,146	1,753
Additions	489	1,427
Disposals		6
Currency translation differences	26	28
Ending Cost	3,661	3,146
Accumulated depreciation [member]
Disclosure of detailed information about property, plant and equipment [line items]
Beginning Cost	(14,568)	(12,712)
Additions	2,574	2,102
Disposals	144	7
Currency translation differences	256	239
Ending Cost	(17,255)	(14,568)
Accumulated depreciation [member] | Laboratory Equipment [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Beginning Cost	(10,476)	(9,303)
Additions	1,501	1,384
Disposals	144	1
Currency translation differences	219	210
Ending Cost	(12,052)	(10,476)
Accumulated depreciation [member] | Computer equipment [member]
Disclosure of detailed information about property, plant and equipment [line items]
Beginning Cost	(2,428)	(2,050)
Additions	508	404
Currency translation differences	30	26
Ending Cost	(2,966)	(2,428)
Accumulated depreciation [member] | Office equipment [member]
Disclosure of detailed information about property, plant and equipment [line items]
Beginning Cost	(1,665)	(1,359)
Additions	565	315
Disposals		6
Currency translation differences	7	3
Ending Cost	€ (2,237)	€ (1,665)

Property, plant and equipment_2

Property, plant and equipment - Summary of Depreciation expense (Detail) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure of detailed information about property, plant and equipment [line items]
Depreciation, property, plant and equipment	€ 2,574	€ 2,102	€ 1,797
Research and development expenses [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Depreciation, property, plant and equipment	1,684	1,502	1,315
General and administrative expenses [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Depreciation, property, plant and equipment	€ 890	€ 600	€ 482

Intangible assets - Summary of

Intangible assets - Summary of Changes to intangible assets (Detail) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Beginning Balance	€ 914
Ending Balance	1,315	€ 914
Patent And Licenses [Member]
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Beginning Balance	730
Ending Balance	1,071	730
Software Licenses [Member]
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Beginning Balance	184
Ending Balance	244	184
Gross carrying amount [member]
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Beginning Balance	1,870	1,863
Additions	481	104
Currency translation differences	107	(97)
Ending Balance	2,459	1,870
Gross carrying amount [member] | Patent And Licenses [Member]
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Beginning Balance	1,132	1,220
Additions	320
Currency translation differences	99	(88)
Ending Balance	1,551	1,132
Gross carrying amount [member] | Software Licenses [Member]
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Beginning Balance	738	643
Additions	162	104
Currency translation differences	8	(9)
Ending Balance	908	738
Accumulated impairment [member]
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Beginning Balance	(957)	(855)
Additions	160	126
Currency translation differences	27	(25)
Ending Balance	(1,144)	(957)
Accumulated impairment [member] | Patent And Licenses [Member]
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Beginning Balance	(403)	(369)
Additions	54	56
Currency translation differences	23	(22)
Ending Balance	(480)	(403)
Accumulated impairment [member] | Software Licenses [Member]
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Beginning Balance	(554)	(486)
Additions	106	71
Currency translation differences	4	(3)
Ending Balance	€ (664)	€ (554)

Intangible assets - Summary o_2

Intangible assets - Summary of Amortization expense (Detail) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure of detailed information about intangible assets [line items]
Amortisation, intangible assets other than goodwill	€ 160	€ 126	€ 111
Research and development expenses [Member]
Disclosure of detailed information about intangible assets [line items]
Amortisation, intangible assets other than goodwill	35	31	28
General and administrative expenses [Member]
Disclosure of detailed information about intangible assets [line items]
Amortisation, intangible assets other than goodwill	€ 125	€ 95	€ 83

Leases - Summary of Right-of

Leases - Summary of Right-of use assets (Detail) - EUR (€) € in Thousands	Dec. 31, 2021	Dec. 31, 2020
Disclosure of quantitative information about right-of-use assets [line items]
Right-of-use assets	€ 9,982	€ 6,149
Buildings [member]
Disclosure of quantitative information about right-of-use assets [line items]
Right-of-use assets	9,028	5,760
Laboratory equipment
Disclosure of quantitative information about right-of-use assets [line items]
Right-of-use assets	669
IT and telecommunication
Disclosure of quantitative information about right-of-use assets [line items]
Right-of-use assets	177	258
Vehicles [member]
Disclosure of quantitative information about right-of-use assets [line items]
Right-of-use assets	74	90
Other assets [member]
Disclosure of quantitative information about right-of-use assets [line items]
Right-of-use assets	€ 34	€ 41

Leases - Details of Lease liabi

Leases - Details of Lease liabilities (Detail) - EUR (€) € in Thousands	Dec. 31, 2021	Dec. 31, 2020
Lease liabilities [abstract]
Lease liability – current	€ 2,711	€ 1,881
Lease liability – non-current	7,142	4,306
Total	€ 9,853	€ 6,187

Leases - Summary of expenses re

Leases - Summary of expenses related to right-of-use assets and lease liabilities (Detail) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Disclosure Of Expenses Related ToRightOfUseAssets And Lease Liabilities [Line Items]
Depreciation, right-of-use assets	€ 2,526	€ 2,195
Interest expense form lease	288	260
Expense relating to short-term leases for which recognition exemption has been used	95	51
Buildings [member]
Disclosure Of Expenses Related ToRightOfUseAssets And Lease Liabilities [Line Items]
Depreciation, right-of-use assets	2,199	2,036
Laboratory equipment
Disclosure Of Expenses Related ToRightOfUseAssets And Lease Liabilities [Line Items]
Depreciation, right-of-use assets	162
IT and telecommunication
Disclosure Of Expenses Related ToRightOfUseAssets And Lease Liabilities [Line Items]
Depreciation, right-of-use assets	98	101
Vehicles [member]
Disclosure Of Expenses Related ToRightOfUseAssets And Lease Liabilities [Line Items]
Depreciation, right-of-use assets	59	50
Other assets [member]
Disclosure Of Expenses Related ToRightOfUseAssets And Lease Liabilities [Line Items]
Depreciation, right-of-use assets	€ 8	€ 8

Leases - Additional Information

Leases - Additional Information (Detail) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure of quantitative information about right-of-use assets [line items]
Additions to right-of-use assets	€ 6,700	€ 5,100
Currency translation of  right-of-use assets	300	300
Cash payments for leases	3,200	2,400
Payments for leases	2,707	€ 2,096	€ 1,862
Until 2025 [member]
Disclosure of quantitative information about right-of-use assets [line items]
Payments for leases	10,300
Later than one year [member]
Disclosure of quantitative information about right-of-use assets [line items]
Payments for leases	€ 2,900

Accounts payable - Summary of A

Accounts payable - Summary of Accounts Payable (Detail) - EUR (€) € in Thousands	Dec. 31, 2021	Dec. 31, 2020
Trade and other current payables [abstract]
Accounts payable	€ 3,009	€ 2,554
Other accrued liabilities	8,615	7,498
Total accounts payable	€ 11,624	€ 10,052

Accounts payable - Additional I

Accounts payable - Additional Information (Detail) - EUR (€) € in Thousands	Dec. 31, 2021	Dec. 31, 2020
Trade and other current payables [abstract]
Other accrued liabilities	€ 8,615	€ 7,498

Revenue from collaboration ag_3

Revenue from collaboration agreements - Additional Information (Detail) € in Thousands, $ in Millions	12 Months Ended
	Dec. 31, 2021EUR (€)	Dec. 31, 2021USD ($)	Dec. 31, 2020EUR (€)	Dec. 31, 2019EUR (€)	Dec. 31, 2021USD ($)
Disclosure Of Revenue From Contract With Customers [Line Items]
Contract with customers liability	€ 98,627		€ 132,075
Capitalized costs of contract net of amortization	900		1,200
Amortization of contract costs capitalized	300		300	€ 200
Potential milestone payment payable	1,600				$ 2
Revenue From Collaboration Agreements	34,763		31,253	18,449
Thereafter [Member]
Disclosure Of Revenue From Contract With Customers [Line Items]
Revenue From Collaboration Agreements	0
Amgen Collaboration Agreement [Member]
Disclosure Of Revenue From Contract With Customers [Line Items]
Upfront payment received	28,000	$ 30
Contract with customers liability revenue recognized	10,200		4,900	6,200
Contract with customers liability	0		10,000
Contract liabilities recognizedContract liabilities recognized	10,200
Genmab Collaboration Agreement [Member]
Disclosure Of Revenue From Contract With Customers [Line Items]
Upfront payment received	46,000	54
Contract with customers liability revenue recognized	6,900		11,200	11,200
Contract with customers liability	20,000		26,000
Genmab Collaboration Agreement [Member] | Milestone Payment For Licensed Product [Member]
Disclosure Of Revenue From Contract With Customers [Line Items]
Milestone payment receivable | $					550
BMS Collaboration Agreement [Member]
Disclosure Of Revenue From Contract With Customers [Line Items]
Upfront payment received	68,000	75
Contract with customers liability revenue recognized	13,100		11,500	€ 1,100
Contract with customers liability	42,000		55,000
BMS Collaboration Agreement [Member] | Option Exercise Development Commecial And Regulatory Milestone Payments [Member]
Disclosure Of Revenue From Contract With Customers [Line Items]
Milestone payment receivable | $					505
GSK Collaboration Agreement [Member]
Disclosure Of Revenue From Contract With Customers [Line Items]
Upfront payment received | $		$ 45
Contract with customers liability revenue recognized	4,500		3,700
Contract with customers liability	€ 37,000		€ 41,000
GSK Collaboration Agreement [Member] | Milestone Programs Based On The Program [Member]
Disclosure Of Revenue From Contract With Customers [Line Items]
Milestone payment receivable | $					$ 575

Revenue from collaboration ag_4

Revenue from collaboration agreements - Summary of Deferred revenue related to the collaboration agreements (Detail) - EUR (€) € in Thousands	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Revenue [abstract]
Current	€ 50,402	€ 46,600	€ 46,600
Non-current	48,225	85,475	€ 85,475
Total	€ 98,627	€ 132,075

Other income - Additional Infor

Other income - Additional Information (Detail) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Text Block [Abstract]
Revenue from grants	€ 0	€ 200	€ 30
Grant agreements government grant receivable	€ 800	€ 900

Other current liabilities - Sum

Other current liabilities - Summary of other current liabilities (Detail) - EUR (€) € in Thousands	Dec. 31, 2021	Dec. 31, 2020
Disclosure of detailed information about other current liabilities [Line Items]
Payroll tax	€ 1,760	€ 1,185
Accrual for vacation	607	525
Accrued bonuses		154
Other	134	161
Total	€ 2,501	€ 2,025

Other current liabilities - Add

Other current liabilities - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2021
Non Interest Bearing Liability [Member]
Disclosure of detailed information about other current liabilities [Line Items]
Borrowings maturity	one year

Financial income and expenses -

Financial income and expenses - Summary of finance income and costs (Detail) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure Of Detailed Information About Finance Income Expense [Abstract]
Interest income from short-term deposits	€ 133	€ 850	€ 790
Foreign currency gains	5,542
Gain on other financial instruments		2,099
Financial income	5,675	2,949	790
Interest expenses	(566)	(289)	(170)
Foreign currency losses	(276)	(9,774)	(94)
Losses on other financial instruments	(884)
Financial expenses	€ (1,726)	€ (10,063)	€ (264)

Financial income and expenses_2

Financial income and expenses - Additional Information (Detail) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Disclosure Of Detailed Information About Finance Income Expense [Abstract]
Realised gain loss from foreign currency forward contracts	€ 30	€ 1,200
Unrealised gain loss from foreign currency forward contracts	€ 900	€ 900

Share listing expense and cha_3

Share listing expense and change in fair value of warrant liabilities - Additional Information (Detail) € / shares in Units, € in Thousands	12 Months Ended
	Dec. 31, 2021EUR (€)Warrantsshares€ / shares	Dec. 31, 2020EUR (€)€ / shares	Jul. 01, 2020EUR (€)sharesWarrants€ / shares	Jul. 01, 2020$ / shares
Disclosure of share listing expense [line items]
Closing price of ARYA ordinary shares | € / shares	€ 0.01
Expense on the closing date		€ 152,787
Gains losses on financial liabilities at fair value through profit or loss	€ (10,990)	17,775
Financial liabilities	40,210	€ 27,883
ARYA [member]
Disclosure of share listing expense [line items]
Fair value of ARYA ordinary shares and warrants	243,100
Closing price of ARYA ordinary shares | $ / shares				$ 15.15
Identifiable net assets	90,284		€ 90,300
Expense on the closing date	€ 152,787
Warrants [member]
Disclosure of share listing expense [line items]
Closing price of ARYA public warrants | € / shares	€ 3.88	€ 2.35	€ 4.82
Gains losses on financial liabilities at fair value through profit or loss	€ 11,000	€ 17,800
Financial liabilities	27,900	€ 16,900
Warrants [member] | ARYA [member]
Disclosure of share listing expense [line items]
Fair value of ARYA ordinary shares and warrants	€ 34,644
ARYA Shares | Warrants	7,187,500		7,187,500
Closing price of ARYA public warrants | € / shares	€ 4.82
Financial liabilities	€ 34,400
Ordinary shares [member]
Disclosure of share listing expense [line items]
Closing price of ARYA ordinary shares | € / shares			€ 0.01
Ordinary shares [member] | ARYA [member]
Disclosure of share listing expense [line items]
Fair value of ARYA ordinary shares and warrants	€ 243,071
Closing price of ARYA ordinary shares | € / shares	€ 13.53
ARYA Shares | shares	17,968,750		17,968,750

Share listing expense and cha_4

Share listing expense and change in fair value of warrant liabilities - Summary of Calculation of the Share listing expense (Detail) € / shares in Units, € in Thousands	12 Months Ended
	Dec. 31, 2021EUR (€)Warrantsshares€ / shares	Dec. 31, 2020EUR (€)€ / shares	Jul. 01, 2020EUR (€)sharesWarrants€ / shares	Jul. 01, 2020$ / shares
Disclosure of detailed information about share listing expense [Line Items]
Closing price of ARYA Ordinary Shares on Nasdaq as of July 1, 2020 | € / shares	€ 0.01
IFRS 2 Expense on the closing date		€ 152,787
Warrants [Member]
Disclosure of detailed information about share listing expense [Line Items]
Closing price of ARYA Warrants on Nasdaq as of July 1, 2020 | € / shares	€ 3.88	€ 2.35	€ 4.82
Ordinary shares [member]
Disclosure of detailed information about share listing expense [Line Items]
Closing price of ARYA Ordinary Shares on Nasdaq as of July 1, 2020 | € / shares			€ 0.01
ARYA [Member]
Disclosure of detailed information about share listing expense [Line Items]
Closing price of ARYA Ordinary Shares on Nasdaq as of July 1, 2020 | $ / shares				$ 15.15
Fair value of outstanding ARYA	€ 243,100
Cash and cash equivalents held in ARYA's trust account	128,849
Current liabilities by ARYA	3,921		€ 3,900
ARYA's identifiable net assets	90,284		€ 90,300
IFRS 2 Expense on the closing date	€ 152,787
ARYA [Member] | Warrants [Member]
Disclosure of detailed information about share listing expense [Line Items]
ARYA Shares | Warrants	7,187,500		7,187,500
Closing price of ARYA Warrants on Nasdaq as of July 1, 2020 | € / shares	€ 4.82
Fair value of outstanding ARYA	€ 34,644
ARYA [Member] | Ordinary shares [member]
Disclosure of detailed information about share listing expense [Line Items]
ARYA Shares | shares	17,968,750		17,968,750
Closing price of ARYA Ordinary Shares on Nasdaq as of July 1, 2020 | € / shares	€ 13.53
Fair value of outstanding ARYA	€ 243,071

Share-based payments - Summary

Share-based payments - Summary of Options Granted Priced Using Black Scholes for SARs, Tandem Awards, Converted Options, Matching Stock Options and Monte Carlo Option Pricing Model (Detail)	Dec. 09, 2021Warrants$ / shares	Oct. 27, 2021Warrants$ / shares	Sep. 29, 2021Warrants$ / shares	Sep. 28, 2021Warrants$ / shares	Jun. 29, 2021Warrants$ / shares	Jun. 17, 2021Warrants$ / shares	Mar. 30, 2021Warrants$ / shares	Dec. 17, 2020Warrants$ / shares	Sep. 14, 2020Warrantsyr$ / shares	Jun. 30, 2020Warrantsyr$ / shares	Sep. 30, 2019yr$ / shares	Dec. 31, 2019yr$ / shares	Dec. 31, 2018yr$ / shares
2016 Tandem Awards [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price											$ 18.30	$ 23.82	$ 16.65
Underlying share price											$ 16.94	$ 67.87	$ 27.21
Volatility											78.00%	73.00%	64.00%
Time period (years) | yr											2.10	1.25	5
Risk free rate											2.04%	1.59%	2.77%
Dividend yield											0.00%	0.00%	0.00%
Combined probability of exit events											60	80	25
Matching Stock Options [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price										$ 10
Underlying share price										$ 15.15
Volatility										75.00%
Time period (years) | yr										5.5
Risk free rate										0.29%
Dividend yield										0.00%
Share Appreciation Rights [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price												$ 1.12	$ 1.12
Underlying share price												$ 67.87	$ 27.21
Volatility												73.00%	64.00%
Time period (years) | yr												1.25	5
Risk free rate												1.59%	2.77%
Dividend yield												0.00%	0.00%
Combined probability of exit events												80	25
Additional Grants Under 2020 Plan [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price	$ 11	$ 13.45	$ 12.75	$ 12.92	$ 11.93	$ 12.05	$ 11.68	$ 9.70	$ 10	$ 10
Underlying share price	$ 11	$ 13.45	$ 12.75	$ 12.92	$ 11.93	$ 12.05	$ 11.68	$ 9.70	$ 9.16	$ 15.15
Volatility	81.80%	82.07%	83.51%	83.57%	84.53%	84.67%	85.77%	84.00%	79.00%	75.00%
Time period (years) | Warrants	6.11	6.11	6.11	6.11	6.11	6.11	6.11	6	6.2	7
Risk free rate	1.29%	1.34%	1.19%	1.19%	1.08%	1.10%	1.17%	0.49%	0.37%	0.29%
Dividend yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Performance Based Options [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price				$ 12.92					$ 10	$ 10
Underlying share price				$ 12.92					$ 9.16	$ 15.15
Volatility				77.16%					78.00%	79.00%
Time period (years)				3.75					6.7	7
Risk free rate				1.49%					0.67%	0.66%
Dividend yield				0.00%					0.00%	0.00%
Converted Options [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price										$ 2.47
Underlying share price										$ 15.15
Volatility										75.00%
Time period (years) | yr										5.6
Risk free rate										0.29%
Dividend yield										0.00%

Share-based payments - Summar_2

Share-based payments - Summary of Employee Share Options (Detail)	Dec. 09, 2021$ / shares	Oct. 27, 2021$ / shares	Sep. 29, 2021$ / shares	Sep. 28, 2021$ / shares	Jun. 29, 2021$ / shares	Jun. 17, 2021$ / shares	Mar. 30, 2021$ / shares	Dec. 17, 2020$ / shares	Sep. 14, 2020shares$ / shares	Jul. 01, 2020$ / shares	Jun. 30, 2020shares$ / shares	Dec. 31, 2021Warrantsshares$ / shares	Dec. 31, 2021Warrantsshares$ / shares	Dec. 31, 2021sharesWarrants$ / shares	Dec. 31, 2021Warrantsshares$ / shares	Dec. 31, 2020shares$ / shares	Dec. 31, 2020shares$ / shares	Dec. 31, 2020shares$ / shares	Dec. 31, 2020sharesWarrants$ / shares	Dec. 31, 2019shares$ / shares	Dec. 31, 2018shares$ / shares
Disclosure of terms and conditions of share-based payment arrangement [line items]
Weighted average exercise price, Outstanding at January 1,													$ 10				$ 17.45			$ 16.65	$ 16.65
SARs forfeited																				16.81	16.65
Weighted average exercise price, Outstanding at December 31,																	10			$ 17.45	$ 16.65
Number of share options, outstanding at January 1, | shares														3,644,000				103,469		74,401	31,880
SARs forfeited | shares														0						2,936	1,443
Number of share options, outstanding at December 31, | shares																		3,644,000		103,469	74,401
Weighted average remaining contract life (years)																				8 years 6 months 21 days	9 years 1 month 13 days
Weighted average fair value of options granted										$ 13.79
Granted On December 2020 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
SARs granted																				$ 23.82
SARs granted | shares																				5,447
Share Appreciation Rights [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Weighted average exercise price, Outstanding at January 1,																	1.12			$ 1.12	$ 1.12
SARs forfeited																				1.12	1.12
Weighted average exercise price, Outstanding at December 31,																				1.12	1.12
SARs vested																				$ 1.12	$ 1.12
Number of share options, outstanding at January 1, | shares																		43,455		43,675	43,978
SARs forfeited | shares																				220	303
Number of share options, outstanding at December 31, | shares																				43,455	43,675
SARs vested | shares																				117	169
Performance Based Options [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Weighted average exercise price, Outstanding at January 1,													10
SARs forfeited													10				10
Weighted average exercise price, Outstanding at December 31,													10.08				10
Number of share options, outstanding at January 1, | shares														3,644,000
SARs forfeited | shares														48,000				255,000
Number of share options, outstanding at December 31, | shares														3,696,000				3,644,000
Weighted average remaining contract life (years)												8 years 11 months 23 days				9 years 7 months 6 days
Performance Based Options [Member] | Granted On September 2021 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
SARs granted													12.92
SARs granted | shares														100,000
Weighted average fair value of options granted				$ 8
Performance Based Options [Member] | Granted On June 2020 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
SARs granted																	10
SARs granted | shares											3,644,000							3,644,000
Weighted average fair value of options granted											$ 11.10
Performance Based Options [Member] | Granted On September 2020 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
SARs granted																	10
SARs granted | shares									255,000									255,000
Weighted average fair value of options granted									$ 6.41
Additional Grants Under 2020 Plan [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Weighted average exercise price, Outstanding at January 1,													9.87
SARs forfeited													10.01				10
SARs exercised													10
Weighted average exercise price, Outstanding at December 31,													10.57				9.87
SARs vested												$ 9.86	$ 9.86	$ 9.86	$ 9.86
Number of share options, outstanding at January 1,														1,910,182	1,910,182
SARs forfeited | shares														149,178				53,384
SARs exercised | Warrants															3,093
Number of share options, outstanding at December 31,														3,725,619				1,910,182	1,910,182
SARs vested | Warrants												557,401	557,401	557,401	557,401
Weighted average remaining contract life (years)												9 years 4 months 9 days				9 years 8 months 19 days
Additional Grants Under 2020 Plan [Member] | Granted On March 2021 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
SARs granted													$ 11.68
SARs granted | Warrants															90,325
Weighted average fair value of options granted							$ 11.22
Additional Grants Under 2020 Plan [Member] | Granted On June 2021 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
SARs granted													11.97
SARs granted | shares														75,980
Weighted average fair value of options granted					$ 11.22	$ 11.22
Additional Grants Under 2020 Plan [Member] | Granted On September 2021 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
SARs granted													12.81
SARs granted | shares														88,875
Weighted average fair value of options granted			$ 11.22	$ 11.22
Additional Grants Under 2020 Plan [Member] | Granted On October 2021 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
SARs granted													13.45
SARs granted | Warrants															53,324
Weighted average fair value of options granted		$ 11.22
Additional Grants Under 2020 Plan [Member] | Granted On December 2021 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
SARs granted													11
SARs granted | shares														1,659,204
Weighted average fair value of options granted	$ 11.22
Additional Grants Under 2020 Plan [Member] | Granted On June 2020 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
SARs granted																	10
SARs granted | shares																		1,087,417
Weighted average fair value of options granted											$ 9.35
Additional Grants Under 2020 Plan [Member] | Granted On September 2020 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
SARs granted																	9.72
SARs granted | shares																		74,000
Weighted average fair value of options granted									$ 9.35
Additional Grants Under 2020 Plan [Member] | Granted On December 2020 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
SARs granted																	9.70
SARs granted | shares																		802,149
Weighted average fair value of options granted								$ 9.35
Converted Options [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Weighted average exercise price, Outstanding at January 1,													2.58
SARs forfeited													1.29				1.08
SARs expired													1.29
Weighted average exercise price, Outstanding at December 31,													2.64				2.58
SARs vested												$ 2.61	$ 2.61	$ 2.61	$ 2.61	$ 2.45	$ 2.45	$ 2.45	$ 2.45
Number of share options, outstanding at January 1,														594,844	594,844
SARs forfeited | shares														8,180				37,540
SARs expired | Warrants															1,805
Number of share options, outstanding at December 31,														566,311				594,844	594,844
SARs vested | shares												193,727	193,727	193,727	193,727	53,856	53,856	53,856	53,856
Weighted average remaining contract life (years)												6 years 3 days				7 years 3 days
Weighted average fair value of options granted													$ 4.83				$ 4.83
Converted Options [Member] | Granted On June 2020 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
SARs granted													1.30				2.49
SARs granted | shares														18,548				632,384
Matching Stock Options [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Weighted average exercise price, Outstanding at January 1,													10
SARs forfeited													10				10
SARs exercised													10
Weighted average exercise price, Outstanding at December 31,													10				10
SARs vested												$ 10	$ 10	$ 10	$ 10
Number of share options, outstanding at January 1,														1,422,556	1,422,556
SARs forfeited | shares														9,254				8,262
SARs exercised | Warrants															6,834
Number of share options, outstanding at December 31,														1,406,468				1,422,556	1,422,556
SARs vested | Warrants												1,413,302	1,413,302	1,413,302	1,413,302
Weighted average remaining contract life (years)												8 years 6 months				9 years 6 months
Matching Stock Options [Member] | Granted On June 2020 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
SARs granted																	10
SARs granted | shares																		1,430,818
Weighted average fair value of options granted																	$ 10.59

Share-based payments - Summar_3

Share-based payments - Summary of Activities Under Share Based Payment Arrangement (Detail)	12 Months Ended
	Dec. 31, 2021shares$ / shares	Dec. 31, 2020shares$ / shares	Dec. 31, 2019shares$ / shares	Dec. 31, 2018shares$ / shares
Statements [Line Items]
Weighted average exercise price, Outstanding at January 1,	$ 10	$ 17.45	$ 16.65	$ 16.65
Weighted average exercise price, Tandem awards forfeited			16.81	16.65
Weighted average exercise price, Outstanding at December 31,		$ 10	17.45	16.65
Weighted average exercise price, Tandem awards vested			$ 16.76	$ 16.65
Weighted average remaining contract life (years)			8 years 6 months 21 days	9 years 1 month 13 days
Number of share options, outstanding at January 1, | shares	3,644,000	103,469	74,401	31,880
Number of share options, Tandem awards forfeited | shares	0		2,936	1,443
Number of share options, outstanding at December 31, | shares		3,644,000	103,469	74,401
Number of share options, Tandem awards vested | shares			16,238	14,350
Granted On June 2020 [Member]
Statements [Line Items]
Weighted average exercise price, Tandem awards granted			$ 18.30	$ 16.65
Number of share options, Tandem awards granted | shares			26,557	43,964
Granted On December 2020 [Member]
Statements [Line Items]
Weighted average exercise price, Tandem awards granted			$ 23.82
Weighted average fair value of options granted			$ 53.41
Number of share options, Tandem awards granted | shares			5,447
Granted On September 2020 [Member]
Statements [Line Items]
Weighted average fair value of options granted			$ 10.27	$ 4.51

Share-based payments - Addition

Share-based payments - Additional Information (Detail) $ / shares in Units, $ in Thousands, € in Millions

Dec. 09, 2021$ / shares

Oct. 27, 2021$ / shares

Sep. 29, 2021$ / shares

Sep. 28, 2021$ / shares

Jun. 29, 2021$ / shares

Jun. 17, 2021$ / shares

Mar. 30, 2021$ / shares

Dec. 17, 2020$ / shares

Sep. 14, 2020shares$ / shares

Jul. 01, 2020$ / shares

Jun. 30, 2020shares$ / shares

Sep. 30, 2019$ / shares

Dec. 31, 2021USD ($)$ / shares

Dec. 31, 2021EUR (€)sharesWarrants

Dec. 31, 2020shares$ / shares

Dec. 31, 2019USD ($)shares$ / shares

Dec. 31, 2018USD ($)$ / shares

Dec. 31, 2021EUR (€)

Sep. 30, 2020USD ($)

Dec. 31, 2019EUR (€)

Dec. 31, 2017

Disclosure of terms and conditions of share-based payment arrangement [line items]

Share based compensation by share based payment arrangement fair value per share

$ 13.79

Granted On December 2020 [Member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Share based compensation by share based payment arrangement options granted during the period | shares

5,447

Share based compensation by share based payment arrangement exercise price per share granted

$ 23.82

Performance Based Options [Member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Weighted average share price of share options granted

$ 12.92

$ 9.16

$ 15.15

Performance Based Options [Member] | Tranche One [Member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Minimum market capitalization | $

$ 1,500,000

Performance Based Options [Member] | Tranche Two [Member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Minimum market capitalization | $

2,000,000

Performance Based Options [Member] | Tranche Three [Member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Minimum market capitalization | $

$ 3,000,000

Performance Based Options [Member] | Granted On June 2020 [Member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Share based compensation by share based payment arrangement options granted during the period | shares

3,644,000

3,644,000

Share based compensation by share based payment arrangement exercise price per share granted

$ 10

Share based compensation by share based payment arrangement fair value per share

$ 11.10

Performance Based Options [Member] | Granted On September 2020 [Member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Share based compensation by share based payment arrangement options granted during the period | shares

255,000

255,000

Share based compensation by share based payment arrangement exercise price per share granted

$ 10

Share based compensation by share based payment arrangement fair value per share

$ 6.41

Performance Based Options [Member] | Granted On September 2021 [Member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Share based compensation by share based payment arrangement options granted during the period | shares

100,000

Share based compensation by share based payment arrangement exercise price per share granted

$ 12.92

Share based compensation by share based payment arrangement fair value per share

8

Additional Grants Under 2020 Plan [Member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Weighted average share price of share options granted

$ 11

$ 13.45

$ 12.75

12.92

$ 11.93

$ 12.05

$ 11.68

$ 9.70

9.16

15.15

Additional Grants Under 2020 Plan [Member] | Granted On June 2020 [Member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Share based compensation by share based payment arrangement options granted during the period | shares

1,087,417

Share based compensation by share based payment arrangement exercise price per share granted

$ 10

Share based compensation by share based payment arrangement fair value per share

9.35

Additional Grants Under 2020 Plan [Member] | Granted On September 2020 [Member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Share based compensation by share based payment arrangement options granted during the period | shares

74,000

Share based compensation by share based payment arrangement exercise price per share granted

$ 9.72

Share based compensation by share based payment arrangement fair value per share

$ 9.35

Additional Grants Under 2020 Plan [Member] | Granted On December 2020 [Member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Share based compensation by share based payment arrangement options granted during the period | shares

802,149

Share based compensation by share based payment arrangement exercise price per share granted

$ 9.70

Share based compensation by share based payment arrangement fair value per share

$ 9.35

Additional Grants Under 2020 Plan [Member] | Granted On March 2021 [Member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Share based compensation by share based payment arrangement options granted during the period | Warrants

90,325

Share based compensation by share based payment arrangement exercise price per share granted

11.68

Share based compensation by share based payment arrangement fair value per share

$ 11.22

Additional Grants Under 2020 Plan [Member] | Granted On June 2021 [Member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Share based compensation by share based payment arrangement options granted during the period | shares

75,980

Share based compensation by share based payment arrangement exercise price per share granted

11.97

Share based compensation by share based payment arrangement fair value per share

$ 11.22

$ 11.22

Additional Grants Under 2020 Plan [Member] | Granted On September 2021 [Member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Share based compensation by share based payment arrangement options granted during the period | shares

88,875

Share based compensation by share based payment arrangement exercise price per share granted

12.81

Share based compensation by share based payment arrangement fair value per share

$ 11.22

$ 11.22

Additional Grants Under 2020 Plan [Member] | Granted On October 2021 [Member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Share based compensation by share based payment arrangement options granted during the period | Warrants

53,324

Share based compensation by share based payment arrangement exercise price per share granted

13.45

Share based compensation by share based payment arrangement fair value per share

$ 11.22

Additional Grants Under 2020 Plan [Member] | Granted On December 2021 [Member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Share based compensation by share based payment arrangement options granted during the period | shares

1,659,204

Share based compensation by share based payment arrangement exercise price per share granted

11

Share based compensation by share based payment arrangement fair value per share

$ 11.22

Converted Options [Member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Weighted average share price of share options granted

$ 15.15

Share based compensation by share based payment arrangement fair value per share

4.83

$ 4.83

Converted Options [Member] | Granted On June 2020 [Member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Share based compensation by share based payment arrangement options granted during the period | shares

18,548

632,384

Share based compensation by share based payment arrangement exercise price per share granted

$ 1.30

$ 2.49

Share Appreciation Rights Two Thousand And Ten Plan [Member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Percentage of outstanding shares to be purchased by third party

50.00%

50.00%

Liabilities arising from share based payment arrangement | €

€ 2.1

Fair value of stock appreciation rights | $

$ 350,000

$ 160,000

2016 Tandem Awards [Member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Percentage of outstanding shares to be purchased by third party

50.00%

Share based compensation by share based payment equity instruments other than shares vesting period

five

Fair value of stock appreciation rights | $

$ 350,000

$ 160,000

Weighted average share price of share options granted

$ 16.94

$ 67.87

$ 27.21

Modification Of Awards Under Two Thousand Ten And Two Thousand And Sixteen Plan [Member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Cash payment award per share payable

10.00%

10.00%

Cash payment to employees stock based awards | €

€ 8.9

Modification Of Awards Under Two Thousand Ten And Two Thousand And Sixteen Plan [Member] | Active Employees [Member] | Bottom of range [member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Percentage of cash proceeds to be reinvested

25.00%

Modification Of Awards Under Two Thousand Ten And Two Thousand And Sixteen Plan [Member] | Active Employees [Member] | Top of range [member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Percentage of cash proceeds to be reinvested

50.00%

Modification Of Awards Under Two Thousand Ten And Two Thousand And Sixteen Plan [Member] | Management Members [Member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Percentage of cash proceeds to be reinvested

50.00%

Modification Of Two Thousand And Ten Plan [Member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Share based compensation expenses modification of awards | €

€ 2.6

Modification Of Two Thousand And Sixteen Plan [Member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Adjustment to additional paid in capital due to modification of previously settled equity awards | €

4.3

Modification Of Two Thousand And Sixteen Plan [Member] | Share Reinvestment [Member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Share based compensation expenses modification of awards | €

€ 4.1

Share based compensation by share based payment arrangement options granted during the period | shares

733,598

Fair value of stock appreciation rights | €

€ 8.5

Weighted average share price of share options granted

$ 15.15

Modification Of Two Thousand And Sixteen Plan [Member] | Share Reinvestment [Member] | Matching Stock Options [Member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Share based compensation by share based payment arrangement exercise price per share granted

10

Share based compensation by share based payment arrangement term of stock options

ten-year

Date of vesting of stock options

Jul. 31, 2021

Share based compensation by share based payment arrangement fair value per share

$ 10.59

Share based compensation by share based payment arrangement grant date

July 1, 2020

Share-based payments - Summar_4

Share-based payments - Summary of Employee Related Share Based Compensation Expense (Detail) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure Of Detailed Information About Share Based Compensation Expense [Line Items]
Share-based compensation expense	€ 26,403	€ 25,519	€ 2,016
Research And Development Expense [Member]
Disclosure Of Detailed Information About Share Based Compensation Expense [Line Items]
Share-based compensation expense	15,564	14,546	1,556
General And Administrative Expense [Member]
Disclosure Of Detailed Information About Share Based Compensation Expense [Line Items]
Share-based compensation expense	€ 10,839	€ 10,973	€ 460

Shareholders' equity (deficit)

Shareholders' equity (deficit) - Additional Information (Detail)	Jun. 30, 2020EUR (€)	Dec. 31, 2021EUR (€)€ / sharesshares	Dec. 31, 2020EUR (€)shares	Jul. 01, 2020EUR (€)€ / sharesshares	Dec. 31, 2019€ / sharesshares	Dec. 31, 2019$ / sharesshares
Disclosure of classes of share capital [line items]
Stock issued during period, value, new issues | €	€ 500,000	€ 0.01
Number of shares outstanding | shares		62,926,816	62,908,617
Par value per share | € / shares		€ 0.01
Number of shares value outstanding | €		€ 629,000	€ 629,000	€ 629,000
Share premium | €		€ 565,192,000	€ 538,695,000
Reorganization [Member]
Disclosure of classes of share capital [line items]
Number of shares outstanding | shares					33,093,838	33,093,838
Par value per share | $ / shares						$ 0.01
Immatics Biotechnologies GmbH [Member]
Disclosure of classes of share capital [line items]
Number of shares outstanding | shares					1,163,625	1,163,625
Par value per share | € / shares					€ 1
PIPE Financing [member] | ARYA Merger [Member]
Disclosure of classes of share capital [line items]
Share premium | €				€ 327,800,000
Ordinary Shares [member]
Disclosure of classes of share capital [line items]
Number of shares outstanding | shares				62,908,617
Par value per share | € / shares				€ 0.01

Non-controlling interests - Add

Non-controlling interests - Additional Information (Detail)	Jul. 01, 2020EUR (€)shares	Jun. 30, 2020EUR (€)	Dec. 31, 2021EUR (€)€ / shares	Dec. 31, 2020EUR (€)	Dec. 31, 2019EUR (€)	Jul. 01, 2020$ / shares
Statements [Line Items]
Par value per share | € / shares			€ 0.01
Ownership interests held by non-controlling interests		5.14%
Stock issued during period, value, new issues		€ 500,000	€ 0.01
Increase (decrease) through changes in noncontrolling interest		€ 500,000
Loss on non-controlling interest					€ 600,000
Non-controlling interests					1,000,000
MD Anderson compensation expense				€ 45,000	700,000
Increase through other contributions by owners, equity				€ 90,077,000	€ 700,000
Restricted Stock Acquisition Agreement [Member]
Statements [Line Items]
Stock issued during period, shares, acquisitions | shares	697,431
ARYA [Member]
Statements [Line Items]
Par value per share | $ / shares						$ 15.15
Increase (decrease) through changes in noncontrolling interest	€ 500,000
MD Anderson [Member]
Statements [Line Items]
Number of shares exchanged in subsidiaries | shares	379,420

Personnel expenses - Summary of

Personnel expenses - Summary of Personnel Expenses (Detail) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Statements [Line Items]
Wages and salaries	€ 29,098	€ 22,245	€ 15,231
Total other employee benefits	5,086	3,639	2,763
Share-based compensation expense	26,403	25,519	2,016
Total	60,587	51,403	20,010
Research and development expenses [Member]
Statements [Line Items]
Wages and salaries	21,993	15,277	11,635
Other employee benefits	3,550	2,624	2,035
Share-based compensation expense	15,564	14,546	1,556
General and administrative expenses [Member]
Statements [Line Items]
Wages and salaries	7,105	6,968	3,596
Other employee benefits	1,536	1,015	728
Share-based compensation expense	€ 10,839	€ 10,973	€ 460

Personnel expenses - Additional

Personnel expenses - Additional Information (Detail) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Classes of employee benefits expense [abstract]
Post-employment benefit expense, defined contribution plans	€ 200	€ 200	€ 100
Employee health insurance cost	600	400	300
Social security contributions	2,400	1,700	1,300
other miscellaneous expenses	€ 100	€ 100	€ 70

Income Tax - Summary of Reconci

Income Tax - Summary of Reconciliation Between Taxes On Income And Expected Income Tax Benefit (Detail) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Major components of tax expense (income) [abstract]
Loss before tax	€ (93,335)	€ (211,841)	€ (32,487)
Expected tax benefit	27,160	61,646	9,454
Difference in tax rates	(3,274)	(2,582)	(1,875)
Non-deductible  tax-expenses	(53)	(599)	(61)
Government grants exempted from taxes	0	45	8
Permanent Differences	(10,881)	(39,288)	0
Non-recognition of deferred taxes on tax losses and temporary differences	(12,953)	(19,222)	(7,526)
Taxes on income	€ 0	€ 0	€ 0

Income Tax - Summary of Deferre

Income Tax - Summary of Deferred Tax Assets (Detail) - EUR (€) € in Thousands	Dec. 31, 2021	Dec. 31, 2020
Statements [Line Items]
Deferred tax assets	€ 0	€ 0
Deferred tax liabilities	0	0
Intangible assets [Member]
Statements [Line Items]
Deferred tax assets	1,288	1,770
Deferred tax liabilities	0	0
Right-of-use asset [Member]
Statements [Line Items]
Deferred tax assets	0	0
Deferred tax liabilities	2,629	1,713
Deferred revenue [Member]
Statements [Line Items]
Deferred tax assets	0	180
Deferred tax liabilities	0	0
Other liabilities [Member]
Statements [Line Items]
Deferred tax assets	0	0
Deferred tax liabilities	0	0
Lease liability [Member]
Statements [Line Items]
Deferred tax assets	2,627	1,776
Deferred tax liabilities	0	0
Deferred expenses [Member]
Statements [Line Items]
Deferred tax assets	12	3
Deferred tax liabilities	0	0
Recognized [Member]
Statements [Line Items]
Deferred tax assets	3,927	3,729
Recognized [Member]
Statements [Line Items]
Deferred tax liabilities	2,629	1,713
Netting [Member]
Statements [Line Items]
Deferred tax assets netting	(2,629)	(1,713)
Netting [Member]
Statements [Line Items]
Deferred tax liabilities netting	2,629	1,713
Nonrecognition Due To History Of Losses [Member]
Statements [Line Items]
Non-recognition due to history of losses	(1,298)	(2,016)
Non-recognition due to history of losses	€ 0	€ 0

Income Tax - Additional Informa

Income Tax - Additional Information (Detail) - EUR (€) € in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2017
Statements [Line Items]
statutory tax rate	29.10%	29.10%	29.10%
corporate income tax rate	21.00%	21.00%	21.00%
Percentage on limitation on tax loss carryforwards after prior period	80.00%
Percentage on limitation on tax loss carryforwards before prior period				100.00%
Effective income tax reconciliation permanent effect share listing expense		€ 153
Indefinite Tax Losses Carryforward [Member]
Statements [Line Items]
Tax effect of tax losses	€ 355	€ 288
Twenty Six Year Tax Losses Carryforward [Member]
Statements [Line Items]
Tax effect of tax losses	€ 26

Financial Risk Management Obj_3

Financial Risk Management Objectives and Policies - Summary of Currency Risk Exposure (Detail) - EUR (€) € in Thousands	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Disclosure Of Currency Risk Exposure [Line Items]
Cash and cash equivalents	€ 132,994	€ 207,530	€ 103,353	€ 39,367
Financial assets	13,496	28,198
Currency risk [member] | Immatics GmbH [Member]
Disclosure Of Currency Risk Exposure [Line Items]
Cash and cash equivalents	11,787	6,788
Financial assets	0	24,448
Total assets exposed to the risk	11,787	31,236
Immatics N.V. [Member] | Currency risk [member]
Disclosure Of Currency Risk Exposure [Line Items]
Cash and cash equivalents	10,410	42,528
Financial assets	0	0
Total assets exposed to the risk	€ 10,410	€ 42,528

Financial Risk Management Obj_4

Financial Risk Management Objectives and Policies - Summary of Sensitivity Analysis of Foreign Currency Risk (Detail) € in Thousands	12 Months Ended
	Dec. 31, 2021EUR (€)	Dec. 31, 2020EUR (€)	Dec. 31, 2019
Disclosure of Sensitivity Analysis For Each Type Of Market Risk [Line Items]
Conversion rate	0.88292	0.8149	0.8902
Euro weakens by 1% against U.S. dollars [Member] | Immatics GmbH [Member]
Disclosure of Sensitivity Analysis For Each Type Of Market Risk [Line Items]
Conversion rate	1.1439	1.2394
Profit/(loss)	€ (117)	€ (309)
Carrying amount	€ 11,670	€ 30,927
Euro weakens by 1% against U.S. dollars [Member] | Immatics N.V. [Member]
Disclosure of Sensitivity Analysis For Each Type Of Market Risk [Line Items]
Conversion rate	1.1439	1.2394
Profit/(loss)	€ (103)	€ (421)
Carrying amount	€ 10,307	€ 42,107
Euro strengths by 1% against U.S. dollars [Member] | Immatics GmbH [Member]
Disclosure of Sensitivity Analysis For Each Type Of Market Risk [Line Items]
Conversion rate	1.1213	1.2148
Profit/(loss)	€ 119	€ 316
Carrying amount	€ 11,906	€ 31,552
Euro strengths by 1% against U.S. dollars [Member] | Immatics N.V. [Member]
Disclosure of Sensitivity Analysis For Each Type Of Market Risk [Line Items]
Conversion rate	1.1213	1.2148
Profit/(loss)	€ 105	€ 430
Carrying amount	€ 10,516	€ 42,958
Euro weakens by 5% against U.S. dollars [Member] | Immatics GmbH [Member]
Disclosure of Sensitivity Analysis For Each Type Of Market Risk [Line Items]
Conversion rate	1.1892	1.2885
Profit/(loss)	€ (561)	€ (1,487)
Carrying amount	€ 11,225	€ 29,749
Euro weakens by 5% against U.S. dollars [Member] | Immatics N.V. [Member]
Disclosure of Sensitivity Analysis For Each Type Of Market Risk [Line Items]
Conversion rate	1.1892	1.2885
Profit/(loss)	€ (496)	€ (2,025)
Carrying amount	€ 9,915	€ 40,503
Euro strengths by 5% against U.S. dollars [Member] | Immatics GmbH [Member]
Disclosure of Sensitivity Analysis For Each Type Of Market Risk [Line Items]
Conversion rate	1.0760	1.1657
Profit/(loss)	€ 620	€ 1,644
Carrying amount	€ 12,407	€ 32,880
Euro strengths by 5% against U.S. dollars [Member] | Immatics N.V. [Member]
Disclosure of Sensitivity Analysis For Each Type Of Market Risk [Line Items]
Conversion rate	1.0760	1.1657
Profit/(loss)	€ 548	€ 2,238
Carrying amount	€ 10,958	€ 44,766
Euro weakens by 10% against U.S. dollars [Member] | Immatics GmbH [Member]
Disclosure of Sensitivity Analysis For Each Type Of Market Risk [Line Items]
Conversion rate	1.2459	1.3498
Profit/(loss)	€ (1,072)	€ (2,840)
Carrying amount	€ 10,715	€ 28,396
Euro weakens by 10% against U.S. dollars [Member] | Immatics N.V. [Member]
Disclosure of Sensitivity Analysis For Each Type Of Market Risk [Line Items]
Conversion rate	1.2459	1.3498
Profit/(loss)	€ (946)	€ (3,866)
Carrying amount	€ 9,464	€ 38,662
Euro strengths by 10% against U.S. dollars [Member] | Immatics GmbH [Member]
Disclosure of Sensitivity Analysis For Each Type Of Market Risk [Line Items]
Conversion rate	1.0193	1.1044
Profit/(loss)	€ 1,310	€ 3,471
Carrying amount	€ 13,096	€ 34,707
Euro strengths by 10% against U.S. dollars [Member] | Immatics N.V. [Member]
Disclosure of Sensitivity Analysis For Each Type Of Market Risk [Line Items]
Conversion rate	1.0193	1.1044
Profit/(loss)	€ 1,157	€ 4,725
Carrying amount	€ 11,567	€ 47,253

Financial Risk Management Obj_5

Financial Risk Management Objectives and Policies - Summary of Sensitivity Analysis of Foreign Currency Risk (Parenthetical) (Detail)	Dec. 31, 2021	Dec. 31, 2020
Immatics GmbH [Member] | Euro weakens by 1 against US dollars [Member]
Disclosure of Sensitivity Analysis For Each Type Of Market Risk [Line Items]
Percentage Of Reasonably Possible Increase In Foreign Currency Risk	1.00%	1.00%
Percentage Of Reasonably Possible Decrease In Foreign Currency Risk	1.00%	1.00%
Immatics GmbH [Member] | Euro strengths by 1 against US dollars [Member]
Disclosure of Sensitivity Analysis For Each Type Of Market Risk [Line Items]
Percentage Of Reasonably Possible Increase In Foreign Currency Risk	1.00%	1.00%
Percentage Of Reasonably Possible Decrease In Foreign Currency Risk	1.00%	1.00%
Immatics GmbH [Member] | Euro weakens by 5 against US dollars [Member]
Disclosure of Sensitivity Analysis For Each Type Of Market Risk [Line Items]
Percentage Of Reasonably Possible Increase In Foreign Currency Risk	5.00%	5.00%
Percentage Of Reasonably Possible Decrease In Foreign Currency Risk	5.00%	5.00%
Immatics GmbH [Member] | Euro strengths by 5 against US dollars [Member]
Disclosure of Sensitivity Analysis For Each Type Of Market Risk [Line Items]
Percentage Of Reasonably Possible Increase In Foreign Currency Risk	5.00%	5.00%
Percentage Of Reasonably Possible Decrease In Foreign Currency Risk	5.00%	5.00%
Immatics GmbH [Member] | Euro weakens by 10 against US dollars [Member]
Disclosure of Sensitivity Analysis For Each Type Of Market Risk [Line Items]
Percentage Of Reasonably Possible Increase In Foreign Currency Risk	10.00%	10.00%
Percentage Of Reasonably Possible Decrease In Foreign Currency Risk	10.00%	10.00%
Immatics GmbH [Member] | Euro strengths by 10 against US dollars [Member]
Disclosure of Sensitivity Analysis For Each Type Of Market Risk [Line Items]
Percentage Of Reasonably Possible Increase In Foreign Currency Risk	10.00%	10.00%
Percentage Of Reasonably Possible Decrease In Foreign Currency Risk	10.00%	10.00%
Immatics N.V. [Member] | Euro weakens by 1 against US dollars [Member]
Disclosure of Sensitivity Analysis For Each Type Of Market Risk [Line Items]
Percentage Of Reasonably Possible Increase In Foreign Currency Risk	1.00%	1.00%
Percentage Of Reasonably Possible Decrease In Foreign Currency Risk	1.00%	1.00%
Immatics N.V. [Member] | Euro strengths by 1 against US dollars [Member]
Disclosure of Sensitivity Analysis For Each Type Of Market Risk [Line Items]
Percentage Of Reasonably Possible Increase In Foreign Currency Risk	1.00%	1.00%
Percentage Of Reasonably Possible Decrease In Foreign Currency Risk	1.00%	1.00%
Immatics N.V. [Member] | Euro weakens by 5 against US dollars [Member]
Disclosure of Sensitivity Analysis For Each Type Of Market Risk [Line Items]
Percentage Of Reasonably Possible Increase In Foreign Currency Risk	5.00%	5.00%
Percentage Of Reasonably Possible Decrease In Foreign Currency Risk	5.00%	5.00%
Immatics N.V. [Member] | Euro strengths by 5 against US dollars [Member]
Disclosure of Sensitivity Analysis For Each Type Of Market Risk [Line Items]
Percentage Of Reasonably Possible Increase In Foreign Currency Risk	5.00%	5.00%
Percentage Of Reasonably Possible Decrease In Foreign Currency Risk	5.00%	5.00%
Immatics N.V. [Member] | Euro weakens by 10 against US dollars [Member]
Disclosure of Sensitivity Analysis For Each Type Of Market Risk [Line Items]
Percentage Of Reasonably Possible Increase In Foreign Currency Risk	10.00%	10.00%
Percentage Of Reasonably Possible Decrease In Foreign Currency Risk	10.00%	10.00%
Immatics N.V. [Member] | Euro strengths by 10 against US dollars [Member]
Disclosure of Sensitivity Analysis For Each Type Of Market Risk [Line Items]
Percentage Of Reasonably Possible Increase In Foreign Currency Risk	10.00%	10.00%
Percentage Of Reasonably Possible Decrease In Foreign Currency Risk	10.00%	10.00%

Financial Risk Management Obj_6

Financial Risk Management Objectives and Policies - Summary of Liquidity Risk (Detail) - Liquidity risk [member] - EUR (€) € in Thousands	Dec. 31, 2021	Dec. 31, 2020
Statements [Line Items]
Financial assets held for managing liquidity risk	€ 145,117	€ 231,978
Cash And Cash Equivalents [Member]
Statements [Line Items]
Financial assets held for managing liquidity risk	132,994	207,530
Bonds [Member]
Statements [Line Items]
Financial assets held for managing liquidity risk	12,123	0
Short-Term Deposits [Member]
Statements [Line Items]
Financial assets held for managing liquidity risk	€ 0	€ 24,448

Financial Risk Management Obj_7

Financial Risk Management Objectives and Policies - Additional Information (Detail) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Statements [Line Items]
Cash and cash equivalents	€ 132,994	€ 207,530	€ 103,353	€ 39,367
Historical volatility for shares, measurement input [member] | ARYA [Member] | Warrants [member]
Statements [Line Items]
Percentage of reasonable possible increase in unobservable inputs	10.00%	10.00%
Percentage of resonably possible decrease in unobservable inputs	10.00%	10.00%
Increase decrease in fair value measurement due to a reasonably possible increase in unobservable input recognized in profit or loss before tax liabilities	€ 2,800	€ 1,700
Increase decrease in fair value measurement due to a reasonably possible decrease in unobservable input recognized in profit or loss before tax liabilities	€ 2,800	€ 1,700
Foreign Exchange Rates [Member] | ARYA [Member] | Warrants [member]
Statements [Line Items]
Percentage of reasonable possible increase in unobservable inputs	10.00%	10.00%
Percentage of resonably possible decrease in unobservable inputs	10.00%	10.00%
Increase decrease in fair value measurement due to a reasonably possible increase in unobservable input recognized in profit or loss before tax liabilities	€ 3,100	€ 1,900
Increase decrease in fair value measurement due to a reasonably possible decrease in unobservable input recognized in profit or loss before tax liabilities	(2,500)	(1,500)
Credit risk [member]
Statements [Line Items]
Maximum exposure to credit risk	145,000	232,000
Cash and cash equivalents	133,000	208,000
Other financial assets	12,000	24,000
Currency risk [member] | Top of range [member]
Statements [Line Items]
Foreign exchange gain (loss)	2,000	6,700
Currency risk [member] | Bottom of range [member]
Statements [Line Items]
Foreign exchange gain (loss)	€ 2,500	€ 8,200
Currency risk [member] | Euro [Member]
Statements [Line Items]
Percentage Of Reasonably Possible Decrease In Foreign Currency Risk	10.00%	10.00%
Currency risk [member] | US [Member]
Statements [Line Items]
Percentage Of Reasonably Possible Increase In Foreign Currency Risk	10.00%	10.00%

Financial Instruments - Summary

Financial Instruments - Summary of Carrying Amounts and Fair values of Group's Financial Instruments (Detail) - EUR (€) € in Thousands	Dec. 31, 2021	Dec. 31, 2020
Disclosure of detailed information about financial instruments [line items]
Financial assets, Carrying amount	€ 13,496	€ 28,198
Financial liabilities, Carrying amount	40,210	27,883
Financial assets, Fair value	13,486	28,198
Financial liabilities, Fair value	40,210	27,883
Financial assets at fair value through profit or loss, category [member] | Positive Market Value Forward Contracts [Member]
Disclosure of detailed information about financial instruments [line items]
Financial assets, Carrying amount	0	914
Financial assets, Fair value	0	914
Financial assets at fair value through profit or loss, category [member] | Other Financial Liabilities [Member]
Disclosure of detailed information about financial instruments [line items]
Financial liabilities, Carrying amount	27,859	16,869
Financial liabilities, Fair value	27,859	16,869
Other Financial Assets At Amortized Cost [Member] | ShortTerm Deposits [Member]
Disclosure of detailed information about financial instruments [line items]
Financial assets, Carrying amount	0	24,448
Financial assets, Fair value	0	24,448
Other Financial Assets At Amortized Cost [Member] | Trade receivables [member]
Disclosure of detailed information about financial instruments [line items]
Financial assets, Carrying amount	682	1,250
Financial assets, Fair value	682	1,250
Other Financial Assets At Amortized Cost [Member] | Other Current Asset [Member]
Disclosure of detailed information about financial instruments [line items]
Financial assets, Carrying amount	691	1,586
Financial assets, Fair value	691	1,586
Other Financial Assets At Amortized Cost [Member] | Accounts Payable [Member]
Disclosure of detailed information about financial instruments [line items]
Financial liabilities, Carrying amount	11,624	10,052
Financial liabilities, Fair value	11,624	10,052
Other Financial Assets At Amortized Cost [Member] | Other Current Liabilities [Member]
Disclosure of detailed information about financial instruments [line items]
Financial liabilities, Carrying amount	727	962
Financial liabilities, Fair value	727	962
Other Financial Assets At Amortized Cost [Member] | Bonds [Member]
Disclosure of detailed information about financial instruments [line items]
Financial assets, Carrying amount	12,123	0
Financial assets, Fair value	€ 12,113	€ 0

Commitments and contingencies -

Commitments and contingencies - Summary of Contractual Obligations (Detail) - EUR (€) € in Thousands	Dec. 31, 2021	Dec. 31, 2020
Disclosure Of Contractual Obligations [Line Items]
Lease liabilities	€ 10,329	€ 6,863
Other Lease Obligations	4,726	513
In-license agreements		249
Contract research organization agreements	1,681	1,924
Total contractual obligation	16,735	9,549
Less than 1year
Disclosure Of Contractual Obligations [Line Items]
Lease liabilities	2,913	2,103
Other Lease Obligations	66	97
In-license agreements		249
Contract research organization agreements	1,681	1,704
Total contractual obligation	4,659	4,153
1 - 3 years
Disclosure Of Contractual Obligations [Line Items]
Lease liabilities	4,477	3,453
Other Lease Obligations	1,258	185
In-license agreements		0
Contract research organization agreements	0	220
Total contractual obligation	5,735	3,858
3 - 5 years
Disclosure Of Contractual Obligations [Line Items]
Lease liabilities	2,007	1,157
Other Lease Obligations	1,362	185
In-license agreements		0
Contract research organization agreements	0	0
Total contractual obligation	3,370	1,342
More than 5 years
Disclosure Of Contractual Obligations [Line Items]
Lease liabilities	932	150
Other Lease Obligations	2,040	46
In-license agreements		0
Contract research organization agreements	0	0
Total contractual obligation	€ 2,972	€ 196

Commitments and contingencies_2

Commitments and contingencies - Additional Information (Detail) - EUR (€) € in Millions	Dec. 31, 2021	Dec. 31, 2020
Collaboration Agreements [Member]
Statements [Line Items]
Unrecorded contingent liability	€ 1.6	€ 1.6

Related party disclosures - Sum

Related party disclosures - Summary of Compensation of Key Management Personnel (Detail) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure Of Compensation Of Key Management Personnel [Abstract]
Fixed	€ 2,481	€ 2,660	€ 1,202
Variable	1,317	886	521
Share-based compensation expense	17,016	13,841	697
Total key management compensation	€ 20,814	€ 17,387	€ 2,420

Related party disclosures - S_2

Related party disclosures - Summary of Compensation for the Supervisory Board (Detail) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [line items]
Supervisory board compensation	€ 348	€ 282	€ 309
Travel expenses	15	4	107
Payment Exit arrangement		2,394
Share-based compensation expense	1,751	1,436
Total cash compensation	2,114	4,116	416
Peter Chambre
Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [line items]
Supervisory board compensation	80	140	300
Travel expenses	0	4	87
Payment Exit arrangement		2,394
Share-based compensation expense	1,143	1,046
Total cash compensation	1,223	3,584	387
Friedrich von Bohlen
Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [line items]
Supervisory board compensation	20
Travel expenses	1
Share-based compensation expense	30
Total cash compensation	51
Harald F.Stock
Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [line items]
Supervisory board compensation		16	9
Travel expenses		0	20
Payment Exit arrangement		0
Share-based compensation expense		0
Total cash compensation		16	€ 29
Michael G. Atieh
Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [line items]
Supervisory board compensation	55	28
Travel expenses	10	0
Payment Exit arrangement		0
Share-based compensation expense	114	70
Total cash compensation	179	98
Paul Carter
Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [line items]
Supervisory board compensation	53	26
Travel expenses	0	0
Payment Exit arrangement		0
Share-based compensation expense	114	70
Total cash compensation	167	96
Heather I. Mason
Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [line items]
Supervisory board compensation	40	20
Travel expenses	3	0
Payment Exit arrangement		0
Share-based compensation expense	114	70
Total cash compensation	157	90
Adam Stone
Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [line items]
Supervisory board compensation	40	20
Travel expenses	0	0
Payment Exit arrangement		0
Share-based compensation expense	114	70
Total cash compensation	154	90
Christoph Hettich
Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [line items]
Supervisory board compensation	20	20
Travel expenses	0	0
Payment Exit arrangement		0
Share-based compensation expense	0	70
Total cash compensation	20	90
Eliot Forster
Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [line items]
Supervisory board compensation	40	12
Travel expenses	1	0
Payment Exit arrangement		0
Share-based compensation expense	122	40
Total cash compensation	€ 163	€ 52

Related party disclosures - S_3

Related party disclosures - Summary of Options Granted to Managing Director and Supervisory Directors (Detail)	12 Months Ended
	Dec. 31, 2021shares$ / shares
Performance Based Options [Member] | Harpreet Singh
Disclosure of transactions between related parties [line items]
Description of Transactions with related party	Harpreet Singh
Type of option	Performance- based options
Grant date	June 30, 2020
Number of Options | shares	1,598,000
Strike Price in USD | $ / shares	$ 10
Expiration date	Jun. 30, 2030
Service Options [Member] | Harpreet Singh
Disclosure of transactions between related parties [line items]
Description of Transactions with related party	Harpreet Singh
Type of option	Service options
Grant date	June 30, 2020
Number of Options | shares	168,000
Strike Price in USD | $ / shares	$ 10
Expiration date	Jun. 30, 2030
Service Options [Member] | Peter Chambre
Disclosure of transactions between related parties [line items]
Description of Transactions with related party	Peter Chambré
Type of option	Service options
Grant date	June 30, 2020
Number of Options | shares	25,000
Strike Price in USD | $ / shares	$ 10
Expiration date	Jun. 30, 2030
Service Options [Member] | Adam Stone
Disclosure of transactions between related parties [line items]
Description of Transactions with related party	Adam Stone
Type of option	Service options
Grant date	June 30, 2020
Number of Options | shares	25,000
Strike Price in USD | $ / shares	$ 10
Expiration date	Jun. 30, 2030
Service Options [Member] | Heather I. Mason
Disclosure of transactions between related parties [line items]
Description of Transactions with related party	Heather L. Mason
Type of option	Service options
Grant date	June 30, 2020
Number of Options | shares	25,000
Strike Price in USD | $ / shares	$ 10
Expiration date	Jun. 30, 2030
Service Options [Member] | Michael G. Atieh
Disclosure of transactions between related parties [line items]
Description of Transactions with related party	Michael G. Atieh
Type of option	Service options
Grant date	June 30, 2020
Number of Options | shares	25,000
Strike Price in USD | $ / shares	$ 10
Expiration date	Jun. 30, 2030
Service Options [Member] | Paul Carter
Disclosure of transactions between related parties [line items]
Description of Transactions with related party	Paul Carter
Type of option	Service options
Grant date	June 30, 2020
Number of Options | shares	25,000
Strike Price in USD | $ / shares	$ 10
Expiration date	Jun. 30, 2030
Service Options [Member] | Eliot Forster
Disclosure of transactions between related parties [line items]
Description of Transactions with related party	Eliot Forster
Type of option	Service options
Grant date	September 14, 2020
Number of Options | shares	25,000
Strike Price in USD | $ / shares	$ 9.16
Expiration date	Sep. 13, 2030
Service Options [Member] | Friedrich von Bohlen
Disclosure of transactions between related parties [line items]
Description of Transactions with related party	Friedrich von Bohlen
Type of option	Service options
Grant date	June 17, 2021
Number of Options | shares	25,000
Strike Price in USD | $ / shares	$ 12.05
Expiration date	Jun. 17, 2031
Service Options One [Member] | Harpreet Singh
Disclosure of transactions between related parties [line items]
Description of Transactions with related party	Harpreet Singh
Type of option	Service options
Grant date	December 17, 2020
Number of Options | shares	168,000
Strike Price in USD | $ / shares	$ 9.70
Expiration date	Dec. 17, 2030
Service Options One [Member] | Peter Chambre
Disclosure of transactions between related parties [line items]
Description of Transactions with related party	Peter Chambré
Type of option	Service options
Grant date	December 9, 2021
Number of Options | shares	15,000
Strike Price in USD | $ / shares	$ 11
Expiration date	Dec. 9, 2031
Service Options One [Member] | Adam Stone
Disclosure of transactions between related parties [line items]
Description of Transactions with related party	Adam Stone
Type of option	Service options
Grant date	December 9, 2021
Number of Options | shares	15,000
Strike Price in USD | $ / shares	$ 11
Expiration date	Dec. 9, 2031
Service Options One [Member] | Heather I. Mason
Disclosure of transactions between related parties [line items]
Description of Transactions with related party	Heather L. Mason
Type of option	Service options
Grant date	December 9, 2021
Number of Options | shares	15,000
Strike Price in USD | $ / shares	$ 11
Expiration date	Dec. 9, 2031
Service Options One [Member] | Michael G. Atieh
Disclosure of transactions between related parties [line items]
Description of Transactions with related party	Michael G. Atieh
Type of option	Service options
Grant date	December 9, 2021
Number of Options | shares	15,000
Strike Price in USD | $ / shares	$ 11
Expiration date	Dec. 9, 2031
Service Options One [Member] | Paul Carter
Disclosure of transactions between related parties [line items]
Description of Transactions with related party	Paul Carter
Type of option	Service options
Grant date	December 9, 2021
Number of Options | shares	15,000
Strike Price in USD | $ / shares	$ 11
Expiration date	Dec. 9, 2031
Service Options One [Member] | Eliot Forster
Disclosure of transactions between related parties [line items]
Description of Transactions with related party	Eliot Forster
Type of option	Service options
Grant date	December 9, 2021
Number of Options | shares	15,000
Strike Price in USD | $ / shares	$ 11
Expiration date	Dec. 9, 2031
Service Options One [Member] | Friedrich von Bohlen
Disclosure of transactions between related parties [line items]
Description of Transactions with related party	Friedrich von Bohlen
Type of option	Service options
Grant date	December 9, 2021
Number of Options | shares	15,000
Strike Price in USD | $ / shares	$ 11
Expiration date	Dec. 9, 2031
Matching Stock Options [Member] | Harpreet Singh
Disclosure of transactions between related parties [line items]
Description of Transactions with related party	Harpreet Singh
Type of option	Matching Stock options
Grant date	June 30, 2020
Number of Options | shares	264,624
Strike Price in USD | $ / shares	$ 10
Expiration date	Jun. 30, 2030
Matching Stock Options [Member] | Peter Chambre
Disclosure of transactions between related parties [line items]
Description of Transactions with related party	Peter Chambré
Type of option	Matching Stock options
Grant date	June 30, 2020
Number of Options | shares	211,974
Strike Price in USD | $ / shares	$ 10
Expiration date	Jun. 30, 2030
Converted Options [Member] | Harpreet Singh
Disclosure of transactions between related parties [line items]
Description of Transactions with related party	Harpreet Singh
Type of option	Converted options
Grant date	June 30, 2020
Number of Options | shares	30,939
Strike Price in USD | $ / shares	$ 1.06
Expiration date	Jul. 1, 2027
Converted Options One [Member] | Harpreet Singh
Disclosure of transactions between related parties [line items]
Description of Transactions with related party	Harpreet Singh
Type of option	Converted options
Grant date	June 30, 2020
Number of Options | shares	145,371
Strike Price in USD | $ / shares	$ 1.17
Expiration date	Jan. 1, 2028
Service Options Two [Member] | Harpreet Singh
Disclosure of transactions between related parties [line items]
Description of Transactions with related party	Harpreet Singh
Type of option	Service options
Grant date	December 9, 2021
Number of Options | shares	168,000
Strike Price in USD | $ / shares	$ 11
Expiration date	Dec. 9, 2031

Related party disclosures - S_4

Related party disclosures - Summary of Compensation for the Supervisory Board (Parenthetical) (Detail) - EUR (€) € in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [abstract]
Key management personnel compensation, short-term employee benefits	€ 2.1	€ 4.1	€ 0.4

Related party disclosures - Add

Related party disclosures - Additional Information (Detail) € in Millions	12 Months Ended
	Dec. 31, 2021EUR (€)shares	Dec. 31, 2019shares	Dec. 31, 2018shares	Dec. 31, 2020shares	Dec. 31, 2017shares
Disclosure of transactions between related parties [line items]
Accrued of key management compensation | €	€ 0.1
Number of share options outstanding		103,469	74,401	3,644,000	31,880
Number of share options forfeited in share-based payment arrangement	0	2,936	1,443
Directors and executive officers [member]
Disclosure of transactions between related parties [line items]
Number of share options forfeited in share-based payment arrangement	0
ARYA [Member]
Disclosure of transactions between related parties [line items]
Number of Converted Stock Options In The Entity	417,415
Number of matching stock option in the entity	750,076
Service Options [Member] | Immatics GmbH [Member]
Disclosure of transactions between related parties [line items]
Number of share options outstanding	588,000
Twenty Twenty Incentive Plan [Member] | Service Options [Member]
Disclosure of transactions between related parties [line items]
Percentage of stock vested over the period of four-year time-based vesting schedule	25.00%			25.00%
Key management personnel of entity or parent [member]
Disclosure of transactions between related parties [line items]
Payment of Payroll Tax of the employees | €	€ 3.4

Net loss per share - Additional

Net loss per share - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2021shares
Text Block [Abstract]
Dilutive effect of share options on number of warrants	7,187,500

Events occurring after the re_2

Events occurring after the reporting period - Additional Information (Detail) € in Millions	1 Months Ended
	Feb. 28, 2022EUR (€)
Text Block [Abstract]
Receipt of upfront payment	€ 150